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ABSTRACT  
Over the last three decades, recombinant monoclonal antibodies (mAbs) have become 
the key tool for basic research, diagnosis and treatment of human diseases. This has 
required the selection of recombinant antibodies with high affinity for appropriate 
epitopes on the target antigen and other desirable characteristics, such as their isotype 
and effector functions. In Biopharmaceutical communities specialised in antibody 
production, expression levels of grams per litre have been reached. However, lack of a 
suitable manufacturing platform, which ensures consistent antibody production, has 
always been one of the major impediments to the development of recombinant antibody 
material in academia. To overcome this barrier, we have developed a unique cloning 
method for one-step assembly of antibody heavy- and light-chain DNAs in a single 
mammalian expression vector. The DNA fragments assembled in this system do not 
rely on restriction enzyme- and ligase-dependant methods, thus minimising the steps 
involved in the cloning procedure. This allows the reproducible generation of fully 
functional recombinant antibodies of any species and isotype with any desired 
specificity. In less than four weeks, tens of milligrams per litre can be achieved, from 
cloning through to harvesting of transfected cell supernatants, providing an unbiased 
manufacturing platform compared to the currently available antibody expression 
methods in academia. The system proved to be very efficient and readily adaptable for 
the high-throughput screening of melanoma patient-derived antibody candidates with 
clinical potential. It enabled the parallel comparative functional studies between IgE and 
IgG1 isotypes in an in vivo xenograft model of melanoma. The IgE isotype showed 
superior efficacy in restricting tumour growth, which encouraged us to continue 
developing antibody discovery methods, and pursuing melanoma antigen-specific 
antibodies as future effective therapies of this disease. 
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In 1890 Behring and Kitasato discovered the presence of “something in the blood that 
was able to neutralize diphtheria toxin”: transfusing sera already containing the 
antitoxin activity would protect the recipient animal from infection with the same toxin 
(Behring E, 1890). This was further elucidated when Paul Ehrlich described the 
interaction between the antitoxin and diphtheria toxin, introducing the term “antibody” 
in 1891 (Ehrlich, 1891).  
 
Today, it is very well known that the immune system is responsible for protecting 
organisms from harmful infections.  The adaptive immune response has evolved to 
recognise various antigens associated with infectious agents and initiate appropriate 
cellular activities to repress the infectious threat.  The molecules responsible for antigen 
recognition are T-cell receptors (TCR) on the surface of T-cells, and B-cell receptors 
(BCR) on the surface of B-cells.  B-cell receptors are secreted as antibodies following 
differentiation of B-cells into plasma cells.  Antibodies are remarkably diverse, not only 
do they recognise millions of antigens, but also each class of antibody has a different 
effector function. TCR antigen binding requires the presentation of antigenic peptides 
by Major Histocompatibility Complex (MHC) molecules present on the surface of 
Antigen Presenting Cells (APC) such as B-cells, dendritic cells and Langerhans cells.  
B-cell receptors (also known as Immunoglobulins) and antibodies can recognise antigen 
in the absence of facilitator cells.  Antigen binding to BCRs may result in internalisation 
and processing for subsequent antigen presentation to TCRs.  Secreted antibodies 
- 15 - 
couple antigen to immune effector cells via antibody-specific cell surface receptors 
(Janeway et al, 2001) 
 
1.2 Antibody structure and function 
Antibodies are produced by B lymphocytes by random combination of V and J (light 
chain), and V, D, and J (heavy chain) regions. Each antibody is a polypeptide ligand 
composed of two identical heavy (H) and two identical light (L) chains, interconnected 
by disulfide bonds. Each of the heavy and light chains can be subdivided into Constant 
(C) and Variable (V) immunoglobulin domains (Figure 1.1). The light chain may be one 
of two isotypes, κ or λ, and is comprised of a single Cκ or Cλ domain plus a 
corresponding Vκ or Vλ domain. The heavy chain C (CH) domains determine the 
antibody class:  Cε for IgE, Cµ for IgM, Cδ for IgD, Cγ for IgG and Cα for IgA.  All 
heavy chains are comprised of a single variable (VH) domain and four CH domains in 
the case of IgE and IgM, or three C domains in IgD, IgG and IgA (Figure 1.2). The Fc 
fragment, comprising CH domains 2, 3 (and 4) of an antibody (Figure 1.2), is 
responsible for binding to specific antibody receptors on the surface of effector cells. As 
different cell types express receptors with different isotype specificity, the Fc fragment 
determines the antibody effector function. The V domains of the heavy and light chain 
participate in antigen recognition and therefore require regions of hypervariability from 
one antibody to another, in order to recognise and bind with a high degree of specificity 
and affinity to the vast plethora of antigens to which the immune system is continuously 
exposed.  Within the antibody structure these regions are localised into six 
hypervariable loops, or complementarity determining regions (CDR), three from VH and 
three from VL (Figure 1.1), which in combination form the antigen binding site of the 
Fab fragment of the antibody (Janeway et al, 2001). 
 




Figure 1.1: Schematic illustrating of antibody structure and arrangement of the V 
regions. The antibody structure comprising of two identical heavy (H) and two identical 
light (L) chains, each possessing variable heavy (VH) and constant heavy (CH) domains 
and variable light (VL) and constant light (CL) domains respectively. Both VH and VL 
are comprised of four framework regions (FWR) that provide the structural support for 
three complementarity determining regions (CDR). The VH domain is encoded by a VH 
gene segment, from the start of FWR1 through to the end of FWR3.  CDR3 is encoded 
primarily by a D gene segment, but can include elements of the VH-D and D-JH 
junctions.  A JH segment encodes the final part of the VH domain, FWR4.  VL domains 
are encoded by VL and JL gene segments from either the kappa or lambda gene loci.  A 
VL gene segment provides the template for FWR1 through to part of CDR3.  A JL gene 
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Figure 1.2: Schematic representation of the five main antibody isotypes, IgE, IgA, 
IgG, IgM and IgD.  Fc portions, comprising isotype specific CH domains 2, 3 (and 4) 
are shown in green and confer antibody effector functions.  IgA, IgG and IgD Fc portion 
have two CH domains and a hinge region, which is replaced by a third CH domain in IgE 
and IgM.  The Fab fragments are shown in purple – light purple for the light chain 
portion and dark purple for the heavy chain VH and CH1.  Within each Fab fragment is 
the antigen binding site, comprised of hypervariable residues from the VH and VL 
domains.  Antibody structure is stabilised by intra- and inter-domain disulphide bridges, 
illustrated by thick black lines.  IgA and IgM are shown in their polymeric forms, with 
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In humans, the sequences of the framework regions of different light or heavy chains 
are relatively conserved, whilst antibodies with different specificities have different 
CDRs. Although it is the CDRs that vary from antibody to antibody, only a limited 
number of amino acid positions within the CDRs are directly involved in antigen 
binding.  These positions within the CDRs are called specificity determining residues 
(SDRs).  The variable domains of an antibody molecule are so termed due to the 
considerable variation in the amino acid sequence of this region observed throughout 
the expressed antibody repertoire.  The genetic structures of the chromosomal loci that 
encode antibodies have evolved to enhance the available range of antibody specificities. 
At each of the three antibody gene loci, on chromosome 14 for the heavy chain, 
chromosome 2 for the kappa light chain and chromosome 22 for the lambda light chain, 
the isotype-specific constant domain exons are preceded upstream by a number of gene 
segments that recombine at random to generate the VH, Vκ or Vλ domain.  The VL 
domains are encoded by a recombined V and Joining (J) gene segment, which joins the 
VL to the appropriate C exon.  In the VH domains an additional Diversity (D) gene 
segment is recombined with the selected V and J gene segments to generate the 
complete VH encoding DNA. Variability at the V(D)J joining site, or junctional 
diversity, is further enhanced by the deletion or addition of nucleotides during the 
joining process. The V(D)J junction encoded CDR3 loops, in particular the CDR3 of the 
heavy chain, constitute the most variable region of the whole antibody (Janeway et al, 
2001). 
 
The cell surface receptors (FcR) specific for the Fc domain are expressed on all cells of 
the immune system and play an important role in immune regulation, by linking the 
antibody-mediated immune responses with cellular effector functions. They are specific 
for each antibody isotype – FcαR for IgA, FcδR for IgD, FcεR for IgE, FcγR for IgG 
- 19 - 
and FcµR for IgM. In the case of FcγR, three distinct classes have been recognised: 
FcγRI, FcγRII, and FcγRIII, with different IgG binding affinities and IgG subclass 
specificities. The structural heterogeneity of FcγR is reflected in a wide range of 
biological activities, including clearance of antigen/antibody immune complexes, 
regulation of antibody production, enhancement of antigen presentation, antibody-
dependent cell-mediated cytotoxicity or phagocytosis, degranulation, and activation of 
inflammatory cells. Many of these responses may be unique for selected cell types 
based on differences in tissue-specific expression of FcγRs (Janeway et al, 2001). The 
IgE receptors FcεRI (the high-affinity receptor) and FcεRII (the low-affinity receptor, 
CD23) participate in the afferent phase of the immune response to allergens. The 
allergens from the environment are internalised and processed by the Langerhans cells 
in epidermal tissues and transported as peptide-MHC class II antigen complexes to the 
local lymphoid tissues to amplify the immune response and reimplant memory of the 
allergen for future responses (Gould et al, 2003). 
 
Each of the five classes of antibodies has a distinct structure, receptor specificity and 
function in the immune system (Janeway et al, 2001) (Table 1.1). Although there are 
differences in the actions of different antibody classes, all of them contribute to disable 
antigen in one way or the other. Functions of antibodies include: 
1. Neutralisation – The interaction of an antibody with its cognate antigen blocks or 
neutralises certain bacterial toxins, and prevents the attachment of bacteria and viruses 
to the cells. 
2. Enhancing opsonisation/phagocytosis – Antibodies bound to an antigen (via their 
variable region) can interact with their receptors on cells such as macrophages, 
neutrophils, basophils and mast cells (via their constant region) allowing them to 
identify a foreign antigen.  
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3. Complement activation – Antigen-antibody complexes initiate the classical pathway 











Main effector functions 
 
Receptors 
IgD 0.03 3 Binding to mast cells & basophils 
Neutralizing airway microbes 
IgD-R 
IgM 1.5 10 Classical pathway of complement activation; Neonatal immunity FcµR 
IgG1 9.0 21 
Classical pathway of complement 
activation 








IgG2 3.0 20 
IgG3 1.0 7 
IgG4 0.5 21 
IgA1 3.0 6 Mucosal immunity: secreted into lumens 
of respiratory and gastrointestinal tracts 




Fcα/µR IgA2 0.5  
IgE 5 x 10-5 2 
High-affinity binding to mast cells and 




Table 1.1: Human serum antibody levels, their receptors and main function. 
 
1.3 Conventional methods for antibody generation  
Monoclonal antibodies include genetically engineered forms such as chimaeric, 
humanised or fully human antibodies (Janeway et al, 2001). A monoclonal antibody is 
an antibody produced by a single clone of B-lymphocytes or by a cell into which the 
light and heavy chain genes of a single antibody have been transfected. The chimaeric 
antibody comprises sequences derived from two different antibodies, which are 
typically derived from different species and usually represent human constant regions 
and murine variable regions. Typically variable segments of the genes from a mouse 
monoclonal antibody are joined to human constant segments by genetic engineering. A 
humanised antibody is an antibody that includes human framework regions and one or 
more CDRs from a non-human antibody. Typically, transferring CDRs from heavy and 
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light variable chains of a murine immunoglobulin into a human variable domain 
produces humanised monoclonal antibody (Jones et al, 1986; Riechmann et al, 1988; 
Verhoeyen et al, 1988). The use of antibody components derived from humanised 
monoclonal antibodies obviates potential problems associated with the immunogenicity 
of the murine portion. A fully human antibody is an antibody that includes human 
framework regions and all of the CDRs from a human immunoglobulin.   
 
Different methods for antibody generation have been established. Methods for 
synthesising polypeptides and immunising a host animal to generate antibodies against 
the immunising polypeptides are well known. Typically, the host animal is inoculated 
intraperitoneally with an amount of immunogen and hybridomas are prepared by fusing 
lymphocytes from immunised animals with immortalised myeloma cells using the 
general somatic cell hybridisation technique (Kohler & Milstein, 1975). Hybridomas 
that produce suitable antibodies may be grown in vitro or in vivo and monoclonal 
antibodies are subsequently isolated from the culture media or body fluids, by 
conventional immunoglobulin purification procedures such as ammonium sulfate 
precipitation, gel electrophoresis, dialysis, chromatography, and ultrafiltration. 
Undesired activity, if present, can be removed by running the preparation over 
adsorbents made of the immunogen attached to a solid phase and eluting or releasing 
the desired antibodies off the immunogen. If desired, the antibody of interest may be 
sequenced and the polynucleotide sequence may then be cloned into a vector for 
expression or propagation. The sequence encoding the antibody may be maintained in a 
vector in a host cell and the host cell can then be expanded and frozen for future use.  
 
Another technique, Phage display, may be used to select and produce human antibodies 
and antibody fragments in vitro, from immunoglobulin variable domain gene repertoires 
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from unimmunised donors (McCafferty et al, 1990). Existing antibody phage display 
libraries may be panned in parallel against a large collection of synthetic polypeptides. 
According to this technique, antibody V domain genes are cloned in-frame into either a 
major or minor coat protein gene of a filamentous bacteriophage, such as M13 or fd, 
and displayed as functional antibody fragments on the surface of the phage particle. 
Because the filamentous particle contains a single-stranded DNA copy of the phage 
genome, selections based on the functional properties of the antibody also result in 
selection of the gene encoding the antibody exhibiting those properties.  Thus antibody 
sequences selected using phage display from human libraries may include human CDR 
or variable region sequences conferring specific binding to antigens, which may be used 
to provide fully human antibodies with therapeutic potential. 
 
Other methods for deriving heavy and light chain sequences from human B cell and 
plasma cell clones are typically performed using polymerase chain reaction (PCR) 
techniques (Kuppers, 2004; Tiller et al, 2008), providing fully human variable region 
sequences.  
 
More than a century since the discovery of antibodies, these molecules have a diverse 
range of applications. One such application is their use as treatment modalities for a 
range of diseases, including a number of human malignancies. 
 
1.4 Cancer Immunotherapy 
Cancer Immunotherapy is the use of the immune system to reject cancer. The main 
premise is stimulating the patient's immune system to attack the malignant tumour cells 
that are responsible for the disease. This can be either through immunisation of the 
patient, in which case the patient's own immune system is trained to recognise tumour 
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cells as targets to be destroyed, or through the administration of therapeutic antibodies 
as drugs, in which case the patient's immune system is recruited to destroy tumour cells 
by the therapeutic antibodies. Since the immune system responds to the environmental 
factors it encounters on the basis of discrimination between self and non-self, many 
kinds of tumour cells that arise as a result of the onset of cancer are more or less 
tolerated by the patient's own immune system since the tumour cells are essentially the 
patient's own cells that are growing, dividing and spreading without proper regulatory 
control. In spite of this fact, however, many kinds of tumour cells display unusual 
antigens that are either inappropriate for the cell type and/or its environment, or are only 
normally present during the organism’s development (e.g. fetal antigens). Other kinds 
of tumour cells display cell surface receptors that are rare or absent on the surface of 
healthy cells, and which are responsible for activating cellular signal transduction 
pathways that cause the unregulated growth and division of the tumour cell.  Such 




Melanoma is an immunogenic, highly aggressive and most lethal form of skin cancer 
arising from malignantly transformed melanocytes.  It affects people of all ages and 
incidence rates of melanoma have been rising by 5% per year, faster than any other 
cancer in the UK (Karim-Kos et al, 2011). Currently, surgical excision remains the 
standard of care for the treatment of primary melanomas. Excision of thin tumours less 
than 1 mm in thickness can result in an over 95% five-year survival rate (Balch et al, 
2009). Despite this however, 20% of primary melanomas will progress to metastatic 
disease for which the treatment options are limited and the prognosis poor with a 
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median survival of 8-18 months (Balch et al, 2009). Therefore, effective treatments are 
urgently needed for patients with this disease. 
 
Significant progress has been made in the treatment of advanced stage disease, with the 
US Food and Drug Administration (FDA) approval of Vemurafenib (BRAF V600E 
kinase inhibitor), Pegylated IFN-α2β (modified IFN-α2β, with increased half life and 
enhanced therapeutic efficacy) and Ipilimumab (fully human mAb targeting the 
inhibitory molecule cytotoxic T-lymphocyte antigen 4) (Lacy et al, 2012). The recent 
approval of the monoclonal antibody Ipilimumab for the treatment of melanoma 
suggests that activating immune responses with antibodies may have therapeutic 
significance and has renewed interest in the field of antibody therapies for the treatment 
of challenging tumours such as melanoma (Culver et al, 2011; Kaehler et al, 2010; 
Natarajan et al, 2011). However, despite the partial success and promise of various 
immunotherapeutic strategies, including antibodies, there are presently no promising 
antibody therapies that directly target antigens on the surface of melanoma cells. 
 
1.6 HMW-MAA as a suitable target for antibody immunotherapy 
The High Molecular Weight Melanoma Associated Antigen (HMW-MAA), also known 
as Melanoma-Associated Chondroitin Sulfate Proteoglycan (MCSP), Human Melanoma 
Proteoglycan (HMP), Melanoma-Associated Proteoglycan Antigen (MPG), Melanoma 
Chondroitin Sulfate Proteoglycan (mel-CSPG) or CSPG4 (Natali et al., 1984), has been 
identified as an appropriate target for antibody immunotherapy. It is a human 
melanoma-associated integral membrane chondroitin sulfate proteoglycan that plays a 
role in stabilising cell-substratum interactions during early events of melanoma cell 
spreading on endothelial basement membranes. The antigen consists of two 
noncovalently associated glycopolypeptides with apparent molecular weight of 280K 
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and 440K. The HMW-MAA core protein is initially translated as a precursor with a 
molecular mass of 240K with asparagine N-linked oligosaccharides of the high 
mannose type. It is over-expressed by more than 80% of human malignant melanoma 
cells (Esko et al, 1988; Spiro et al, 1989), including cancer-initiating cells, but not 
normal melanocytes. Staining of various types of tumours with a HMW-MAA-specific 
monoclonal antibody has shown that its expression is not restricted to melanoma. For 
solid tumours, HMW-MAA is also expressed on tumours of neuroectodermal origin 
(astrocytomas, gliomas, and neuroblastomas), squamous cell carcinoma of the head and 
neck, basal breast cancer, mesothelioma, pancreatic carcinoma, some types of renal cell 
carcinoma, chordoma, chondrosarcoma and soft tissue sarcomas (Wang et al, 2010a; 
Wang et al, 2010b). Its expression on primary and metastatic lesions and limited 
heterogeneity across tumours, represents a highly suitable therapeutic target (Campoli et 
al). Furthermore, the expression in malignant lesions does not vary following treatment 
with chemotherapeutic agents (Ferrone et al, 1993). 
 
The presence of the HMW-MAA in activated pericytes in tumour-associated angiogenic 
vasculature suggests a role in regulating and promoting tumour angiogenesis (Maciag et 
al, 2008). This could offer an additional advantage for antibody therapy, not only in 
targeting HMW-MAA-expressing tumour cells, but also in restricting angiogenesis and 
reducing tumour cell growth and migration. HMW-MAA enhances motility, migration 
and the metastatic capacity of melanoma cells by enhancing interactions with the 
extracellular matrix. It may also act as an auxiliary growth factor and has a role in 
melanoma cell proliferation (Yang et al, 2009; Yang et al, 2004). This gives the hope of 
preferential elimination of the most proliferative and metastatic HMW-MAA-
expressing melanoma cells by specific antibodies. 
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1.7 Rationale for the choice of HMW-MAA-specific monoclonal antibody 
Pre-clinical and clinical studies have investigated the efficacy of HMW-MAA-directed 
immunotherapy of melanoma. A murine monoclonal IgG antibody 225.28s raised 
against an epitope of the human HMW-MAA has been generated by immunising female 
BALB/c mice with human melanoma M21 cells (Imai et al, 1980). The original mouse 
clone was made in a hybridoma format and variable region sequences published (Neri et 
al, 1996). The antibody reacted strongly with most of the melanoma cells tested and the 
epitope recognised by the mAb 225.28s was proven to be located on the core protein of 
the HMW-MAA (Kantor et al, 1986; Wilson et al, 1981). It has been established that 
the antibody binds with high affinity and specificity to the epitope and its efficacy was 
tested in a number of in vitro and in vivo models (Ferrone & Kageshita, 1988; Hafner et 
al, 2005). Moreover, the mAb 225.28S was found to bind to an epitope distinct from 
those detected by other HMW-MAA specific antibodies and was found to exhibit 
univalent binding with no detectable endocytosis, suggesting that the mAb 225.28s 
remains on the membrane of melanoma cells (Temponi et al, 1992). These early in vitro 
studies also show that the murine 225.28s antibody weakly activates both complement 
and cell-mediated melanoma cell toxicity. The main mechanisms associated with 
reduced proliferation and neovascularisation, restriction of cell migration and metastasis 
have recently been reported in the context of triple-negative breast cancer cells which 
express the antigen (Wang et al, 2010a). Furthermore, the ability of murine 225.28s IgG 
antibody to suppress melanoma tumour growth has been demonstrated in a human 
xenograft grown s.c. in severe combined immunodeficiency (SCID) mice (Hafner et al, 
2005), but the mechanisms of its function were not fully analysed and it was conceded 
by the authors that the restricted access of IgG antibodies to solid tissues was a likely 
explanation for the modest extent of tumour regressions observed. Furthermore, the 
murine antibody is expected to induce HAMA (human anti-murine antibody) responses 
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in patients, resulting in neutralisation of the antibody and rapid clearance from the 
circulation, thereby significantly reducing any efficacy against tumour cells. In addition, 
the murine Fc region is not expected to effectively recruit FcR-expressing human 
immune effector cells which may target and kill tumour cells by mechanisms such as 
cytotoxicity and/or phagocytosis.  
 
Therefore, engineering HMW-MAA-specific antibodies with human constant regions 
that may trigger human Fc-expressing effector cell functions could help us evaluate 
novel immunotherapeutic tools for the treatment of solid cancers, and will enrich our 
understanding of therapeutically-relevant antibody-mediated mechanisms of action 
against cancer cells. 
 
1.8 IgG in cancer immunotherapy 
The use of monoclonal antibodies in cancer immunotherapy has become a successful 
and important treatment modality in the clinical management of malignancies over the 
past 15 years. Currently, 12 antibodies have been approved by the FDA for treatment of 
cancers, and a large number of antibodies are being tested in early- and late-stage 
clinical trials (Scott et al, 2012). However, nearly all antibodies developed in clinic 
today rely on only one of the nine human antibody classes (IgM, IgD, IgG1-4, IgA1, 
IgA2 and IgE), namely IgG1, the most abundant antibody class in the blood. The 
preference for IgG1 in cancer immunotherapy arose from the early work of Neuberger, 
showing that IgG1 was the most efficacious of nine different antibody classes in 
complement-mediated lymphoma cell killing by human peripheral blood mononuclear 
cells (PBMC) in vitro (Bruggemann et al, 1987). Subsequent clinical trials with 
antibodies recognising the B cell marker, CD20, supported the inference that IgG1 
would be the subclass best suited for immunotherapy of patients with B cell 
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malignancies such as non-Hodgkin’s lymphoma (Alduaij & Illidge, 2011). However, 
the human immune system naturally deploys the nine antibody classes to perform 
immune surveillance and to mediate destruction of pathogens in different anatomical 
compartments. Whilst IgG antibodies have been shown to be efficacious, it is known 
that they diffuse inefficiently into solid tissues, and bind with low affinity to their 
receptors on immune effector cells.  
It is now known that complement-mediated tumour cell death is only one of several 
mechanisms by which antibodies may mediate tumour growth restriction (Weiner, 
2007). Other known mechanisms include engaging immune effector molecules through 
their Fc regions to induce immune cell-mediated destruction of targeted cells by 
antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP) 
(Figure 1.3). Antibodies can also act directly on tumour cells to inhibit growth 
signalling pathways, induce apoptosis, restrict proliferation and cell differentiation of 
tumour cells, or block tumour cell adhesion and migration. The poor tissue penetration 
of IgG antibodies and low affinity of IgGs for their receptors on immune cells may 
partly account for the weak immune responses observed and resulting poor performance 
of many IgG antibodies against solid tumours. Therefore, there is still a need for 
improved therapeutic antibodies, particularly for the treatment of neoplastic diseases 
such as skin cancer.  In particular, there is a need for antibodies having improved 
effector functions compared to IgG antibodies, which may lead to an improved clinical 
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Figure 1.3. Schematic representation depicting the mechanisms of action of anti- 
tumour monoclonal antibodies. Antibodies, with specificity to TAAs, may operate 
through several mechanisms to kill cancer cells. These include 1 direct attack resulting 
in blockade of growth signalling pathways, restriction of proliferation and cell 
differentiation, or induction of apoptosis; 2 complement-dependent cytotoxicity (CDC); 
3 antibody-dependent cellular cytotoxicity (ADCC); or 4 antibody-dependent cellular 
phagocytosis (ADCP). In favourable situations, these mechanisms may also lead to the 
induction of long-lasting adaptive anti-tumour immune responses 5. TAA = tumour 
associated antigen, mAb = monoclonal antibody, FcR = Fc receptor. Figure courtesy of 








Figure 1.2. Schematic representation depicting the mechanisms of action of anti-
tumour monoclonal antibodies. Antibodies, with specificity to TAAs, may operate 
through several mech isms to kill canc r cells. These include 1 direct attack resulting 
in blockade of growth signalling pathways, restriction of proliferation and cell 
differentiation, or induction of apoptosis; 2 complement-dependent cytotoxicity (CDC); 
3 antibody-dependent cellular cytotoxicity (ADCC); or 4 antibody-dependent cellular 
phagocytosis ( P). In favourable situations, these mechanisms may als  lead to the 
induction -lasting adaptive anti-tumour immune responses 5. TAA = tumour 
associated antigen, mAb = monoclonal antibody, FcR = Fc receptor. Adapted from 
(Abes and Teillaud, 2011). 
 
It is clear therefore that, although many mAbs may exert their anti-tumour effects 
through a multitude of mechanisms, Fc-mediated mechanisms of immune system 
engagement appear to play a role in the anti-tumour efficacy of the majority of 
approved mAbs for cancer therapy today (Table 1.1 and Table 1.2). In light of this, 
recently a number of innovative antibody engineering strategies have been developed 
which are aimed at optimising antibody-immune system interactions that may tip the 
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1.9 Rationale for using IgE for the treatment of solid tumours 
IgE antibodies, known for their role in the allergic response and parasite protection, 
function through high-affinity Fc receptors, FcεRI and CD23, on a different spectrum of 
effector cells to IgG, and naturally reside in tissues where they exert immunological 
surveillance. These properties may translate to superior efficacy in targeting tissue-
resident tumours such as melanoma. IgE is actively transported into tissues by the low 
affinity IgE receptor FcεRII (also known as CD23), a mechanism that is not available to 
IgGs (Gould et al, 2003), and retained locally by powerful IgE receptor-expressing 
resident cells. The affinity of IgE for its high-affinity receptor,  FcεRI, (Ka=1011 M-1) is 
102-105 times higher than that of IgG1 for FcγRIII (the antibody receptor responsible for 
IgG1-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) of tumour 
cells), making it the only antibody strongly retained by effector cells in the absence of 
antigen (Gould & Sutton, 2008; Kinet, 1999; Ravetch & Kinet, 1991). The slow 
dissociation of the IgE- FcεRI  complex and local retention of IgE in tissues may 
translate to lower effective therapeutic doses and/or reduced frequency of administration 
compared to IgG. The half-life of IgE in tissues has been shown to be of the order of 
two weeks, which is proportionately longer than that of IgG (2-3 days) (Gould et al, 
2003; Hellman, 2007). Unlike IgG, IgE is subject to no inhibitory receptor (cf. FcγRIIb) 
(Clynes et al, 2000). 
 
IgE antibodies are primarily known for their role in immediate hypersensitivity 
reactions – the basis of condition’s such as allergic rhinitis and asthma. IgE antibodies 
against allergens remain permanently bound to IgE receptors on the surface of mast 
cells and Langerhans cells. The cross-linking of FcεRI on mast cells by allergen, leads 
to the release of histamine, leukotrienes, proteases and cytokines which increases 
circulation to the tissue and the influx and activation of inflammatory and potentially 
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cytotoxic cells (monocytes, eosinophils, basophils) at the site of allergen provocation. 
These activated cells may also migrate to local lymph nodes to stimulate T-cells, which 
in turn migrate to the tissue (Gould et al, 2003). In the context of their protective role in 
parasitic infections, IgE antibodies are known to trigger both ADCC, and antibody-
dependent cell-mediated phagocytosis (ADCP) of parasites. Both IgE receptors (FcεRI 
and CD23) are up-regulated by IgE and IL-4 on effector cells in situ, and are known to 
participate in these mechanisms of action (Gould et al, 2003).  
 
These properties of IgE antibodies may be redirected to enhance cytotoxicity and 
phagocytosis of tumour cells, as well as initiate IgE antibody-dependent antigen 
presentation by IgE receptor-bearing antigen-presenting cells such as dendritic cells, B 
cells and macrophages. Thus, passive and active immunity against solid tumours could 
act in conjunction in tissues such as skin, naturally populated by IgE effector cells. The 
strength of IgE-mediated immune responses in tissues, then, carries the expectation of 
increased potency as well as longevity of immune surveillance by IgE and effector cells 
against skin tumours.  
 
The main reservation about clinical use of IgE has been a perceived risk of inducing 
Type I hypersensitivity that may, in some circumstances contribute to systemic 
anaphylaxis. The most important basic principle in Type I hypersensitivity is that only 
allergens which are able to target more than one IgE bound to FcεRI on effector cells 
will lead to productive crosslinking and mediator release (Larche et al, 2006). 
Therefore, Type I hypersensitivity may occur when IgE, attached to FcεRI on 
circulating basophils and lung/mucosal mast cells, is cross-linked by soluble multivalent 
antigens. To avoid this circumstance, a target antigen that is not shed in a multivalent 
form into the circulation must be chosen: indeed the HMW-MAA is monomeric in its 
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soluble form. In addition, the tolerability of a fully human anti-HER2/neu IgE antibody 
in a preliminary study conducted in Macaca fascicularis (cynomolgus) monkeys has 
been reported (Daniels et al, 2012). 
 
Previously, we have reported the therapeutic efficacy of MOv18, an IgE antibody 
recognising the tumour-associated antigen Folate Receptor α (FRα) which is expressed 
in 70% of ovarian carcinomas and by a proportion of other cancers such as 
mesothelioma, breast and melanoma cancers. MOv18 IgE was more effective than the 
corresponding IgG1 in eliciting immune responses against cancer in two mouse 
xenograft models of ovarian carcinoma (Gould et al, 1999; Karagiannis et al, 2003). 
Mechanistically, MOv18 IgE induced monocytes to kill up to 70% of ovarian carcinoma 
cells; tumour killing was mediated by two mechanisms: ADCC and ADCP of tumour 
cells, both known IgE mechanisms of action in protection from parasitic infections. The 
antibody did not exert any direct effects on tumour cell viability or proliferation 
(Bracher et al, 2007; Karagiannis et al, 2008b; Karagiannis et al, 2007). Furthermore, a 
specifically engineered trastuzumab IgE was as effective as trastuzumab IgG1 at 
directly mediating tumour cell growth arrest in cellular viability (MTT) assays in vitro 
(Karagiannis et al, 2009). In addition, both trastuzumab IgG1 and IgE antibodies 
activated monocytic cells to kill tumour cells, but operated by different mechanisms: 
trastuzumab IgG1 functioned by ADCP, whereas trastuzumab IgE, unlike MOv18 IgE 
in ovarian carcinoma, functioned by inducing moderate levels of ADCC only.  
 
Based on all these properties of the IgE antibodies and their activity in our ovarian 
carcinoma models, we suggest that they may demonstrate both superior tissue 
bioavailability and higher receptor affinity. This may result in improved efficacy of 
immunotherapy for solid tumours by the use of IgE antibodies in place of the currently 
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conventional IgG. We therefore wished to conduct a direct comparison, based on 
engineered chimaeric 225.28s antibodies of different classes, IgG1 and IgE, and 
examine their potential efficacy in the treatment of melanoma. 
 
1.10 Project aims  
Guy’s & St Thomas’ NHS Foundation Trust (GSTFT) and King’s College London 
(KCL) are strategic and academic partners of one of five National Institute for Health 
Research (NIHR) comprehensive Biomedical Research Centres (BRC) under the 
Department of Health’s strategy for R&D.  The aim of the GSTFT/KCL NIHR 
Biomedical Research Centre is to create a unique Centre that enables a pipeline of 
excellent basic biomedical research to deliver real change in the management of the 
patients. The BRC focuses on seven research themes encompassing Asthma & Allergy, 
Atherosclerosis, Cutaneous Medicine, Cancer, Immunity and Infection, Oral Health and 
Transplantation and has cross cutting disciplines encompassing Genetics, Paediatrics, 
Imaging Sciences, Stem Cell Research, Cell and Molecular Biophysics, Age-related 
diseases and Health & Social Care Research. The “Discovery to Phase I trials of Novel 
Therapeutic Antibodies for Cancer” program within the Biomedical Research Centre 
(BRC) led by Dr. James Spicer, Dr. Sophia Karagiannis, Prof. Philip 
Blower, Prof. Hannah Gould & Dr. Andrew Beavil aims to: 
1) isolate patient derived melanoma antigen-specific antibody variable gene 
sequences  
2) re-format these into recombinant monoclonal antibodies 
3) test the function and efficacy of newly discovered recombinant monoclonal 
antibodies in vitro and in vivo 
The BRC engaged three PhD students to deliver its program aims, one for each aim. My 
contribution to the program was to deliver aim 2, but inevitably I was closely involved 
- 34 - 
in aim 1 and 3. My main objectives include: 
a) implementation and optimisation of our existing transient antibody expression 
method to enhance transfection efficiency, increase production and further 
support the characterisation of an existing melanoma antigen-specific antibody 
(Chapter 3)  
b) improvement of antibody cloning and expression by constructing a dual 
antibody expression cassette using an alternative to conventional restriction 
enzyme- and ligase-dependent cloning methods, allowing time-efficient 
generation of stable cell lines for production of fully functional recombinant 
antibodies in large quantities  (Chapter 4) 
c)  Production and characterisation of melanoma antigen-specific IgG1 and IgE, 
followed by parallel comparative functional studies between the two isotypes 
using validated in vitro and in vivo assays (Chapter 5)  
d) Supporting the antibody discovery program by re-formatting the isolated patient 
derived melanoma antigen-specific variable gene sequences as whole antibodies, 
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2 MATERIAL AND METHODS 
 
2.1 General reagents and solutions 
All materials and reagents used in this thesis are shown in the table below:  
Product name Supplier 
Catalogue 
number 
0.2ml PCR tube, flat cap, natural 
Elkay Laboratory 
Products (UK) Ltd THER-02NF 
1kb DNA Ladder  New England Biolabs N3232S 
2-isopropanol Fluka 59310 
2-log DNA ladder (0.1 - 10kb) NEB N3200S 
2-Mercaptoethanol 50mM 20ml Gibco 31350-010 
2.0ml Cryovial Internally Threaded Self-
Standing Sterile  
Alpha Laboratories 
Limited  LW3334 
Acrylamide Solution, Pre-made, 30% (w/v) 
Ratio 37.5 Severn Biotech Ltd  20-2100-05 
Agarose Bioline BIO41025 
  Agarose, Molecular Grade   Bioline Limited BIO-41026 
Amicon Ultra -15 Ultra cel- 30k Millipore UFC903008 
Ammonium Persulfate Sigma-Aldrich A3678 
Antarctic Phosphatase 5000U/ml NEB M0289S 
BsiW I  New England Biolabs  R0553S 
BssH II New England Biolabs  R0199S 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich D2650 
DNA Sequencing Vouchers  
Source BioScience 
AUTOGEN  GSL1501 
Dual Mini Gel Cast Set 
Genetic Research 
Instrumentation Ltd  2393010 
Dulbecco's Modified Eagle Medium (D-
MEM) (1X), liquid (high glucose)  
Invitrogen Life 
Technologies  11960085 
Dulbecco's Phosphate Buffered Saline (D-
PBS) (1X), liquid  
Invitrogen Life 
Technologies  14190169 
EcoR1 10,000U NEB R0101S 
EcoRI-HF  New England Biolabs R3101S 
Ethanol Sigma-Aldrich 45-986-6 
Ethidium Bromide 10mg/ml Sigma-Aldrich E1510-10ML 
F-12 Nutrient Mixture (Ham), liquid  
Invitrogen Life 
Technologies  21765029 
Flp-In™ Complete System 
Invitrogen Life 
Technologies K6010–01 
Flp-In™-293 Cell Line  
Invitrogen Life 




Foetal Bovine Serum (FBS) Invitrogen Life 10106169 
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Technologies  
Geneticin® Selective Antibiotic, liquid  
Invitrogen Life 
Technologies  10131027 
Glycerol Sigma-Aldrich G-6279 
Glycine Sigma-Aldrich G-7403 
HEK-293E ATCC  CRL-1537 
Hind III  New England Biolabs  R0104S 
HindIII 10,000U NEB R0104S 
HiSpeed ® Plasmid Maxi Kit QIAGEN 12663 
HiTrap™ NHS-activated HP Column GE Healthcare 17-0717-01 
Hydrochloric acid ACS reagent, 37%  Sigma  258148-2.5L 
Hygromycin B in PBS 50mg/ml Invitrogen 10687-010 
KpnI 3000U NEB R0142S 
LB Agar, powder (Lennox L Agar) 
Invitrogen Life 
Technologies  22700025 
LB Broth Base, powder (Lennox L Broth 
Base)® 
Invitrogen Life 
Technologies  12780052 
Marvel, dried skimmed milk 
Premier International 
Foods  
MEM 10 x 500ml  Invitrogen 31095-052 
MEM Non Essential Amino Acids (100X), 
liquid Invitrogen 11140-035 
Methanol Fisher Scientific M/3950/PK4 
Microcentrifuge tube with lip seal screwcap 
and loop polypropylene tube polyethylene 
cap Fisherbrand 1.5mL  Fisher Scientific Ltd  FB74345 
N,N,N′,N′-Tetramethylethylenediamine for 
molecular biology, ≥99% (GC)  Sigma  T7024-25ML 
Nar I  New England Biolabs  R0191S 
NheI-HF New England Biolabs  R3131S 
NruI 1000U NEB R0192S 
Nunc-Immuno™ Plates 96-well plate, 
Maxisorp  Sigma  M9410-1CS 




o-Phenylenediamine Dihydrochloride tablet, 
5 mg substrate per tablet  Sigma  
P6912-
100TAB 
OptiMAb® Monoclonal Antibody 




Technologies  10378-016 
Penicillin-Streptomycin, liquid  
Invitrogen Life 
Technologies  15140122 
Pens, lab marker, extra fine tip, black, VWR International 811-0060 
Phusion Flash High-Fidelity PCR Master 
Mix  New England Biolabs  F-548S 
Plasmid Maxi Kit (25), 25 QIAGEN-tip 
500, Reagents, Buffers QIAGEN 12163 
Polyclonal Goat Anti-Human IgE-
Peroxidase,  Specific for Epsilon-Chains Sigma A9667 
Polyclonal Rabbit Anti-Human IgE, Dako A0094 
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Specific for Epsilon-Chains 
Quick Ligation Kit  New England Biolabs  M2200S 
QuikChange Lightning Site-Directed 
Mutagenesis Kit Stratagene 210518 
Sac II  New England Biolabs  R0157S 
SDS Solution, 20%, 1000ml  Severn Biotech Ltd  20-4002-10 
SEAKEM GTG AGAROSE  VWR International  733-1541 
SeeBlue® Plus2 Pre-Stained Standard  
Invitrogen Life 
Technologies LC5925 
Sfi I  New England Biolabs  R0123S 
Sodium Azide Sigma-Aldrich S-2002 
Sodium chloride Sigma-Aldrich S-9625 
Sodium Hydrogen Carbonate BDH Chemicals 30151 
Spectrafuge™ Mini Centrifuge Sigma  
S7816GB-
1EA 
Stable Peroxide Substrate Buffer (10X) Fisher Scientific Ltd  34062 
Tissue culture flask TripleFlasks 
polystyrene Nunclon  Fisher Scientific Ltd  
TKT-130-
030V 
Trypan blue solution, 0.4% Sigma-Aldrich T8154 
TrypLE™ Express Stable Trypsin 
Replacement Enzyme without Phenol Red  
Invitrogen Life 
Technologies  12604021 
Tween20 (Polyoxyethylene (20) sorbitan 
monolaurate Sigma-Aldrich P-5927 
Vacuum filter unit sterile Millipore 250ml 
funnel 250ml receiver  Fisher Scientific Ltd  
FDR-120-
050L 
Wide Mini-Sub Cell GT System 
BIO-RAD laboratories 
europe ltd 170-4468 
Wizard Plus SV Minipreps DNA 
Purification System Promega  A1330 
Wizard SV Gel and PCR Clean-Up System  Promega  A9281 
XbaI 5000U NEB R0145S 
XhoI 5000U NEB R0146S 
XL1-Blue Competent Cells Stratagene  200249 
XL10-Gold Ultracompetent cells Stratagene 200314 
XL2-Blue Ultracompetent Cells Stratagene 200150 
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All solutions used in this thesis are shown in the table below: 
Solution Constituents 
0.2M Glycine 0.2M Glycine , pH 2.5, 0.1% NaN3 
1 M Tris 
121.14 g Trizma base, MilliQ water up to 1L, pH 8.6, 0.1% 
NaN3 
10% APS APS dissolved 10% w/v solution in MilliQ water 
10X SDS-PAGE run 
buffer 
30 g Trizma base, 144 g Glycine, 100 ml 10% SDS, MilliQ 
water up to 1L 
5xSDS-Sample Buffer  
3.125 ml 1 M Tris (pH 6.8), 5ml glycerol, 0.25 g SDS and 
1 ml 2-mercaptoethanol (prior to analysis) to 10ml MilliQ 
water 
Coomassie blue destain 5% v/v methanol, 7.5% v/v acetic acid in MilliQ water 
Coomassie blue stain 
0.05% coomassie blue powder in 45% v/v Methanol, 45% 
v/v MilliQ water and  9% v/v acetic acid  
ELISA Blocking Buffer 2% milk powder (Marvel) in 1xPBS 
ELISA Carbonate 
Buffer 
1.59 g Na2CO3 ,  2.93 g NaHCO3, up to 1000 ml MilliQ 
water, pH 9.6  
ELISA Wash Buffer 1xPBS-Tween20 (0.05%) 
FACS Buffer 
1xPBS supplemented with 5% Normal Goat Serum and 
kept at 4ºC 
HPLC buffer 
0.5 M Tris-HCl, 250 mM NaCl, 0.05% Sodium azide, pH 
adjust to 7.2, filtered 
Lower Tris 1.5M Tris, 0.4% SDS, pH8.8 
OPD Buffer 




1ml Stable Peroxide Substrate Buffer (10x) in 9ml  MilliQ 
water 
Upper Tris 0.5M Tris, 0.4% SDS, pH 6.8 
 
Table 2.1.2: Solution reagents and their constituents 
 
2.2 PCR and Sequencing Primers 
Primers were obtained using the Custom DNA Oligo service from Sigma. The 
sequences of each primer used in this thesis are listed in the table below: 










































Table 2.2: PCR and sequencing primers 
 
2.3 LB Culture Medium  
LB culture medium was made by dissolving LB powder (Invitrogen) in MilliQ water at 
a ratio of 20g LB per litre of water and the solution was autoclaved.  The medium was 
kept at room temperature. Ampicillin (Sigma-Aldrich), was added at 100µg/ml, prior to 
culture inoculation. 
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2.4 LB Agar Culture Plates 
To make LB agar culture plates, LB agar powder (Invitrogen) was added to MilliQ 
water at a ratio of 32g powder per litre of water and autoclaved.  The molten LB agar 
was cooled to approximately 50°C before addition of ampicillin (Sigma-Aldrich) at 
100µg/ml, and poured into 90mm diameter Petri dishes (20-25ml per dish) to set.  Plates 
were stored at 4°C until used. 
 
2.5 SOB Medium 
SOB Medium required for SOC Medium preparation, was prepared by adding 20.0 g of 
tryptone (Sigma), 5.0 g of yeast extract (Fisher Scientific Ltd), 0.5 g of NaCl (Sigma), 
MilliQ water to a final volume of 1 liter and autoclaved. Then 10 ml of filter-sterilized 1 
M MgCl2 (Sigma) and 10 ml of filter-sterilized 1 M MgSO4 (Sigma) were added. SOB 
Medium was kept at RT. 
 
2.6 SOC Medium 
Prepared by adding 2 ml of filter-sterilized 20% (w/v) glucose (Sigma) or 1 ml of filter-




General transformations were performed using XL1-Blue Competent Cells (Stratagene).  
Ligation products were transformed using XL2-Blue Ultracompetent Cells (Stratagene). 
When using QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene), the 
DNA was transformed into XL10-Gold Ultracompetent cells. All transformations were 
done with the protocols recommended by Stratagene, using SOC (described above) for 
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XL1-Blue Competent Cells and LB (described above) for XL2-Blue and XL10-Gold 
Ultracompetent cells as the medium for outgrowth following the heat pulse. The 
transformation mixture was plated onto LB agar Petri dishes with 100µg/ml ampicillin. 
 
2.8 Overnight Bacterial Cultures 
Single colonies selected for growth LB agar Petri dishes were transferred by pipette tip 
into 4ml LB medium containing 100µg/ml ampicillin.  Cultures were incubated 
overnight at 37°C with shaking at 250rpm. 
 
2.9 Long term storage of bacterial strain 
It is lab policy to prepare a frozen stock of newly created strains as soon as possible. 1 
ml of the 4mls Overnight Bacterial Culture is used for long term storage of bacterial 
strain and the rest 3ml for mini-preparation of Plasmid DNA.  150 µl sterile 100% 
glycerol (Sigma) and 850 µl of the bacterial culture (frozen stock is 15% glycerol) were 
added to a sterile, labelled cryo-vial. This was mixed well and stored at -80°C. A 
miniprep was then performed for DNA purification. 
 
2.10 Mini-preparation of Plasmid DNA from Overnight Cultures 
Plasmid DNA was purified from 3ml overnight cultures using a Wizard Plus SV 
Minipreps DNA Purification System (Promega), following the kit’s micro-
centrifugation protocol.  The concentration and purity of eluted DNA was measured 
with NanoDrop ND-1000 spectrophotometer at 260 nm and 280 nm wavelengths. The 
260:280 ratios of the DNA preparations were typically between 1.80 – 1.93.   The DNA 
was stored at -20°C. When DNA was needed for large-scale transfection a maxi-
preparation of Plasmid DNA was used. 
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2.11 Maxi-preparation of Plasmid DNA from Overnight Cultures 
Plasmid maxi preparation was done using Plasmid Maxi Kit (QIAGEN). As a starter 
culture, 1 µl from overnight culture was diluted in 5ml LB medium containing 
100µg/ml ampicillin and incubated for approx. 8 h at 37°C with vigorous shaking 
(approx. 250 rpm). The culture was diluted 1/500 and inoculated in 500 ml LB medium 
containing 100µg/ml ampicillin. It was grown at 37°C for 12–16 h with vigorous 
shaking (approx. 2500 rpm). The DNA was then purified following the kit’s protocol.  
 
2.12 Restriction Digests 
Once plasmid DNA has been purified from E. coli a diagnostic restriction digest was 
used for verifying the correctness of the DNA. All restriction enzymes used in this 
report were purchased from New England Biolabs. The digestion reactions were 
performed strictly following each restriction enzyme’s recommended buffer and 
conditions. The restriction enzyme cutting site/sites on the template DNA and the 
expected band/bands sizes after the digest were estimated using NEBcutter V2.0 
(http://tools.neb.com/NEBcutter2). This tool takes a DNA sequence and finds the large, 
non-overlapping open reading frames using the E.coli genetic code and the sites for all 
commercially available restriction enzymes that cut the sequence. When double 
restriction digest was required (as common timesaving procedure), Double Digest 
Finder (http://www.neb.com/nebecomm/DoubleDigestCalculator.asp) was used, which 
selects reaction conditions amenable to any two NEB restriction enzymes. When 
performing a diagnostic restriction digest, 4 units of enzymes were sufficient to digest 
500ng of DNA. The digestion of DNA for subsequent cloning required 10 units of 
enzyme for 2 µg of template DNA. Products of restriction digestions were separated by 
gel electrophoresis. 
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2.13 Agarose Gel Electrophoresis 
DNA resulting from PCR and restriction digestions was separated by electrophoresis on 
1% agarose gels. 1.5g agarose (Bioline) were dissolved in 150ml 1 x TBE by heating.  
The molten gel was allowed to cool before addition of 0.5 µg/ml ethidium bromide 
(Sigma-Aldrich) and poured into a gel tray.  Once set, the gel was placed in an 
electrophoresis tank of 1 x TBE and the gel comb removed. Samples pre-mixed with 
Gel Loading Dye, Blue (6X) (New England Biolabs) were applied to wells, alongside a 
molecular weight marker, and run through the gel at 130V for approximately 45 
minutes.  DNA bands were visualised by exposure to UV light and photographed using 
a Syngene Gene Genius Bioimaging System (Cambridge, UK). However, when DNA 
resulting from PCR or Restriction Digestion was meant to be used for a ligation 
reaction, SeaKem® GTG® Agarose (VWR International) was used for DNA 
separation. 
 
2.14 DNA Molecular Weight Markers 
1 kb DNA ladder  (New England Biolabs) and 100bp DNA ladder  (New England 
Biolabs) were used to estimate the size of DNA fragments separated by gel 
electrophoresis (Figure 2.1).  As each DNA fragment of the ladders were of known 
concentration, the markers could also be used to estimate the quantity of DNA in 
sample bands by intensity comparisons. Prior to first use these ladders were mixed with 
MilliQ water and an appropriate volume of Gel Loading Dye, Blue (6X) (New England 
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 Figure 2.1:  DNA ladders. Ladders visualized by ethidium bromide staining on a 0.8% 
TAE agarose gel. Mass values are for 0.5 µg/lane. a) 1 kb DNA Ladder; b) 100bp DNA 
Ladder. Images from www.neb.com . 
 
2.15 DNA Sequencing Reactions 
Once the diagnostic restriction digest had shown the correct bands, the DNA was 
sequenced using specific forward and/or reverse primer/s.  5µl plasmid DNA at 
100ng/µl concentration and 5 µl primer at 3.2pmol/µl were used.  Sequencing reactions 
were forwarded to the Geneservice (Source BioScience, Cambridge, UK) for processing 
on an Applied Biosystems 3730 DNA Analyzer. The data was emailed back to me and 
analysed on MacVector (V12.6) 
 
2.16 PCR 
Phusion™ Flash High-Fidelity PCR Master Mix (New England Biolabs) was used for 
general PCR procedures. The unique composition of Phusion Flash PCR Master Mix 
enables the use of extremely short PCR protocols (15 s/1 kb) with both low and high 
complexity DNA templates. The Master Mix contains all reagents required for PCR 
    A                                         B 
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except for the DNA template and primers. 20µl reactions were set up in which the 
primers were each used at 0.5µM. Reactions were initially denatured at 98°C for 2 
minutes, followed by 30 cycles of 98°C denaturation for 30 seconds, annealing at 59°C 
for 30 seconds, extension at 72°C for 30 seconds and final extension at 72°C for 1 
minute, then a hold at 4°C.  PCR products were analysed by gel electrophoresis. 
 
2.17 Colony PCR 
Transformant colonies were analysed by PCR to ensure they had correctly taken up the 
plasmid DNA.  This is very quick strategy and especially useful after a ligation reaction, 
giving the opportunity to quick-check the ligated insert and its orientation (when single 
restriction site has been used). It involves the use of a forward primer specific to the 
insert and a reverse primer with specificity to a portion of the vector, then adding a 
small amount of the selected single colony to act as a template. The following steps in 
this method are the same as for general PCR, except an initial 5 minutes denaturation.  
 
2.18 DNA Gel Extraction and PCR Clean-Up 
Restriction digest products of the appropriate size, used for subsequent cloning, were 
visualized by a long-wavelength UV lamp (as normal one would damage the DNA) and 
excised from SeaKem agarose gels using a razor blade.  The masses of the gel slices 
were determined and the DNA purified using a Wizard® SV Gel and PCR Clean-Up 
System (Promega), following the kit’s centrifugation protocol.  The concentration of 
eluted DNA was measured with a NanoDrop ND-1000 Spectrophotometer and stored at 
-20°C. 
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2.19 Ligation reactions 
All ligations were predominately carried out with inserts in excess to vectors. Typically, 




utilising the Quick Ligation Kit (New England Biolabs) according to manufacturer’s 
recommendations. DNA extractions on transformed clones were typically carried out 
with a Wizard Plus SV Minipreps DNA Purification System (Promega). Positive clones 
were determined by diagnostic restriction digest followed by sequencing.  
 
2.20 Cell lines 
All cells were maintained in a 5% CO2 humidified incubator at 37oC. 
 
HEK293E – Human Embryonic Kidney (HEK) 293, expressing the Epstein-Barr Virus 
nuclear antigen-1 (EBNA-1) (Durocher et al., 2002), were cultured in DMEM, 10% 
FBS, 1% Penicillin-Streptomycin-Glutamine and 250 µg/ml G418 to maintain selection 
of transfected EBNA-1 plasmid, and kept between 1 – 9 x 105 cells/ml. 
 
293-F - Human Embryonic Kidney (HEK) 293-F Suspension FreeStyleTM cells (Life 
Technologies) were cultured in FreeStyleTM 293 Expression Medium.  
 
RBL-SX38 – Cells of the Rat Basophilic Leukaemia (RBL) cell line, expressing both 
human and rat FcεRI (Dibbern et al., 2003), were cultured with MEM, 10% FBS, 1% 
Penicillin-Streptomycin-Glutamine and 1 mg/ml G418 and kept between 1 – 8  x 105 
cells /ml.  
ng of vector x kb size of insert        x           Molar ratio of insert/vector 
kb size of vector 
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U-937 - This non-adherent human monocyte-like cell line was also kindly provided by 
Professor J.P Kinet (Harvard University, Boston, MA, USA). Cells were maintained in 
RPMI 1640 media with standard additives at a density between 2 x 105 to 2 x 106 
cells/mL. Where U937 cells were cultured in IL-4, this involved supplementation of the 
standard culture media with 320 U/mL recombinant human IL-4, four days prior to 
experiments. 
 
A375 – Human Melanoma cell line, naturally expressing High Molecular Weight 
Melanoma Associated Antigen (HMW-MAA) (CRL-1619, ATCC, Manassas, VA) was 
grown in Dulbecco’s Modified Eagles Media (DMEM) supplemented with10% FCS, 2 
mM L-glutamine, penicillin (5000 U/mL) and streptomycin (100 µg/mL).  
 
2.21 Thawing Adherent Cells 
The following protocol has been designed to thaw adherent cells to initiate cell culture. 
All cell lines are supplied in vials containing 5 x 106 cells in 1 ml of Freezing Medium. 
The vial of cells was taken out from the liquid nitrogen and thawed quickly in a 37°C 
water bath. Just before the cells are completely thawed, the outside of the vial was 
decontaminated with 70% ethanol, and transferred to a 15 ml centrifuge tube containing 
9 ml of culture medium. The cells were centrifuged for 5 minutes at 1000 rpm in Sorval 
RT 5000D centrifuge, fitted with the H1000B rotor. The medium was poured out and 
cells resuspended with 15 ml of fresh medium. They were transferred to a T-75 flask 
and incubated overnight in a humidified, 37°C, 5% CO2 incubator. The next day 
selection agent was added to the flask to maintain selection of transfected plasmid 
(where required) at previously determined concentration. Cells were checked daily until 
80-90% confluent and then passaged. 
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2.22 Passaging Adherent Cells 
When cells were ~80-90% confluent, the medium was removed from the flask and the 
cells washed once with 10 ml PBS to remove excess medium and serum ( as serum 
contains inhibitors of trypsin). A minimal amount of TrypLE™ Trypsin (Invitrogen) 
was used to coat the flask surface and incubated for 5 minutes at 37°C. The cells were 
observed under a microscope and it was confirmed that most of them had detached. If 
cells were not detached, longer incubation was needed. 10 ml of fresh medium was 
added to stop trypsinization. The solution was pipetted up and down to break up clumps 
of cells and 1 ml (to split them at 1/10) was transferred to a new 75 cm2 flask and 14 ml 
fresh medium was added (with selection agent where required). Cells were incubated in 
a humidified, 37°C, 5% CO2 incubator until 80-90% confluent and then passaged again. 
 
2.23 Freezing Cells 
Before starting, freezing medium (90% FCS, 10% DMSO) was prepared and kept on 
ice. Cell were detached from the flask ( see Passaging Adherent Cells) and 10 ml of 
fresh medium was added. They were mixed, counted with haemocytometer (see 
Determination of Cell Numbers) and centrifuged for 5 minutes at 1000 rpm. The cells 
were then resuspended at a density of at least 5 x106 cells/ml in chilled freezing medium 
and 1 ml of the cell suspension was aliquoted into each cryovial. The cryovials were left 
in freezing box at -80°C. For ideal cryopreservation, the freezing rate should be a 
decrease of 1°C per minute. The next day the cryovials were transferred to liquid 
nitrogen for long-term storage. 
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2.24 Determination of Cell Numbers 
Cells were diluted five times to a volume of 20µl in 0.4% Trypan Blue (Sigma-Aldrich).  
The total volume was loaded onto a Neuberger Improved haemocytometer and the dead 
cells, identified by their blue colour due to uptake of Trypan Blue, were excluded from 
the count.  The recorded cell number was then multiplied by 5x104 to give the number 
of live cells per ml. 
 
2.25 Killing curve 
Killing curves on HEK293E and HEK293F cells were performed to optimize selection 
of stable transfectants using the following concentrations of Hygromycin:  0 µg/ml, 50 
µg/ml 100 µg/ml, 200 µg/ml, 300 µg/ml, 400 µg/ml, 500 µg/ml. The cells were seeded 
at low densities, targeting 50% confluence (typically 5 x 105/ml), in 24 well plates in 
culture media. Varying concentrations of Hygromycin were added after overnight 
incubation for the cells attachment. After 10 days, cell viability was assessed visually, 
using the dye-exclusion method with trypan blue. Dead (blue) and viable (transparent) 
cells were then quantified using the haemocytometer. The lowest concentrations of the 
mammalian selection drug that had < 10% viable cells were determined as the minimal 
killing concentration (MKC) and used subsequently.   
 
2.26 Transfection 
All transfections in this report were performed using Polyethylenimine (Boussif et al., 
1995) as transfection reagent. Polyethylenimine (PEI) was prepared as previously 
described (Smith K. et al., 2009) by dissolving 1 mg/ml PEI in 80ºC MilliQ water. It 
was left to cool down, and then the pH was adjusted to 7.2 with HCl. The solution was 
filter sterilized with a 0.45-mm syringe filter and stored at -20 ºC. The transfections 
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were performed as recommended (Durocher et al., 2002). Briefly, the procedure 
involves plating 2x105cells per ml of medium (containing FBS) the day before 
transfection. The next day, the medium is poured off and replaced with 90% (of the total 
volume) fresh medium (containing FBS) and the cells are left in the incubator. 10% of 
the final volume is used for transfection mixture. To the transfection mixture, fresh 
medium (FBS free), is added DNA and vortexed for 1sec. The PEI is then added and 
vortexed for 1sec. The solution is left for 15 min at room temperature. After the 
incubation time, the transfection mixture is added to the cells and mixed to ensure an 
equal distribution of DNA/PEI complexes. The cells are left in the incubator overnight 
and the volume of medium doubled the day after. Transfected cells were usually left in 
the incubator for 10-14 days. IgE detection was confirmed by anti-IgE ELISA.  
 
2.27 Anti-IgE ELISA 
Anti-IgE ELISA was used for detection of IgE and measurement of its production levels 
during the optimization of transfection conditions. The ELISA was performed as 
previously described (McCloskey et al., 2007). Briefly, plates were sealed for all 
incubations at 37oC, with the exception of overnight incubation, which was performed 
at 4oC. Plate washings were performed using an Anthos Fluido ELISA plate washer 
(Jencons PLS), programmed for 4 washes with ELISA wash buffer (see table 2.2). For 
IgE detection, Nunc flat-bottomed ELISA plates were coated with 100 µl/well rabbit 
polyclonal anti-human IgE (1:7000 dilution) in ELISA carbonate buffer (see table 2.1.2) 
and incubated overnight at 4oC. The plates were then flicked to remove the unbound 
coating antibody, blocked with 300 µl/well ELISA blocking buffer (see table 2.1.2) and 
incubated for 1 hour at 37ºC. Blocking buffer was removed by standard washing. Test 
samples were added to relevant wells in triplicate using appropriate dilutions (typically 
1 in 10 and 1 in 20) in 1% Marvel-PBS-T20. The IgE standard (WHO) was added in 2-
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fold dilutions (diluted in 1% Marvel-PBS-T20) down from 800 to 8 ng/ml, leaving the 
last well as blank. The plate was incubated for 2 hours at 37ºC, followed by standard 
washing.  Bound material was detected by the addition of HRP-conjugated secondary 
anti-human IgE antibody (Sigma) diluted 1:2000 in 1% Marvel-PBS-T20 (100 µl/well, 
2 hour at 37oC). After washing, 50 µl/well of OPD Buffer (see table 2.1.2) were added 
and left for colour development in the dark at room temperature for around 15 minutes 
(or untill the yellow colour was vesible). Colour development was terminated by 
addition of 3 M HCl (50 µl /well). Absorbance of each well was measured at 492 nm 
using an automatic ELISA plate reader (Titertek Multiskan, Flow) linked to the Ascent 
software.  
 
2.28 Processing Supernatants 
Once IgE has been detected by Anti-IgE ELISA and the expression level was high 
enough to continue with the purification process after 10-14 days of incubation, the 
culture supernatants were collected and filtered using vacuum Stericup filter devices 
(Millipore). After addition of sodium azide (0.1% final concentration) the supernatants 
were left at 4ºC or directly applied to affinity chromatography. 
 
2.29 Affinity chromatography 
Purification of IgE isotype antibodies were performed using an IgG4-Fc-(sFcεRIα)2  
fusion protein (Shi et al., 1997). The fusion protein was expressed and purified as 
previously described (Shi et al, 1997) and amine coupled to 5ml HiTrap NHS-activated 
HP column (GE Healthcare) according to the manufacturer’s instructions. All 
purifications were performed using an ÄKTA Prime system (Amersham, Uppsala 
Sweden)All affinity chromatography purifications of IgE were performed using an 
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automated apparatus fitted with a peristaltic pump (ÄKTA Prime), passing fluid over 
the column at 1 ml/min. The first steps involved washing the column with TBS, then 
passing the cell culture supernatant over the column to bind to FcεRIαγ. Captured 
antibody was then eluted with 0.2 M glycine, pH 2.5. The eluate was immediately 
neutralized with 1 M Tris, pH 8.6. The column was then re-equilibrated by cycling of 
PBS solution. In order to exclude any aggregated and/or degradation antibody products, 
size-exclusion chromatography was performed. 
 
2.30 Size-exclusion chromatography 
Size-exclusion chromatography was used for analysis and fractionation of the affinity 
column-purified antibodies. Fractionation was performed to isolate pure monomeric 
antibodies from oligomers and aggregated materials according to size. Aggregated 
molecules and contaminants passed through the porous bead matrix faster, followed by 
dimers, monomers, and finally, degradation products, which are trapped in the smaller 
pores of the matrix. Gel filtration was performed on a Gilson HPLC system using the 
Superdex™ 200 column (Amersham Pharmacia Biotech), which is suitable for 
separating proteins between 10 – 600kDa. Fractions were collected between 10 to 20 
minutes.  
 
2.31 Protein concentrating and buffer exchange 
Fractions of monomeric, dimeric, and polymeric antibodies were pooled together, and 
concentrated using Amicon® Ultra-15 centrifugal filter devices (Millipore). The devices 
contain cellulose membranes with a molecular cut off at 30 kDa. Purified IgE 
preparations were spun in refrigerated centrifuge for 4000 rpm, until the antibody 
volume was concentrated to approximately 200 µl. Buffer exchange to PBS was 
performed by adding PBS onto the filter unit, and re-concentrating. Antibody 
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concentration (mg/ml) was measured with NanoDrop ND-1000 Spectrophotometer at 
280 nm wavelength. Antibody purity was then assessed on SDS-PAGE. 
 
2.32 Protein sample preparation for SDS PAGE 
Prior to PAGE analysis, 3.1µl β-mercaptoethanol was added in 31µl 5xSDS-Sample 
Buffer (see Table 2.2) for SDS-PAGE in reducing conditions. The protein dye was 
added, and the samples were denatured at 90°C for 2 minutes. The samples were then 
loaded on a gel. 
 
2.33 SDS-PAGE 
Antibody purity was assessed on SDS-PAGE using the discontinuous buffer system 
(Laemmli 1970). An 8-15% gradient gel was prepared according to a standard recipe 
(Maniatis et al., 1982). Atto system gel apparatus was used. The apparatus was filled 
with 400ml 1xSDS-PAGE Running Buffer (see Table 2.2). 1 – 2 µg of the protein 
samples in 10 – 20 µl solution was loaded, alongside 10 µl of either SeeBlue ™ Plus2 
pre-stained standard marker (Invitrogen), Spectra™ multicolor high range protein 
ladder (Fermentas) or the Protein ladder 10-250kDa (NEB). Samples were run at 120V, 
until the bromophenol dye was at the bottom of the gel plates. The plates were then 
separated, and the gel stained with Coomassie Blue staining solution (see Table 2.2) 
overnight before de-staining with Coomassie Blue destaining solution (see Table 2.2) 
for 20min for visualization of proteins.  
 
2.34 Flow cytometry 
For standard flow cytometric analysis 5 x 105 cells were used for each experiment. The 
cells were placed in 5ml FACS tubes and washed twice with 2mls FACS buffer. For 
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staining experiments, RBL-SX38 cells were resuspended in 200 µl of FACS buffer 
containing 1µg of IgE and left on ice for one hour. The tubes were then topped up with 
FACS buffer, followed by two washes with 2mls buffer. At last the buffer was removed 
and the tubes wiped out with paper towel. Cells were then incubated with anti-human 
IgE FITC (Dako), diluted 1:500 in FACS buffer (before each experiment), and left on 
ice for 45 minutes in dark. The secondary incubation was followed by two washes with 
2mls buffer and the cells were then resuspended in 500 µl buffer. Collection of Flow 
Cytometry data was conducted using a FACS CaliburTM (BD Biosciences), with gating 
on live cells determined by forward versus side scatter, and events analysed using 
CELLQuest™ (BD Biosciences). 
 
2.35 RNA Extraction from B cells 
RNAlater buffer was removed from the cultured B cells and replaced with 600µl RLT 
lysis buffer (Qiagen) containing 1% β-mercaptoethanol (Sigma-Aldrich).  The B cells 
were homogenised in the lysis buffer using a hand held cordless motor homogeniser 
(Anachem, Luton, UK).  RNA was purified from the homogenate using Qiagen’s 
RNeasy Protect Mini Kit; the homogenate was spun down for 3 minutes at 13000rpm in 
a microcentrifuge and the supernatant transferred to a fresh, RNase free tube.  600µl 
70% ethanol (BDH, Poole, UK) was mixed with the supernatant and the sample, 
including any precipitate formed on ethanol addition, applied to an RNeasy mini 
column in a 2ml collection tube.  The column was spun for 15 seconds at 10000rpm and 
the flow-through discarded.  700µl Buffer RW1 was then added to the column and spun 
through for 15 seconds at 10000rpm.  The flow-through and the collection tube were 
discarded at this point and the column placed in a new 2ml collection tube.  500µl 
Buffer RPE was added to the column and spun through for 15 seconds at 10000 rpm.  
The flow-through was discarded and an additional 500µl Buffer RPE placed on the 
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column.  This second wash was centrifuged for 2 minutes at 10000rpm to dry the 
column membrane.  RNA was eluted from the column by addition of 40µl RNase free 
water and centrifuging for 1 minute at 10000rpm.  RNA samples were stored at -70°C. 
 
2.36 cDNA Synthesis 
cDNA was generated from 0.5-5µg RNA using 400U Maloney Murine Leukaemia 
Virus Reverse Transcriptase (Invitrogen), 0.05ng random primers, 0.2ng oligo dT 
primers (both Promega), 0.4mM dNTPs (Invitrogen) and 8U RNase OUT (Invitrogen) 
in 1 x 1st strand buffer (Invitrogen) and 5mM DTT (Invitrogen).  The reaction mix was 
heated to 70°C for 2 minutes before addition of the RT on ice.  The whole reaction was 
then incubated at 37°C for 10 minutes, 42°C for 45 minutes and 50°C for 10 minutes.  
160µl nuclease free water was added to the completed reaction and incubated for 2 
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3 TRANSIENT ANTIBODY EXPRESSION SYSTEM 
 
3.1 Introduction  
Over the last decade, antibody-based immunotherapies have been developed to treat a 
variety of diseases. This has required the selection of recombinant antibodies with high 
affinity for the appropriate epitopes on the target antigen and other desirable 
characteristics, such as the antibody isotype and effector functions. The antigen-binding 
variable (V) regions of the heavy- and light-chains, are in fact the products of three gene 
segments, namely the VH, DH, and JH, for the heavy-chain, and two gene segments, 
namely the VL and JL, for the light-chain. During expression of the heavy-chain, one of 
each of multiple germline VH, DH and JH gene segments are joined tail to head to form 
the final complete VH coding DNA (Janeway et al, 2001). Thus the heavy-chain V-
region coding sequence can occur in various combinations of VDJ, which generates the 
combinational diversity of antibodies, together with the VL, which is assembled in the 
same way, except for the absence of the D- genes (Janeway et al, 2001). 
 
Large cDNA libraries of the V gene segments of antibodies are frequently generated in 
the study of immune disorders that involve B-cells, such as autoimmune diseases 
(Foreman et al, 2007), allergy and asthma (Coker et al, 2003; Coker et al, 2005; Janezic 
et al, 1998; Snow et al, 1995; Snow et al, 1997; Snow et al, 1999) or cancer (Bende et 
al, 2002; Küppers et al, 1996; Tobin, 2005; Tobin et al, 2006). While this provides an 
insight at the genetic level, the antigen binding and effector function may only be 
elucidated from the expressed antibody. Similarly, large libraries of V gene segments 
may be generated during phage display. This is an in-vitro technology, in which the V 
genes are usually expressed as Fab or scFv antibody fragments and screened to identify 
antigen specificity (Hoogenboom, 2005). In this case, a method for rapid reformatting 
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as full-length antibodies would be highly beneficial in order to evaluate their biological 
function.  
 
Conventional methods for recombinant expression of whole antibodies of interest 
typically requires the establishment of cell lines derived from CHO, mouse myeloma or 
PER.C6 cells (Bebbington et al, 1992; Filpula, 2007; Jain et al, 2007; Jones et al, 2003; 
Maynard & Georgiou, 2000; Zafir-Lavie et al, 2007). This tends to be a lengthy, low 
efficiency process involving extensive selection and screening and is consequently 
unfavourable for expressing large numbers of antibodies for functional studies, as may 
be required after generating a variable gene library. Therefore, our group aimed to 
design and develop a novel cloning methodology involving a cassette that allows 
exchange of both the variable and constant domain genes and facilitates the recombinant 
expression of a large number of antibodies.  Tailoring the cassette for use in a vector 
suitable for transient transfection in mammalian HEK293E cells would enable rapid 
antibody production (Baldi et al, 2005; Berntzen et al, 2005; Li et al, 2007; Wright et al, 
2003) in quantities sufficient to assay their biological characteristics. A HEK293E 
system for the expression of variable genes isolated from single cells e.g., human IgG1, 
has been described previously, which introduced restriction sites into the 5’ and 3’ ends 
of the variable domains of the heavy and light chain to enable ligation into vectors 
containing human Cγ1, Cκ1 or Cλ2 genes, as appropriate (Tiller et al, 2008).  However, 
the restriction sites used are not compatible with all human constant gene isotypes. 
Moreover, a murine Ig gene secretary leader directed the protein secretion in each of 
these vectors.  In attempt to tackle this problem, our group sought to generate a system 
with improved flexibility in which a human/chimeric antibody of any isotype and 
specificity could be expressed, utilising human IgH, Igκ or Igλ specific secretary 
leaders. Three cloning cassettes coding for either IgH, Igκ or Igλ chain expression have 
- 58 - 
been designed.  In each cassette, a restriction site has been introduced by silent mutation 
into the junction between chain specific secretary leader and V gene. An additional 
restriction site was also introduced at the junction between V gene and C gene (Figure 
3.1), to allow easy exchange of variable/constant domain genes by restriction enzymes 
and ligase-dependent cloning.  For the heavy chain (IgH) cassette, BssHII restriction 
site was introduced by silent mutation into the VH 1-02 secretary leader sequence, SacII 
was introduced into the Vκ A26 secretary leader sequence of the Igκ cassette and SalI 
was introduced into the Vλ8a leader sequence of the Igλ cassette. Similarly, NheI was 
introduced into VH-CH domain boundary, BsiWI into the Vκ-Cκ boundary and AvrII 
into the Vλ-Cλ boundary. The restriction site combinations are compatible with all 
human C gene isotypes and all known human and murine antibody framework regions.   
 
The designed cassettes were subsequently ligated into vector pTT3 (Durocher et al, 
2002) and the generated vectors named pSGH, pSGK and pSGL, coding for the 
expression of IgH, Igκ and Igλ, respectively (Figure 3.2). The final transient expression 
system thus employs a two-vector system (Fouser et al, 1992; Wood et al, 1990) or a 
co-transfection of pSGH and pSGK/pSGL vectors. The latter utilises polyethylenimine 
(PEI) (Boussif et al, 1995) as transfection reagent for DNA incorporation into 
HEK293E cells (Durocher et al, 2002). 
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Figure 3.1: Schematic representation of restriction sites within pSG vectors. 
Restriction sites positioned by silent mutations into the junctions between chain specific 
secretary leader and variable heavy (A), variable kappa (B) or variable lambda gene (C), 
and between variable genes and constant heavy (D), constant kappa (E) or constant 





               M   D   W   T   W   R   I   L   F   L   V   A   A   A   T   G   A   H   S 
                    
    VH 1-02:  ATG GAC TGG ACC TGG AGG ATC CTC TTC TTG GTG GCA GCA GCC ACA GGA GCC CAC TCC 
 
       1-02:  ATG GAC TGG ACC TGG AGG ATC CTC TTC TTG GTG GCA GCA GCC ACA GGC GCG CAC TCC 




               M   L   P   S   Q   L   I   G   F   L   L   L   W   V   P   A   S   R   G 
Vk lead A26:  ATG TTG CCA TCA CAA CTC ATT GGG TTT CTG CTG CTC TGG GTT CCA GCC TCC AGG GGT 
 
        A26:  ATG TTG CCA TCA CAA CTC ATT GGG TTT CTG CTG CTC TGG GTT CCA GCC TCC CGC GGT 





              M   A   W   M   M   L   L   L   G   L   L   A   Y   G   S   G   V   D   S 
 Vλ lead 8a:  ATG GCC TGG ATG ATG CTT CTC CTC GGA CTC CTT GCT TAT GGA TCA GGA GTG GAT TCT 
 
        8a:  ATG GCC TGG ATG ATG CTT CTC CTC GGA CTC CTT GCT TAT GGA TCA GGA GTC GAC TCT 




                 V   T   V   S   S   A   S 
      JH-IgA2:  GTC ACC GTC TCY TCA GCA TCC 
 
       JH-IgE:  GTC ACC GTC TCY TCA GCC TCC 
 
      JH-IgG1:  GTC ACC GTC TCY TCA GCC TCC 
    
      JH-IgG2:  GTC ACC GTC TCY TCA GCC TCC 
 
      JH-IgG3:  GTC ACC GTC TCY TCA GCT TCC 
 
      JH-IgG4:  GTC ACC GTC TCY TCA GCT TCC 
 
       JH-IgH:  GTC ACC GTC TCG AGC GCT AGC 





                I   K   R   T   V   A   A   P   S 
       Jk-Ck:  ATY AAA CGA ACT GTG GCT GCA CCA TCT 
 
       Jk-Ck:  ATY AAA CGT ACG GTG GCT GCA CCA TCT 





                                 T   V   L   G   Q   P   K   A   A   P   S   V   T 
        JL-CL:  ACC GTC CTM GGT CAG CCC AAG GCT GCC CCC TCG GTC ACT 
 
        JL-CL:  ACC GTC CTA GGT CAG CCC AAG GCT GCC CCC TCG GTC ACT 
                       AvrII                    
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To demonstrate the capacity of our transient expression system to make fully functional 
antibodies, I have expressed and characterised previously cloned IgEs in our laboratory.  
To further establish the system’s versatility to swap variable regions, I have cloned, 
expressed and characterised a High Molecular Weight Melanoma-Associated Antigen 
(HMW-MAA) specific IgE.  
 
Figure 3.2: Schematic representation of pSGH and pSGK vectors. Transient 
expression vectors pSGH and pSGK consisting of pTT3 vector backbone, VH 1-02 
secretory leader and immunoglobulin Epsilon (blue) heavy chain expression cassette 
and Vκ A26 secretory leader and immunoglobulin Kappa (red) light chain expression 
cassette respectively, for the co-transfection and production of IgE. 
 
 
It is accepted that antigen-cross-linked IgE triggers signalling, and activates mast cells 
and basophils through FcεRI aggregation. However, this long-held dogma was 
challenged in 2001, when two research groups working on rodent mast cells reported 
that monomeric IgE, in the absence of known antigen, was able to elicit mast cell 
Figure 3.2: Sche atic represe tation of pSGH nd pSGK vectors. Transient 
expression vec  pSGH consist ng of pTT3 vector backbone, VH 1-02 secr tory leader 
and immunoglobulin Epsilon (blue) heavy chain expression cassette, alongside with 
vector pSGK consisting of pTT3 vector backbone, VK A26 secretory leader and 
immunoglobulin Kappa (red) light chain expression cassette for the co-transfection and 
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survival (Asai et al, 2001; Kalesnikoff et al, 2001). These IgE molecules exhibited 
different antigen-independent activities in promoting mast cell survival and cytokine 
production and were later named cytokinergic IgEs. Based on the cytokinergic activity 
elicited by the IgE molecules, an operational classification of ‘highly cytokinergic’ 
(HC) and ‘poorly cytokinergic’ (PC) was used (Kitaura et al, 2003). The cytokinergic 
IgE phenomenon has not been a part of my studies and is therefore not reported in this 
thesis. However, as cytokinergic IgEs have been cloned, expressed and characterised in 
our laboratory (Gan, 2008), I have used them as a model for my studies and as a 
standard for further optimisations of the transient antibody expression system. 
 
3.2 Methods 
3.2.1 Transient transfection and expression of cytokinergic IgEs 
pSGH and pSGK/pSGL vectors coding for the expression of cytokinergic IgEs (Gan, 
2008) were transformed into XL1-Blue competent cells (Stratagene) according to the 
manufacturer’s instructions. Single colonies were picked for each clone and inoculated 
in 5mls LB broth (Invitrogen) supplemented with 100µg/ml ampicillin (Sigma).  After 
overnight culture at 37°C with shaking at 200rpm, bacteria were harvested and plasmid 
DNA purified with a Wizard Plus SV Minipreps DNA Purification System (Promega). 
Following sequencing confirmation of the heavy and light chain expression cassettes 
using pTT3-F and pTT3-R primers (Table 2.2), each confirmed colony was inoculated 
in 500ml LB broth containing 100µg/ml ampicillin and cultured overnight at 37°C with 
shaking at 200rpm. The plasmid DNA was purified from the inoculated cultures using a 
HiSpeed Plasmid Maxi Kit (Qiagen) according to the manufacturer’s instructions. 
The human embryonic kidney cell line HEK293E (ATCC no CRL-1537) was seeded at 
2 x 105 cells per ml in DMEM High Glucose supplemented with 10% FCS, 2mM 
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glutamine 10U penicillin / streptomycin and 250µg/ml Geneticin (all Invitrogen) onto 
500cm2 triple layered flasks (Nunc) to a final volume of 250ml and cultured overnight 
at 37°C, 5% CO2.  Cells were transiently transfected following S. Gan’s protocol using 
a 2:1 ratio of polyethylenimine (PEI) (Sigma) to DNA and a 4:1 ratio of pSGK/pSGL 
(expressing kappa/lambda light chain) to pSGH (expressing heavy chain). To produce 
0.5-4mg of each cytokinergic IgE antibody (based on previously reported expression 
levels), four 500cm2 triple layered flasks with adherent seeded cells had to be 
transfected for a final volume of 1L. For each triple layered flask, 500µg PEI was mixed 
with 200µg pSGK/pSGL and 50µg pSGH in 15ml serum free DMEM and incubated for 
15 minutes at room temperature.  Media from the overnight culture was replaced with 
235ml fresh DMEM High Glucose plus 10% FCS, 2mM glutamine 10U penicillin / 
streptomycin and 250µg/ml Geneticin and topped up to 250ml with the pre-incubated 
15ml transfection mix.  After a second overnight culture, the media was again replaced 
with 250ml fresh DMEM High Glucose supplemented with 10% FCS, 2mM glutamine 
10U penicillin / streptomycin and 250µg/ml Geneticin and the cells were left in culture 
for antibody expression. Following 20 days incubation, the media was harvested and 
centrifuged at 1000 x g for 15 minutes to pellet cell debris.  Supernatants were passed 
over 0.45µm filters (Sartorius) and stored at 4°C with 0.1% sodium azide (Sigma) till 
further analysis/use.  
 
3.2.2 Affinity purification  
IgEs were purified on AKTA prime system. The affinity column was equilibrated with 
10 CV (Column Volumes) of phosphate buffered saline (PBS) washing buffer (pH 7.0, 
0.45 µm filtered). The supernatants were loaded onto the column at a flow rate of 2 
ml/min and the column washed with 10 CV washing buffer. Captured IgE was eluted 
with 0.2M Glycine, pH 2.5 and 2.5 ml fractions were collected into tubes containing 0.5 
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ml 1M Tris–HCl pH 8.6 for neutralisation. The column was re-equilibrated with 10 CV 
washing buffer. 
3.2.3 Gel filtration 
Gel filtration was performed on a Gilson HPLC system using a Superdex™ 200 10/300 
GL column (Amersham, Uppsala Sweden), suitable for purifying proteins between 10 – 
300kDa, at a flow rate of 0.75 ml/min in PBS pH 7.0 and fractions collected between 10 
to 30 minutes. 
3.2.4 Cloning of HMW-MAA IgE expression constructs  
Previously described high-affinity murine IgG2a monoclonal antibody 225.28S (Natali 
et al, 1984) specific for the HMW-MAA, has been cloned in single-chain Fv 
configuration (scFv) for soluble expression in bacteria, showing conserved binding 
specificity of the parental antibody (Neri et al, 1996). The specific DNA antibody 
variable sequences for the heavy and light chains published by Neri et al (1996) were 
analysed using sequence alignment software 
(http://www.imgt.org/IMGT_vquest/share/textes/) for alignment of the V- J genes and 
allele identification. Once the first and last amino acids of the variable regions have 
been identified, restriction sites (according to our pSGH and pSGK cassettes) were 
designed to flank the variable sequences for subsequent cloning. BssHII restriction site 
(present in the VH 1-02 leader in pSGH vector) has been integrated together with the 
rest of VH 1-02 leader at the N-terminal of the variable heavy chain region and NheI 
restriction site integrated at the C-terminal. The variable light chain region was treated 
equally integrating SacII site (present in the Vκ A26 leader in pSGK vector) together 
with the rest of VK A26 leader at the N-terminal of the variable light chain region and 
BsiWI at the C-terminal. The amino acid sequence corresponding to variable heavy 
chain region (5’-
AHSQVKLQQSGGGLVQPGGSMKLSCVVSGFTFSNYWMNWVRQSPEKGLEWI
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AEIRLKSNNFGRYYAESVKGRFTISRDDSKSSAYLQMINLRAEDTGIYYCTSYG
NYVGHYFDHWGQGTTVTVSSAS-3’) and variable light chain region (5’-
RGDIELTQSPKFMSTSVGDRVSVTCKASQNVDTNVAWYQQKPGQSPEPLLFSA
SYRYTGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGGGTKLEI
KRT-3’) were then synthesised (Geneart, Germany) using human codon optimisation. 
5µg of plasmid DNA, containing the variable heavy and light chain regions ligated in 
ampicillin-resistant holding vectors from Geneart were diluted into 50 µl MilliQ water. 
1 µl of the diluted DNA was transformed into XL1-Blue Competent Cells (Stratagene) 
according to the manufacturer’s instructions. Plasmid DNA from overnight cultures was 
purified using a Wizard Plus SV Minipreps DNA Purification System (Promega) and 
subjected to restriction digests (New England Biolabs). 2 µg of variable heavy region 
DNA was initially digested with 10 units NheI for 2 hours in 25 µl total reaction volume 
and subsequently digested with 10 units BssHII for 2 hours in 50 µl total reaction 
volume according to the manufacturer’s instructions. Simultaneously, 2 µg of variable 
light region DNA was initially digested with 10 units SacII for 2 hours in 25 µl total 
reaction volume and subsequently digested with 10 units BsiWI for 2 hours in 50 µl 
total reaction volume. The digested DNA was resolved on a 1% SeaKem Agarose gel 
and gel purified using Wizard® SV Gel and PCR Clean-Up System (Promega). 
Meanwhile, 2 µg of the expression vectors pSGH (expressing heavy chain) and pSGK 
(expressing light chain) were digested with NheI-BssHII and SacII- BsiWI respectively. 
The digested pSG vectors were heat inactivated for 20 minutes at 80ºC and treated with 
Antarctic Phosphatase (New England Biolabs) according to the manufacturer’s 
instructions, following another heat inactivation for 5 minutes at 65ºC. The Antarctic 
Phosphatase removes 5' phosphates from the digested DNA, and thus prevents 
recircularisation of cloning vectors. The purified variable region DNAs and linearised 
pSGH and pSGK were then ligated utilising the Quick Ligation Kit (New England 
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Biolabs) according to manufacturer’s instructions and 2 µl of each ligation reaction 
were transformed into XL2-Blue Ultracompetent Cells (Stratagene). Single colonies 
were picked for each clone and inoculated in 5mls LB broth (Invitrogen) supplemented 
with 100 µg/ml ampicillin.  After overnight culture at 37°C with shaking at 200rpm, 
bacteria were harvested and plasmid DNA purified with a Wizard Plus SV Minipreps 
DNA Purification System (Promega). Following sequencing confirmation of the heavy 
and light chain expression cassettes using pTT3-F and pTT3-R primers, the generated 
vectors were named pSGH-MAA and pSGK-MAA. Each confirmed colony was 
subjected to Maxi preparations (see section 3.2) and the purified plasmid DNA used for 
subsequent transfections. 
3.2.5 Flow Cytometry 
Recombinant IgE was incubated with each cell line (A375 melanoma cells, primary 
human melanocytes, and RBL cells expressing both human and rat FcεRI (Dibbern et 
al, 2003)) for 30 min at 4oC, followed by two washes in PBS supplemented with 5% 
normal goat serum (FACS buffer). Cells were then incubated with anti-human IgE-
FITC (10 µg/mL) for 30 min at 4oC and washed with FACS buffer prior to acquisition 
and analysis on a FACSCantoTM (BD Biosciences) 
 
3.3 Results 
3.3.1 Transient expression of cytokinergic IgEs 
The transient antibody expression system has been shown to produce functional 
antibodies (Gan, 2008). However, the antibody expression levels have been insufficient 
to support animal model experiments for comparative functional studies of different 
antibody isotypes. To increase the antibody expression levels, as one of the main goals 
of my project, I was given the opportunity to study the system by transiently expressing 
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the cytokinergic IgEs. Given that the average expression levels of these antibodies have 
already been measured (Gan, 2008), the main aim of this part of the project was to 
obtain the previously expressed levels and if possible, exceed them. Concentrations of 
expressed IgEs (Figure 3.3) in culture supernatants were determined by anti-human IgE 
ELISA as described previously (McCloskey et al, 2007). As the expression levels of all 
tested cytokinergic IgEs, confirmed by ELISA, matched the previously reported 
expression levels, it enabled me to continue with the purification process and optimise 
the system for better yields. 
 
Figure 3.3: Quantification of transiently expressed IgEs. Anti-human IgE ELISA 
result-based comparison of antibody expression yields from transiently transfected 
HEK293E cells. The antibody concentration at mg/L was determined by reference to a 
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3.3.2 Optimisation of PEI : DNA ratio 
Ideally, to reach the highest antibody productivity, all cells should uptake and express 
the transgene DNA with minimal toxicity (e.g., all cells should survive after 
transfection) caused by the transfecting agent. Polyethylenimine (PEI) has previously 
been utilised for large-scale transfection in studies using HEK293E cells (Pham et al, 
2003). PEI was also characterised to have low cell toxicity and rapid efficient uptake by 
cells (Godbey et al, 2000; Godbey et al, 1999a; Godbey et al, 1999b; Godbey et al, 
1999c; Godbey et al, 1999d). For the purpose of this project, PEI also provided the 
option of scaling up the production of antibody, without being prohibitively costly. 
Although a 2:1 ratio of PEI : DNA   
 of VH4 heavy chain and HerVk1 light chain, respectively) DNA concentration constant 
at 1 µg/ml, was further carried out. HEK293E cells were transiently transfected with 
1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1 and 8:1 ratios of PEI : DNA and sample supernatants 
collected 5 days post-transfection for anti-human IgE ELISA analysis as described 
previously (McCloskey et al, 2007). Simultaneously, the cells were trypsinised and the 
cell viability estimated using Trypan blue exclusion method (Figure 3.4). Optimum cell 
viability and maximum antibody expression level within 5 days incubation period was 
found to be the best at 4µg PEI : 1µg DNA ratio. 
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Figure 3.4: Optimisation of PEI:DNA ratio for transient expression of antibodies. 
(A) Anti-human IgE ELISA result-based comparison of antibody expression yields. The 
antibody concentration at mg/L was determined by reference to a standard curve and the 
results represent the mean of triplicate readings ± SD. (B) Cell viability determined by 
cell count using Trypan blue exclusion method 5 days post-transfection.  
Figure 3.4: Optimisation of PEI:DNA ratio for transient expression of antibodies. 
(A) Anti-human IgE ELISA result-based comparison of antibody expression yields from 
transiently transfected HEK293E cells with increasing concentrations of PEI. Sample 
supernatants were collected 5 days post-transfection. The antibody concentration at mg/
L was determined by reference to a standard curve and the results represent the mean of 
triplicate readings ± SD. (B) Cell viability determined by cell count using Trypan blue 
exclusion method 5 days post-transfection. Optimum cell viability and maximum 









































































































































































- 69 - 
3.3.3 Optimisation of light : heavy chain DNA ratio 
Previous studies (Baldi et al, 2005; Schlatter et al, 2005) have shown an important role 
of light-chain expression in Ig production, suggesting a higher light-chain expression 
increases antibody production yield. To investigate this phenomenon and further boost 
the antibody production, optimisation of transfection conditions with HEK293E was 
then carried out to determine the most effective light : heavy chain ratio. HEK293E 
cells were transiently transfected with increasing concentrations of pSG-HerVk1 
(HerVk1 light chain) DNA, whilst keeping the pSG-VH4 (VH4 heavy chain) DNA 
concentration constant, limiting the total DNA concentration to 1 µg per ml of culture 
media, with previously optimised 4:1 ratio of PEI : DNA. Sample supernatants were 
collected 10 days post-transfection and the concentrations of IgE expression in culture 
supernatants (Figure 3.5) were determined by anti-human IgE ELISA as described 
previously (McCloskey et al, 2007). 
The ELISA analysis showed the highest antibody expression yield was present in 
cultures transfected with a 2:1 ratio of light : heavy chain DNA. This optimisation 
halved the DNA amount of the light chain previously used (4:1) to transfect cells, hence 
shortening the DNA production process. Therefore, subsequent HEK293E transfections 
were performed using 2:1 ratio of light : heavy chain DNA. 
 







- 70 - 
 
Figure 3.5: Optimisation of Light : Heavy chain DNA ratio for transient expression 
of antibodies. Anti-human IgE ELISA result-based comparison of antibody expression 
yields after 10 days incubation of transiently transfected HEK293E cells with increasing 
concentrations of light chain DNA. The antibody concentration at mg/L was determined 
by reference to a standard curve and the results represent the mean of triplicate readings 
± SD.  
 
3.3.4 Optimisation of media supplements 
Despite the successful use of HEK293E cells for antibody expression by large-scale 
transfection, the labour intensive procedure and the high cost / low yield characteristics 
of mammalian cell culture processes remain an important drawback. Therefore, I sought 
to optimise various production parameters and to increase the volumetric antibody 
productivity. Previous studies (Pham et al, 2005) reported the addition of Tryptone N1 
(a casein peptone, TN1) to the cell culture media 24 h post-transfection (hpt), led to a 2-
fold increase in protein production after 5 days incubation.  In addition, an Invitrogen 
product called Optimab, a monoclonal antibody production enhancer, has been 
previously shown to increase antibody production. I strove to maximise antibody yields 
following large-scale transfection by supplementing the culture media with Tryptone 
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(HerVk1 light chain) and pSG-VH4 (VH4 heavy chain) with previously optimised 2:1 
ratio of light : heavy chain DNA and 4:1 ratio of PEI : DNA, following 24h post-
transfection supplementation of the culture media with Optimab or Tryptone N1. 
Sample supernatants were collected after 12 days incubation and the antibody 
expression levels (Figure 3.6) were determined by anti-human IgE ELISA as described 
previously (McCloskey et al, 2007). 
 
The ELISA analysis showed a 4-fold decrease in antibody expression level in the 
cultures supplemented with Tryptone N1, suggesting the peptone depletion was not 
limiting antibody production yield in HEK293E cells (Figure 3.6). However, the 
Optimab supplementation represented a 2-fold increase in volumetric antibody 
productivity obtained 12 days post-transfection.       
 
 
Figure 3.6: Optimisation of media supplements for transient expression of 
antibodies. Anti-human IgE ELISA result-based comparison of antibody expression 
yields from transiently transfected HEK293E cells, following 24h post-transfection 
media supplementation with Optimab or Tryptone N1. The antibody concentration at 
mg/L was determined by reference to a standard curve and the results represent the 
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3.3.5 Purification of IgE antibodies 
The transiently expressed IgEs antibodies were purified by affinity chromatography 
using IgG4-Fc-(sFcεRIα)2  fusion protein, a soluble fragment of the high-affinity IgE 
receptor R-chain fused to the Fc region of IgG4. The fusion protein was expressed and 
purified as previously described (Shi et al, 1997) and amine coupled to 5ml HiTrap 
NHS-activated HP column (GE Healthcare) according to the manufacturer’s 
instructions. All purifications were performed using an ÄKTA Prime system 
(Amersham, Uppsala Sweden) (Figure 3.7).  
 
 
Figure 3.7: Affinity chromatography analysis of transiently expressed IgEs. Elution 
profile from affinity purification of transiently expressed IgE on a IgG4-Fc-(sFcεRIα)2 
fusion protein column by AKTA Prime. IgE is eluted by low pH in the 2nd and 3rd 
fractions. 
 
3.3.6 Size-exclusion chromatography of affinity purified IgEs 
Gel filtration/size-exclusion chromatography is a common polishing step, following 
affinity purification of recombinant antibodies. However, during purification of some 
IgE antibodies, aggregation was observed, where certain combinations of IgE displayed 
aggregative tendencies. Therefore, size-exclusion chromatography was used for analysis 
Figure 3.7: Affinity chromatography analysis of transiently expressed IgEs. 
Elution profile from affinity purification of transiently expressed IgE on a FcεRIαγ-
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and fractionation of the affinity column-purified IgEs as previously described (Hunt et 
al, 2005). Fractionation was performed to isolate pure monomeric antibodies from 
aggregated materials according to size. Aggregated molecules passed through the 
porous bead matrix faster, followed by monomers, which are trapped in the smaller 
pores of the matrix. The size-exclusion chromatography analysis confirmed the 
aggregation observed in some samples as a very small peak eluted between 12th and 14th 
minute. To purify monomeric IgE antibodies, only fractions eluted between 14th and 
16th minute were collected (Figure 3.8). 
 
 
Figure 3.8: Size-exclusion chromatography analysis of affinity purified IgEs. 
Elution profile of affinity purified IgE antibodies from Superdex™ 200 gel filtration. 
Single peaks (1) corresponding to aggregated products in some antibodies eluted 
between 12th and 14th minute from the start of the run; monomeric antibodies eluted 
between 14th and 16th minute. 
 
Figure 3.8: Size-exclusion chromatography analysis of transiently expressed 
IgEs. Elution profile of affinity purified IgE antibodies from Superdex™ 200 gel 
filtration. Single peaks (1) corresponding to aggregated products for some of the 
antibodies eluted between 12th and 14th minute from the start of the run; 
monomeric antibodies eluted between 14th and 16th minute. 
!


























- 74 - 
3.3.7 SDS-PAGE analysis of affinity purified IgEs 
Monomeric antibodies isolated from the size-exclusion chromatography were 
concentrated using Amicon® Ultra-15 centrifugal filter devices (Millipore) and 
subjected to Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-
PAGE). The SDS-PAGE of samples with identical charge per unit mass due to binding 
of SDS results in fractionation by size. 2µg of each purified IgE were loaded on 4-15% 
gradient gels under reducing and non-reducing conditions (Figure 3.9). Under non-
reducing conditions (Figure 3.9A), the purified IgEs were found as single bands 
between 180 kDa and 250 kDa of the Spectra™ multicolor high range protein ladder 
corresponding to the expected ~190 kDa whole IgE molecule. However, under reducing 
conditions (Figure 3.9B), single bands were found at 25 kDa of the Protein ladder 10-
250kDa (NEB) corresponding to the antibody light chains (25 kDa) and single bands 
found at 80 kDa possibly corresponding to glycosylated forms of the antibody heavy 
chains (~60 kDa). 
None of the purified antibodies showed significant contamination with other proteins, as 
judged by the absence of bands of molecular weight inconsistent with those expected 
for an IgE antibody polypeptide chain. This demonstrated that the affinity column 
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Figure 3.9: SDS-PAGE analysis of affinity purified IgEs. Affinity purified antibodies 
analysed under reducing and non-reducing conditions and visualised by Coomassie 
staining. (A) Antibodies analysed under non-reducing conditions, alongside with 
Spectra™ multicolor high range protein ladder, showing a single band corresponding to 
the ~190 kDa expected to whole IgE molecule. (B) Antibodies analysed under reducing 
conditions, alongside with Protein ladder 10-250kDa (NEB), showing 25kDa light 
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an ibodies were a alysed under non-reducing conditions (A), along ide with Spectra™ 
multi olor high range protein ladder, and re ucing conditions (B), longside with Protein 
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3.3.8 Receptor-binding activity of affinity purified IgEs  
To assess the functionality of the transiently expressed and affinity-purified antibodies, 
I tested the receptor-binding activity of IgEs. For the purpose, RBL-SX38 cells 
expressing both human and rat FcεRI (Dibbern et al, 2003) were incubated with the 
purified IgEs and subsequently stained with anti-human IgE FITC (Dako). Collection of 
flow cytometry data was conducted using a FACS CaliburTM (BD Biosciences), with 
gating on live cells determined by forward versus side scatter, and events analysed 
using FlowJo (Treestar). The flow cytometry analysis (Figure 3.10) of RBL-SX38 cells 
incubated with three of the purified IgEs shows a clear right shift of fluorescence 




Figure 3.10: Receptor-binding activity of affinity purified IgEs. Flow cytometric 
histograms showing fluorescent intensity of RBL-SX38 cells incubated with affinity 
purified IgEs plus FITC-labelled anti-human IgE (filled in grey) and RBL-SX38 cells 
alone (not filled) against the number of cells. The IgE-Fc fragments of the purified 






Figure 3.10: Receptor-binding activity of transiently expressed IgE. Flow cytometric 
histograms showing fluorescent intensity of RBL-SX38 cells incubated with affinity 
purified IgEs plus FITC-labelled anti-human IgE (filled in grey) and RBL-SX38 cells alone 
(not filled) against the number of cells. The IgE-Fc fragments of the purified antibodies 















Figure 3.23: Flow cytometric histograms showing HMW-MAA-IgG binding. Binding of HMW-
MAA-IgG to A375 melanoma tumour cells (left) and U937 monocytic cells (right). Antibody 




Figure 3.24:  Immunocytochemical confirmation of binding of HMW-MAA-IgE and IgG1 
antibodies to A375 melanoma tumour cells. Isotype control was a hapten specific IgE 
antibody (NIP IgE). Antibodies bound to tumour cells were detected using a goat anti-human 
IgE-FITC antibody. Images were captured using a 63x oil objective. Scale bar = 20 µm. 
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3.3.9 Swapping variable regions within pSG vectors 
The superiority of the IgE isotype over IgG1 in cancer immunotherapy has been 
demonstrated in murine models (Gould et al, 1999; Karagiannis et al, 2003). We aim to 
test this hypothesis further by developing IgE isotypes of melanoma-specific and other 
anti-tumour antibodies (described in details in Chapter 5). The first example, also used 
as a control for our antibody discovery program (described in details in Chapter 6), was 
the conversion of an existing IgG against a melanoma-specific antigen, the High 
Molecular Weight Melanoma-Associated Antigen (HMW-MAA), into IgE.  
Having successfully expressed, purified and characterised the previously cloned 
cytokinergic IgEs, I strove to study the versatility of the cloning cassette to exchange 
variable regions and to demonstrate the capacity of the expression system to make fully 
functional antibodies. As an example, I have exchanged the existing V genes from 
pSGH and pSGK with those specific for the HMW-MAA, utilising the BssHII and NheI 
restriction sites in the heavy chain cassette and SacII and BsiWI in the light chain 
cassette (Figure 3.11). The sequencing confirmation of the newly generated pSGH-
MAA and pSGK-MAA vectors demonstrated an effective exchange of the variable 
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Figure 3.11: Schematic representation of conventional antibody cloning into pSG 
expression vectors. Restriction enzymes and ligase-dependent cloning procedure of 
HMW-MAA specific antibody variable regions into pSGH and pSGK vectors. 
Swapping of variable heavy (A) and variable kappa regions (B) by double digest of pSG 
and HMW-MAA holding vectors with unique restriction enzymes, followed by gel 
purification of variable genes and ligation of linearised pSG vectors with gel purified 
variable genes. Production of HMW-MAA specific IgE is achieved by co-transfection 
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3.3.10 Transient expression of HMW-MAA specific IgE 
Following successful exchange of variable genes within pSG vectors, I proceeded with 
transfection and transient expression of HMW-MAA specific IgE antibody. HEK293E 
cells were transiently transfected with pSGH-MAA and pSGK-MAA with the 
previously optimised 2:1 ratio of light : heavy chain DNA and 4:1 ratio of PEI : DNA as 
described previously. Sample supernatants were collected 5 days post-transfection and 
the antibody expression levels were determined by anti-human IgE ELISA as described 
previously (McCloskey et al, 2007). The ELISA analysis showed the HMW-MAA 
specific IgE antibody was expressed at 0.7mg/L after 5 days incubation period (Figure 
3.12). The result demonstrated successful transfection of HEK293E cells with the newly 
generated pSGH-MAA and pSGK-MAA vectors, and the capacity of the expression 





Figure 3.12: Quantification of transiently expressed HMW-MAA specific IgE. 
Anti-human IgE ELISA analysis of HMW-MAA specific IgE transient expression in 
triple layer flask. The antibody concentration at mg/L was determined by reference to a 
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3.3.11 Flow cytometric assessment of transiently expressed HMW-MAA specific 
IgE  
To assess the functionality of the transiently expressed recombinant HMW-MAA 
specific IgE antibody, antigen specificity and receptor-binding activity were 
investigated by flow cytometry (Figure 3.13). Antigen specificity was analysed by 
selective binding to native HMW-MAA on the cell surface of A375 melanoma cells as 
opposed to primary human melanocytes, normally present in the skin of healthy 
patients. The receptor-binding activity of the antibody was analysed by binding to RBL 
cells which express both human and rat FcεRI (Dibbern et al, 2003). Flow cytometric 
analysis (Figure 3.13) of A375 melanoma cells incubated with the HMW-MAA specific 
IgE antibody, shows a clear right shift of fluorescence intensity, indicating preserved 
specific binding to native HMW-MAA and no binding above background to primary 
melanocytes. Furthermore, the IgE bound to human FcεR1 receptor, expressed on RBL 




Figure 3.13: Flow cytometric assessment of transiently expressed HMW-MAA 
specific IgE. HMW-MAA specific IgE antibody shows specific binding to native 
HMW-MAA present on A375 melanoma cells and no binding above background to 
primary melanocytes. The IgE-Fc fragment of the antibody demonstrate effector-
binding to RBL SX38 mast cells, expressing human FcεR1 receptor. 
 
Figure 3.13: Flow cytometric assessment of transiently expressed HMW-MAA specific IgE. 
Transiently expressed by co-transfection of pSGH-MAA and pSGK-MAA vectors into HEK293E 
cells, the affinity purified HMW-MAA specific IgE antibody shows specific binding to native 
HMW-MAA present on the cell surface of A375 melanoma cells and no binding above 
background to primary melanocytes. The IgE-Fc fragment of the purified antibody demonstrate 
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3.4 Discussion 
To study the functional properties of antibody variable gene libraries, which are 
frequently generated in the study of B-cell associated immune diseases (Bende et al, 
2002; Coker et al, 2003; Coker et al, 2005; Foreman et al, 2007; Janezic et al, 1998; 
Küppers et al, 1996; Snow et al, 1995; Snow et al, 1997; Snow et al, 1999; Tobin, 2005; 
Tobin et al, 2006), recombinant expression of the variable as well as constant region 
genes is required for whole antibodies.  However, most well established methods of 
producing recombinant antibody at levels sufficient for biological assay require time- 
and labour- intensive methodologies (Bebbington et al, 1992; Filpula, 2007; Jain et al, 
2007; Jones et al, 2003; Maynard & Georgiou, 2000; Zafir-Lavie et al, 2007).  To 
address this, we have designed and constructed a set of cloning cassettes for antibody 
heavy, kappa and lambda chains in which restrictions sites flanking the variable and 
constant domain genes have been introduced by silent mutation (Figure 3.2).  The 
restriction sites are compatible with all human constant gene isotypes and all human and 
murine germline variable genes, which allow exchange of either the variable or constant 
domain by restriction enzymes and ligase-dependent cloning. This means any 
conceivable human or mouse-human chimeric antibody may be expressed using this 
system.  
 
To test the transient antibody expression system, I strove to produce cytokinergic IgEs 
and obtain the previously reported expression levels (Gan, 2008). pSGH and 
pSGK/pSGL vectors coding for the expression of 8 cytokinergic IgEs were co-
transfected into HEK293E cells and supernatants harvested after 20 days to analyse 
antibody production by IgE specific ELISA. The expression levels of all tested IgEs, 
confirmed by ELISA, matched the previously reported expression levels, which enabled 
me to continue with the purification process and optimisation of the expression system 
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for better yields. The labour-intensive process and the high cost / low yield 
characteristics of HEK293E mammalian cell culture processes for antibody expression 
by large-scale transfection thus required optimisation of various production parameters 
to increase the volumetric antibody productivity. 
 
An important parameter that affects antibody productivity is cell toxicity caused by the 
transfecting agent. Polyethylenimine (PEI) has previously been utilised for large-scale 
transfection into HEK293E cells (Pham et al, 2003) and shown to have low cell toxicity 
and rapid efficient uptake by cells (Godbey et al, 2000; Godbey et al, 1999a; Godbey et 
al, 1999b; Godbey et al, 1999c; Godbey et al, 1999d). To test the effectiveness of PEI in 
our expression system, an optimisation step with increasing PEI concentrations, whilst 
keeping the DNA concentration constant at 1 µg/ml, was carried out. Most favourable 
cell viability and maximum antibody expression level within 5 days incubation period 
was found to be the best at 4µg PEI : 1µg DNA ratio. 
 
An important role of light-chain expression in Ig production has been shown (Baldi et 
al, 2005; Schlatter et al, 2005), suggesting a higher light-chain expression increases 
antibody production yield. To investigate and the role of light chain expression in our 
cloning system, optimisation of transfection conditions with HEK293E was carried out 
to determine the most effective light : heavy chain ratio. The ELISA analysis showed 
the optimum ratio of light : heavy chain DNA for the maximum antibody expression 
yield was found at 2:1, thus suggesting that double amount of light chain DNA 
contributed towards higher antibody production. This optimisation halved the DNA 
amount of the light chain previously used (4:1) to transfect cells, hence shortening the 
DNA production process. Furthermore, this result was consistent with the previously 
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observed requirement for light chain excess to render antibody folding and assembly 
more efficiently in transient transfections (Schlatter et al, 2005).  
 
Previous studies (Pham et al, 2005) reported that addition of Tryptone N1 (a casein 
peptone, TN1) to the cell culture media 24 h post-transfection, led to a 2-fold increase in 
protein production after 5 days incubation.  In addition, an Invitrogen product called 
Optimab, a monoclonal antibody production enhancer (consisting of alternate carbon 
sources, a monoclonal antibody production inducer, and essential nutrients been shown 
to be significantly depleted during the high-density culture phase), has been previously 
shown to increase antibody production. To maximise antibody yields, the culture media 
of transiently transfected HEK293E cells was supplemented independently with 
Tryptone N1 and Optimab 24h post-transfection. The ELISA analysis showed a 4-fold 
decrease in antibody expression level in the cultures supplemented with Tryptone N1 
after 12 days incubation, suggesting the peptone depletion was not limiting antibody 
production yield in HEK293E cells. However, the Optimab supplementation 
represented a 2-fold increase in volumetric antibody productivity. Unfortunately, soon 
after the optimisation step was conducted, we discovered that Invitrogen discontinued 
Optimab. So far, no appropriate alternatives of Optimab have been found. 
 
The transiently expressed IgEs antibodies were purified by affinity chromatography 
using IgG4-Fc-(sFcεRIα)2  fusion protein (Shi et al, 1997). During purification of some 
IgE antibodies, an aggregation was observed, where certain combinations of IgE 
displayed aggregative tendencies. Therefore, the affinity column-purified IgEs were 
subjected to gel filtration/size-exclusion chromatography used for analysis and 
fractionation of monomeric antibodies and aggregated materials according to size (Hunt 
et al, 2005). Monomeric antibodies isolated from the size-exclusion chromatography 
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were concentrated and analysed by SDS-PAGE. Under non-reducing conditions, the 
purified IgEs appeared as single bands between 180 kDa and 250 kDa protein marker 
bands, corresponding to the expected ~190 kDa whole IgE molecule. Under reducing 
conditions, single bands were found at 25 kDa corresponding to the antibody light 
chains (25 kDa) and single bands found at 80 kDa possibly corresponding to 
glycosylated forms of the antibody heavy chains (~60 kDa). None of the purified 
antibodies showed significant contamination with other proteins, as judged by the 
absence of bands of molecular weight inconsistent with those expected for an IgE 
antibody polypeptide chains, indicating the affinity column purification and size-
exclusion chromatography were effective in yielding pure monomeric IgEs.  
 
Finally, to assess the biological functionality of the transiently expressed and affinity-
purified cytokinergic IgE antibodies, I performed flow cytometric experiments, where 
RBL-SX38 cells expressing both human and rat FcεRI (Dibbern et al, 2003) were 
incubated with the IgEs and subsequently stained with anti-human IgE FITC. The flow 
cytometry analysis showed a clear right shift of fluorescence intensity, indicating the 
functional receptor-binding activity of the recombinant IgE antibodies. 
 
Having successfully expressed, purified and characterised the previously cloned 
cytokinergic IgEs, I strove to demonstrate the versatility of our transient expression 
system to swap variable regions and its capacity to make fully functional antibodies, by 
cloning, expressing and characterising a High Molecular Weight Melanoma-Associated 
Antigen (HMW-MAA) specific IgE antibody. The existing V genes from pSGH and 
pSGK vectors were substituted with those specific for an HMW-MAA, utilising the 
BssHII and NheI restriction sites in the heavy chain cassette and SacII and BsiWI in the 
light chain cassette (Figure 3.11). The sequencing confirmation of the newly generated 
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pSGH-MAA and pSGK-MAA vectors demonstrated an effective exchange of the 
variable genes within pSG vectors using restriction enzymes and ligase-dependent 
cloning. Following successful PEI transfection of HEK293E cells with vectors coding 
for the expression of HMW-MAA specific IgE, the antibody expression level as 
determined by ELISA, was shown to be 0.7mg/L after 5 days incubation period. 
Antigen specificity and receptor-binding activity of the expressed HMW-MAA IgE 
antibody were analysed by flow cytometry The flow cytometric analysis of A375 
melanoma cells incubated with the HMW-MAA specific IgE antibody, showed a clear 
right shift of fluorescence intensity, indicating preserved specific binding to native 
HMW-MAA as presented on the cell surface of A375 cells. No binding above 
background was detected to primary human melanocytes normally present in the skin of 
healthy patients. Furthermore, the IgE bound to human FcεR1 receptor, expressed on 
RBL SX38 mast cells (Dibbern et al, 2003), further demonstrating functional receptor-
binding activity of the recombinant antibody. 
 
To summarise, we have designed and produced a set of antibody cloning cassettes in 
which multiple cloning sites have been incorporated into the immunoglobulin coding 
sequence, enabling exchange of the variable and constant antibody genes by restriction 
enzymes and ligase-dependent cloning.  This facilitates the expression of human or 
murine V genes of any human (or mouse-human chimeric) antibody isotype. The 
transient antibody expression system is capable of delivering 0.5-4mg/L antibodies, 
sufficient for antibody characterisation, produced in four weeks, from cloning of the V 
region through to harvesting of transfected cell supernatants, with preserved antigen 
binding and receptor-binding activities. This is particularly advantageous for 
characterisation of large libraries of V genes as a large panel of recombinant antibodies 
may be generated in a relatively short period of time compared to other available 
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antibody expression methods (Bebbington et al, 1992; Filpula, 2007; Jain et al, 2007; 
Jones et al, 2003; Maynard & Georgiou, 2000; Zafir-Lavie et al, 2007). Using the 
optimised protocol to clone and express HMW-MAA specific IgE antibody, an 
expression level of 0.7mg/L was detected 5 days after transient transfection.  Thus, 
based on HMW-MAA IgE expression and expression levels of other IgEs expressed by 
the transient expression system, an estimated average production at 2mg/L of HMW-
MAA specific IgE can be achieved in four weeks. To achieve this level, we estimate 
that four 500cm2 triple layered flasks with adherent seeded cells will have to be 
transfected for a final volume of 1L. We planned to use HMW-MAA specific mAb as a 
control for our antibody discovery program, as well as for comparative functional 
studies between different isotypes in animal models. On an average, 10 mg of antibody 
is required to conduct one set of studies in a mouse model. Using our transient 
transfection system, transfection of 20 triple layered flasks would be required for 10 mg 
antibody production. One of the drawbacks of the pTT3 vector is that the backbone 
lacks a selection marker for generation of stable cell lines and thus contributes for the 
labour intensive procedure of repeating transfections. Although, the transient antibody 
expression system described in this chapter is capable of producing sufficient material 
for characterisations of multiple antibodies, it is unable to support animal model 
experiments in its current state. The modification of the transient antibody expression 
system to a stable antibody expression system, capable of producing over a 100mg/L 
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4 STABLE ANTIBODY EXPRESSION SYSTEM 
 
4.1 Introduction  
Over the last three decades, recombinant monoclonal antibodies (mAbs) have become a 
key tool for basic research, diagnosis and treatment of human diseases. The increasing 
demand for therapeutic antibodies has resulted in a significant improvement in antibody 
production systems, allowing biopharmaceutical communities to reach grams per liter 
expression levels. However, the lack of a suitable manufacturing platform, which 
ensures consistent antibody production, has always been one of the major impediments 
to the development of recombinant antibody material in academia.  
Matched Ig heavy- and light-chain variable (V)-regions have been amplified from single 
B cell-derived cDNA encoding antibodies of the desired specificity (Koelsch et al, 
2007; Smith et al, 2009; Tiller et al, 2008; Volkheimer et al, 2007; Wrammert et al, 
2008) and linked to the desired Ig constant (C) region cDNA (Braren et al, 2007; 
Madritsch et al, 2011). However, there are still limitations in cloning and expression of 
recombinant mAbs. For example, co-transfection of separate vectors coding for either 
the heavy- or light-chain cDNA (Boel et al, 2000; Furtado et al, 2002; Koelsch et al, 
2007; Madritsch et al, 2011; Tiller et al, 2008) might lead to low antibody expression, 
since the site of integration has a major effect on the level of expression of transfected 
genes (Wurm, 2004). Moreover, these antibody cloning systems rely on restriction 
enzyme- and ligase-dependent cloning procedures, whilst the restriction sites used in the 
vectors may not be compatible with all human constant gene isotypes. Our transient 
antibody expression system has overcome this limitation by incorporating restriction 
sites, compatible with all human constant gene isotypes and all human and murine 
germline variable genes, which allow exchange of either the variable or constant 
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domain by restriction enzyme- and ligase-dependent cloning. This facilitated the 
expression of human or murine V genes of any human (or mouse-human chimeric) 
antibody isotype, with preserved antigen binding and receptor-binding activities. 
Although the system is useful for the production of a large number of proteins in a short 
time, the lack of an antibiotic-based selection step limits expression yields and requires 




Figure 4.1: Triple layer flasks for transfections and transient expression of 
antibodies. Time-consuming large volume transfections in triple layer flasks are 
required for large-scale production of antibody using the transient expression system. 
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Different vectors hosting a dual antibody expression cassette have been exploited and 
shown to produce higher antibody expression levels (Braren et al, 2007; Hecker et al, 
2011; Wiberg et al, 2006). However, they rely on restriction enzyme- and ligation-
dependent cloning methods, which are time-consuming, prevent high-throughput 
analysis of antibody candidates and sometimes impractical due to the lack of compatible 
restriction sites. For example, swapping of variable genes within pSGH vector is 
possible due to unique BssHII and NheI restriction sites in the heavy chain cassette. 
However, the BssHII restriction site was present within the CDR3 region of clone G7 
(Figure 4.2), the first antibody derived from our antibody discovery program (described 
in detail in chapter 6). This required a complex, labour-intensive cloning procedure 
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Figure 4.2: Schematic representation of restriction site within CDR3. Restriction 
site GCGCGC (in red box) present in the CDR3 of clone G7 is recognised by restriction 
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IMGT/V-QUEST programme version: 3.2.30; IMGT/V-QUEST reference directory release: 201237-3
A. Detailed results for the IMGT/V-QUEST analysed sequences
 
Number of analysed sequences: 1
 
G7
 This release of IMGT/V-QUEST uses IMGT/JunctionAnalysis for the analysis of the JUNCTION
 Hyphens (-) show nucleotide identity, dots (.) represent gaps
Sequence number 1: G7









Result summary: Productive IGH rearranged sequence (no stop codon and in-frame junction)
V-GENE and allele Homsap IGHV3-33*01 F, or Homsap_IGHV3-33*04 F or Homsap_IGHV3-33*06F
score =
1066 identity = 85,76% (247/288 nt)
J-GENE and allele Homsap IGHJ4*02 F score = 163 identity = 82,98% (39/47 nt)
D-GENE and allele by IMGT/JunctionAnalysis Homsap IGHD2-8*01 F D-REGION is in reading frame 2
FR-IMGT lengths, CDR-IMGT lengths and AA
JUNCTION [25.17.38.11] [8.8.14] CGRERASNKGREVDFW
1. Alignment for V-GENE and allele identification
Closest V-REGIONs (evaluated from the V-REGION first nucleotide to the 2nd-CYS codon)
                                    Score       Identity
AB019439 Homsap IGHV3-33*01 F       1066        85,76% (247/288 nt)
M77335 Homsap IGHV3-33*04 F         1066        85,76% (247/288 nt)
HM855436 Homsap IGHV3-33*06 F       1066        85,76% (247/288 nt)
M77305 Homsap IGHV3-33*03 F         1057        85,42% (246/288 nt)
M77334 Homsap IGHV3-33*05 F         1048        85,07% (245/288 nt)
Alignment with FR-IMGT and CDR-IMGT delimitations
                                    <---------------------------------- FR1-IMGT ---------------
G7                                  caggtgcagctggtgcagtctggggga...ggcgtggtccagcctgggaattcgctgacg
AB019439 Homsap IGHV3-33*01 F       ---------------g-----------...-------------------gg--c----ga
M77335 Homsap IGHV3-33*04 F         ---------------g-----------...-------------------gg--c----ga
HM855436 Homsap IGHV3-33*06 F       ---------------g-----------...-------------------gg--c----ga
M77305 Homsap IGHV3-33*03 F         ---------------g-----------...-------------------gg--c----ga
M77334 Homsap IGHV3-33*05 F         ---------------g-----------...-------------------gg--c----ga
                                    ----------------->______________ CDR1-IMGT ___________<-----
G7                                  atctcctgtgaagcgtctggattcaccttc............agcacttatgccatgcac
AB019439 Homsap IGHV3-33*01 F       c---------c-------------------............--t-gc----g-------
28/01/2013 14:30IMGT/V-QUEST
Page 2 of 9http://www.imgt.org/IMGT_vquest/vquest
M77335 Homsap IGHV3-33*04 F         c---------c-------------------............--t-gc----g-------
HM855436 Homsap IGHV3-33*06 F       c---------c-------------------............--t-gc----g-------
M77305 Homsap IGHV3-33*03 F         c---------c-------------------............--t-gc----g-------
M77334 Homsap IGHV3-33*05 F         c---------c-------------------............--t-gc----g-------
                                    --------------- FR2-IMGT ------------------->___________ CDR
G7                                  tgggtccgccaggctccaggcaaggggctggagtgggtgggcatcatatggcatgac...
AB019439 Homsap IGHV3-33*01 F       ----------------------------------------cag-t------t----t...
M77335 Homsap IGHV3-33*04 F         -----------------------------a----------cag-t------t-----...
HM855436 Homsap IGHV3-33*06 F       ----------------------------------------cag-t------t----t...
M77305 Homsap IGHV3-33*03 F         ----------------------------------------cag-t------t----t...
M77334 Homsap IGHV3-33*05 F         ----------------------------------------cag-t----cat----t...
                                    2-IMGT ________<--------------------------------------------
G7                                  ...ggaggtctaaagtattatggagactccgtgaag...ggccgattcggtatctggaga
AB019439 Homsap IGHV3-33*01 F       ...---a--aat--a--c----c-------------...---------acc----cc---
M77335 Homsap IGHV3-33*04 F         ...---a--aat--a--c----c-------------...---------acc----cc---
HM855436 Homsap IGHV3-33*06 F       ...---a--aat--a--c----c-------------...---------acc----cc---
M77305 Homsap IGHV3-33*03 F         ...---a--aat--a--c----c-------------...---------acc----cc---
M77334 Homsap IGHV3-33*05 F         ...---a--aat--a--c----c-------------...---------acc----cc---
                                    --------- FR3-IMGT -----------------------------------------
G7                                  gacaattccaagaacactctccatctgaatatgaagaacgtgagatccgaggacacggct
AB019439 Homsap IGHV3-33*01 F       -----------------g--gt-----c-a-----c-g-c-----g--------------
M77335 Homsap IGHV3-33*04 F         -----------------g--gt-----c-a-----c-g-c-----g--------------
HM855436 Homsap IGHV3-33*06 F       -----------------g--gt-----c-a-----c-g-c-----g--------------
M77305 Homsap IGHV3-33*03 F         -----c-----------g--gt-----c-a-----c-g-c-----g--------------
M77334 Homsap IGHV3-33*05 F         -----------------g--gt-----c-a-----c-g-c-----g--------------
                                    ----------->_________________ CDR3-IMGT ______________
G7                                  gtgtactattgtgggagagagcgcgccagtaataagggcagggaagttgacttctggggc
AB019439 Homsap IGHV3-33*01 F       -----t--c----c------
M77335 Homsap IGHV3-33*04 F         -----t--c----c------
HM855436 Homsap IGHV3-33*06 F       -----t--c----c--a---
M77305 Homsap IGHV3-33*03 F         -----t--c----c--a---
M77334 Homsap IGHV3-33*05 F         -----t--c----c------
                                    
G7                                  cagggaaccctcgtcatcgtctcctca
AB019439 Homsap IGHV3-33*01 F       
M77335 Homsap IGHV3-33*04 F         
HM855436 Homsap IGHV3-33*06 F       
M77305 Homsap IGHV3-33*03 F         
M77334 Homsap IGHV3-33*05 F         
3. Alignment for J-GENE and allele identification
Closest J-REGIONs
                                    Score       Identity
X86355 Homsap IGHJ4*02 F            163         82,98% (39/47 nt)
J00256 Homsap IGHJ4*01 F            154         80,85% (38/47 nt)
M25625 Homsap IGHJ4*03 F            154         80,85% (38/47 nt)
J00256 Homsap IGHJ5*01 F            142         76,00% (38/50 nt)
X86355 Homsap IGHJ5*02 F            142         76,00% (38/50 nt)
Alignment
G7                                  gcgcgccagtaataagggcagggaagttgacttctggggccagggaaccctcgtcatcgt
X86355 Homsap IGHJ4*02 F            ....................act-ct------a------------------g----c---
J00256 Homsap IGHJ4*01 F            ....................act-ct------a---------a--------g----c---
M25625 Homsap IGHJ4*03 F            ....................-ct-ct------a---------a--g-----g----c---
J00256 Homsap IGHJ5*01 F            .................a--actggt-c----c---------a--------g----c---
X86355 Homsap IGHJ5*02 F            .................a--actggt-c---cc------------------g----c---
G7                                  ctcctca
X86355 Homsap IGHJ4*02 F            -------g
J00256 Homsap IGHJ4*01 F            -------g
M25625 Homsap IGHJ4*03 F            -------g
J00256 Homsap IGHJ5*01 F            -------g
X86355 Homsap IGHJ5*02 F            -------g
4. Results of IMGT/JunctionAnalysis
Maximum number of accepted mutations in: 3'V-REGION = 2, D-REGION = 4, 5'J-REGION = 2
Maximum number of accepted D-GENE = 1
Analysis of the JUNCTION
D-REGION is in reading frame 2.
Click on mutated (underlined) nucleotide to see the original one:
 
Input V name 3'V-REGION N1 D-REGION N2 5'J-REGION J name D name Vmut Dmut Jmut Ngc


















Figure 4.3: Schematic representation of restriction enzymes used for antibody 
cloning. (A) Swapping antibody variable regions by unique restriction enzymes. (B) 
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An alternative to conventional restriction enzyme- and ligation-dependent cloning 
methods is overlapping of DNA fragments for assembling antibody heavy- and light-
chain cDNAs in expression vectors (Liao et al, 2009). An inherent difficulty of this 
approach is an additional PCR reaction relying on a specific annealing temperature of 
the overlapping fragments by means of a gradient PCR step.  
I sought to generate an improved flexible system for the expression of antibodies with 
any desired specificity. My specific aims were as follows: 
 
i) to minimise the time required to clone antibody heavy and light chains into a 
single mammalian expression vector  and 
ii) stable transfection of a suitable cell line that allows a scalable production 
process, which can deliver sufficient material for pre-clinical studies.  
 
In order to demonstrate the system’s versatility and capacity to make fully functional 
antibodies and to fulfil current limitations, I have developed a dual antibody expression 
cassette that facilitated the seamless exchange of variable and constant domain genes to 
produce HMW-MAA specific IgE and IgG4 antibody isotypes as a proof-of-principle. 
The choice of these antibodies was dictated by the search for therapeutic antibodies for 
the immunotherapy of melanoma and the availability of functional assays for the IgE 
and IgG4 isotypes in our laboratory. In this chapter I have described an easy and 
efficient method for antibody cloning and production based on established techniques, 
which is novel in their combination and application.  
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4.2 Methods 
4.2.1 Generation of a dual antibody expression cassette  
In order to integrate the heavy chain expression cassette into multiple cloning site 2 
(MCS2), pVITRO1 was linearised (Figure 4.5 1A) using primers MCS2_F and 
MCS2_R (Table 2.2). In parallel, the heavy chain expression cassette from a previously 
constructed vector (pSGH-G7) was amplified using primers HC_F and HC_R (Table 
2.2), in which the 5′-ends are complementary to the MCS2 of pVITRO1 and the 3′-ends 
complementary to the VH1-02 secretary leader and Cε terminus respectively (Figure 4.5 
1B).  
The linearisation of the vector and amplification of the heavy chain expression cassette 
was performed using PhusionTM Flash High-Fidelity PCR Master Mix (Finnzymes) 
according to the manufacturer’s instructions, except the final extension step was 
omitted. The unpurified PCR products (heavy chain DNA and linearised pVITRO) were 
mixed 1:1 (v/v) as previously described (Klock et al, 2008), and 2 µl of the mixture was 
transformed into XL1-Blue competent cells (Stratagene) according to the 
manufacturer’s instructions. Transformed cells were plated on LB petri dishes 
supplemented with 50 µg/ml Hygromycin B (Invitrogen). There was no risk of 
background template contamination at this stage, as the pSG vectors have ampicillin 
resistance only. Single colonies were picked and inoculated in 5 ml LB broth 
(Invitrogen) supplemented with 50 µg/ml Hygromycin B.  After overnight culture at 
37°C with shaking at 200rpm, bacteria were harvested and plasmid DNA purified with a 
Wizard Plus SV Minipreps DNA Purification System (Promega). Purified plasmid DNA 
was then sequenced with primers pVitro1F and pVitro1R (Table 2.2) to confirm 
integration of the heavy chain expression cassette within MCS2. The newly generated 
vector was named pVitro-IgH. Moreover, this confirmed that the PIPE cloning method 
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is extremely quick and cost effective, which encouraged me to continue with the 
construction of the dual antibody expression cassette in pVITRO1. 
 
The light chain expression cassette was then integrated into MCS1 within pVitro-IgH. 
First the vector was linearised using primers MCS1_F and MCS1_R (Table 2.2). The 
light chain expression cassette was amplified from a previously constructed pSGK-G7 
vector using primers LC_F and LC_R (Table 2.2), in which the 5′-ends are 
complementary to the MCS1 and 3′-ends complementary to the VK A26 secretary leader 
and Cκ terminus respectively. Vector construction was performed as described for the 
heavy chain. Sequencing confirmed the integration of the light chain expression cassette 
within MCS1 thus validating the generation of a novel expression vector, pVitroG7-IgE, 
coding for the expression of G7 IgE antibody. 
 
4.2.2 Swapping variable regions 
pVitroG7-IgE vector was linearised by two sets of primer pairs flanking G7 VK and VH; 
Linear_Kfwd/Linear_Hrev and Linear_Hfwd/Linear_Krev (Table 2.2), in two 
independent PCR reactions. The two resulting vector fragments were treated with the 
endonuclease enzyme Dpn I (NEB) which destroys the E.Coli-derived vector template 
(Figure 4.7) thus reducing background contamination from pVitroG7-IgE vector. 
 
Simultaneously, the HMW-MAA specific VH and VK were amplified by primer pair 
MAAH_Fwd and MAAH_Rev and primer pair MAAK_Fwd and MAAK_Rev (Table 
2.2) respectively in two independent PCR reactions, for generation of vector fragment 
terminal end-homology (Figure 4.7).  The Dpn I treated vector fragments were mixed 
with unpurified HMW-MAA specific VH and VK in 1:1:1:1 (v/v) ratio and 2 µl from the 
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mixture transformed into XL1-Blue competent cells as described previously (Section 
4.2). 
 
4.2.3 Swapping constant regions  
To exchange Cε with Cγ4 within pVitroMAA-IgE construct, the vector was linearised, 
using primer pairs flanking the Cε region (pAn_Fwd and VH_Rev, Table 2.2) and 
subsequently treated by Dpn I (NEB) (Figure 4.9). The human Cγ4 region was 
amplified from an existing pSG vector (James et al, 2012) using primer pair Cg4_Fwd 
and Cg4_Rev (Table 2.2), for generation of vector fragment terminal end-homology. 
The Dpn I treated linearised vector and unpurified Cγ4 PCR product were mixed in 1:1 
(v/v) ratio, followed by 30 minutes incubation at 60°C and 2 µl from the mixture 
transformed into XL1-Blue competent cells. The newly generated vector was named 
pVitroMAA-IgG4, coding for the expression of chimeric HMW-MAA specific IgG4 
antibody (Figure 4.9). 
 
4.2.4 Stable expression of antibodies 
293-F were cultured at a density of 1 - 3x106cells/ml in FreeStyleTM 293-F Expression 
Medium (Life Technologies) in sterile 125 ml Erlenmeyer flasks (Sigma), rotating at 
135 rpm on orbital shaker platform. For transfection, 3x107 cells were transfected with 
40 µg of pVitroMAA-IgE or pVitroMAA-IgG4 DNA, coding for the expression of the 
HMW-MAA specific IgE and IgG4 respectively, using FreeStyleTM MAX transfection 
reagent according to manufacturer’s instructions. For the generation of stable cell lines, 
50 µg/ml Hygromycin B was added to the media 24 h post-transfection, and the cells 
were kept under selection for 2 weeks at 1-3x106 viable cells/ml. 1 ml samples were 
collected every 48 h for antibody quantification by anti-human IgE ELISA as described 
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previously (McCloskey et al, 2007). The Hygromycin-selected cells expressing the 
HMW-MAA specific IgG4 were expanded into 1L spinner and the supernatants 
harvested after two weeks. The antibody expression level was determined by anti-
human IgG4 ELISA as described previously (James et al, 2012).  
 
4.2.5 Purification of IgG 
Cell supernatants were harvested and centrifuged at 1000 x g for 15 minutes to remove 
cell debris. Supernatants were passed over 0.45µm filters (Sartorius) and stored at 4°C 
with 0.1% sodium azide (Sigma) until purification. The HMW-MAA-specific IgG4 
isotype was purified by affinity chromatography with a 5 ml HiTrap Protein-G HP 
column (GE Healthcare) using an ÄKTA Prime system (Amersham, Uppsala Sweden). 
The column was equilibrated with 10 Column Volumes (CV) of washing buffer (PBS, 
pH 7.0). Filtered supernatant was loaded onto the column at a flow rate of 2 ml/min and 
the column washed with 10 CV washing buffer. The antibody was eluted with 0.2M 
Glycine, pH 2.5 and 2.5 ml fractions were collected into tubes containing 0.5 ml 1M 
Tris–HCl pH 8.6 for neutralization.  
 
4.2.6 Flow Cytometry 
Recombinant HMW-MAA-specific IgE and IgG4 were incubated with HMW-MAA+ 
(A375 melanoma cells) and HMW-MAA- (primary human melanocytes) cells for 30 
min at 4oC. Cells were washed twice in PBS supplemented with 5% normal goat serum 
(FACS buffer). Cells were then incubated with 10 µg/ml anti-human IgE-FITC (Jackson 
ImmunoResearch) or IgG-FITC (Jackson ImmunoResearch) for 30 min at 4oC and 
washed with FACS buffer prior to acquisition and analysis on a FACSCantoTM flow 
cytometer (BD Biosciences). 
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4.3 Results 
4.3.1 Design and construction of a versatile dual antibody expression cassette  
The first antibody variable regions (clone G7) derived from our antibody discovery 
program (described in detail in chapter 6) were cloned utilising BssHII and NheI 
restriction sites and a ligase-dependent cloning procedure (Figure 4.2). However, this 
was a labour- and time-intensive proves, hence, I strove to improve flexibility and 
reduce the cloning time of this method, by adapting the Polymerase Incomplete Primer 
Extension (PIPE) method (Klock et al, 2008). I also aimed to maximise expression 
yields by designing and constructing a dual antibody expression cassette using the 
pVITRO1 mammalian expression vector (InvivoGen). This enables stable transfection 
in a mammalian cell line and an easily scalable production process, which can deliver 
sufficient material for animal model experiments. The pVITRO1 mammalian 
expression vector (Figure 4.4), has multiple advantages over pSG vectors, making it 
much more suitable for expression of antibodies. Firstly, pVITRO contains a dual 
expression cassette for simultaneous expression of both heavy and light chain genes, 
thus eliminating the requirement for co-transfection of two vectors and halving the time 
and effort needed for DNA preparation and transfection. Second, efficient recombinant 
antibody production is dependent on the ratio of heavy to light chain gene expression 
(Schlatter et al, 2005). I therefore placed the heavy chain expression cassette under the 
control of the Simian Virus 40 (SV40) enhancer and the light chain expression cassette 
under the control of human cytomegalovirus (HCMV) enhancer. HCMV is several fold 
more active than the SV40 enhancer so maintains the optimal ratio of Heavy to Light 
chain gene expression. Finally,  pVITRO contains the hph gene, part of the vector 
backbone, which confers resistance to Hygromycin B in both E. coli and mammalian 
cells, allowing a selection step and generation of stable cell lines. 
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Figure 4.4: Schematic representation of the pVITRO1 vector. pVITRO1 
mammalian expression vector (InvivoGen) used for construction of a dual antibody 
expression cassette with Hygromycin selection marker for generation of stable cell lines 
 
 
Cloning the heavy and light chain expression cassettes into a large vector negatively 
affects the swapping of variable or constant genes due to the lack of compatible 
restriction sites, reinforcing the demand for an alternative to the conventional restriction 
enzyme- and ligation-dependent cloning methods. The PIPE cloning method has been 
shown to be extremely quick, cost effective, and highly efficient, capable of supporting 
the high-throughput cloning of thousands of genes in parallel (Klock et al, 2008). This 
method eliminates the use of restriction enzymes and ligation, and thus the 
incorporation of restriction sites, which could sometimes encode extra, unwanted 
residues into expressed proteins (Hartley et al, 2000). The PIPE method relies on the 
inefficiency of the amplification process in the final cycles of a PCR reaction, possibly 
due to the decreasing availability of dNTPs. This incomplete 5′-3′ primer extension 
results in a mixture of products with variably single-stranded 5′-ends (Olsen & Eckstein, 
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cloning method represents a simple two-step protocol with complete design flexibility. 
In the first step, a set of vector-specific primers are used for PCR vector linearisation 
and another set of primers with 5’-vector-end overlapping sequences are used for insert 
amplification, generating incomplete extension products by PIPE. In the second step, 
the single-stranded overlapping sequences of the incomplete extension products are 
mixed with complementary strands which then anneal and assemble as a complete 
vector (Klock et al, 2008).  I adapted the PIPE method for antibody cloning and 
construction of the dual antibody expression cassette in pVITRO1.  The basic rules for 
designing primer pairs when swapping variable (V) or constant (C) antibody regions by 
PIPE are illustrated in details in Figure 4.5. Integrating the heavy and light chain 
expression cassettes into pVITRO1 (Figure 4.6), completed the construction of a dual 
antibody expression cassette within a mammalian expression vector, using a restriction 
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Figure 4.5: Schematic representation of primer design for PIPE cloning. 1 A) A set 
of primers flanking the existent V/C antibody region are designed for vector 
linearisation. 1 B) Simultaneously, the desired V/C antibody region is amplified by 
another set of 3’ V/C region specific, 5’ vector-end homologous primers. 2) The 
incomplete extension products anneal directionally across the complementary sequences 
encoded in the primers and nicks and gaps are repaired in vivo after transformation. 
 
 
                                                                                                                                              Ins_Rev !      3’-CCTTGGAGTCAGTGGCAGAGGAGTCGATCGTGTGTCTCGG-5’!!
5’-...CAAGGAACCTCAGTCACCGTCTCCTCA-3’!
3’-...GTTCCTTGGAGTCAGTGGCAGAGGAGT-5’!  !
      !








V/C Region B 
-3’!
-5’!
                5’-CAGGTTCAACTGCAGCAGTCTGGAGCT...-3’!
                3’-GTCCAAGTTGACGTCGTCAGACCTCGA...-5’!
  !5’-CACAGGCGCGCACTCCCAGGTTCAACTGCAGCAGTCTGGA-3’!






1.  Vector Linearisation and V/C Region Amplification  
Polymerase Incomplete  





2. Vector and V/C region Assembly  
                                           Vec_Rev  !      3’-GGCGGTGTCCGCGCGTGAGG-5’!!
5’-...CGGCCGCCACAGGCGCGCACTCCAGC...-3’!
3’-...GCCGGCGGTGTCCGCGCGTGAGGTCG...-5’!  !
      !





  !      5’-GCTAGCACACAGAGCCCATC-3’!




A) Vector Primer Design and Linearisation 







Polymerase Incomplete  
Primer Extension (PIPE)  
Nicks and Gaps  
Repaired In Vivo 
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Figure 4.6: Schematic representation of the dual antibody expression cassette. 
pVITRO1 mammalian expression vector with heavy chain expression cassette 
integrated under the action of the Simian Virus 40 (SV40) enhancer and light chain 
expression cassette under human cytomegalovirus (CMV) enhancer, several fold more 
active than the SV40 enhancer, coding for the expression of G7-IgE antibody. 
 
4.3.2 Swapping variable regions by PIPE 
Having successfully utilised the PIPE cloning method for construction of the dual 
antibody expression cassette, I next optimised the procedure for swapping the 
specificity of the antibody in a single day. This process requires exchanging VH and VK 
regions in pVitroG7-IgE, without affecting the Cκ and Cε. To achieve this, four primer 
pairs were designed. The first two primer pairs, flanking the existing VH and VK, were 
used for double fragment linearisation of the pVitroG7-IgE vector. The second two 
primer pairs, with 5’-fragment-end overlapping sequences, were used for amplification 
of the incoming VH and VK. The primers were used to exchange the variable regions 
(VH and VK) from pVitroG7-IgE vector with a VH and VK directed against the human 















Figure 4.6: Schematic representation of the dual antibody expression cassette. 
pVITRO1 mammalian expression vector with heavy chain expression cassette 
integrated under the action of the Simian Virus 40 (SV40) enhancer and light chain 
expression cassette under human cytomegalovirus (CMV) enhancer, several fold more 
active than the SV40 enhancer, coding for the expression of G7-IgE antibody 
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Figure 4.7: Schematic representation of variable genes swapping by PIPE. 
pVitroG7-IgE vector is linearized by VH and VK flanking primer pairs in two 
independent PCR reactions, resulting in two vector fragments subsequently treated by 
Dpn I. Simultaneously, the HMW-MAA specific VH and VK are amplified for 
generation of vector fragment terminal end-homology. The vector fragments are mixed 
with unpurified HMW-MAA specific VH and VK. The single-stranded DNA fragments 
anneal directionally across the complementary sequences and nicks and gaps are 























PCR Double  
Vector Linearization 
Dpn I Treatment 
PCR Amplification  
for Fragment Terminal  
End-Homology    





VK MAA  
Holding Vector 
















Unpurified PCR Products  



















VH G7- -Vκ G7 
- 103 - 
DNA sequencing of a single colony confirmed the correct assembly of the vector 
fragments with the HMW-MAA specific VH and VK by the PIPE cloning reaction in 
pVitroMAA-IgE, coding for the expression of chimeric HMW-MAA specific IgE 
(Figure 4.7). This cloning experiment has proved the exchange of the specificity of an 
antibody by PIPE cloning is possible in a single day. This is very advantageous for the 
high-throughput screening of antibody candidates derived from our antibody discovery 
program (described in details in chapter 6). 
 
4.3.3 PIPE cloning optimisation 
The use of PIPE cloning for exchange of the variable antibody regions in the dual 
antibody expression vector is both time- and cost-efficient. However, during the initial 
cloning experiments, low cloning efficiency was observed with only one or two 
colonies per plate. The PIPE method relies on the inefficiency of the polymerase to 
amplify polynucleotide chains in the final cycles of a PCR reaction, possibly due to the 
decreasing amount of dNTPs available and more template copies that remain to be 
synthesised (Olsen & Eckstein, 1989). Based on these observations, I aimed to increase 
cloning efficiency by increasing the number of single-stranded 5′-ends to provide more 
complementary strands to anneal. This was done by decreasing the dNTPs and template 
concentration in the PCR reaction, as well as minimising the extension time needed by 
the polymerase to synthesise the polynucleotide chain. 
 
During initial PIPE cloning experiments, PhusionTM Flash High-Fidelity PCR Master 
Mix (Finnzymes) was used according to the manufacturer’s recommendations, except 
the final extension step was omitted. In order to optimise the reaction for the purposes 
of PIPE cloning I compared template concentration, initial denaturation time as well as 
duration of the denaturation, annealing and extension within the PCR cycles.  I found 
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that 1 ng template (versus 10 ng) was sufficient to obtain a PCR product (data not 
shown). I also found that a shortened initial denaturation step (30 seconds versus 2 
minutes) and shortened denaturation, annealing and extension times within the cycles 
(10s, 15s and 5-55s vs 30s, 30s, 15s respectively) led to an improved PCR (Figure 4.8). 
Next, to test the effect of temperature on transformation efficiency, variables and vector 
fragments generated with optimised conditions as described above, were mixed with 
1:1:1:1 (v/v) ratio and incubated for 30 minutes at RT, 50°C, 55°C, 60°C, 65°C, 70°C 
and 75°C before transformation into XL1-Blue competent cells. This experiment 
showed the highest cloning efficiency was present when the reaction was incubated for 
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Figure 4.8: Extension time optimisation. Extension time optimisation of PhusionTM 
Flash polymerase for generation of incomplete extension products required for PIPE 
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Figure 4.8: Extension time optimisation. Extension time optimisation of PhusionTM 
Flash polymerase for generation of incomplete extension products required for PIPE 
cloning, using HMW-MAA specific variables and vector fragments 
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4.3.4 Swapping Constant Regions by PIPE 
To take advantage of the varied effector functions conferred by different isotypes, it is 
often advantageous to compare two or more isotypes of immunoglobulin with the same 
specificity e.g to demonstrate differential tissue distributions between subclasses. 
Therefore to show that the pVITRO system is capable of exchanging isotypes and 
expressing functional antibodies, the CH region of pVitroMAA-IgE was exchanged 
from Cε to Cγ4. These cloning experiments represent the system’s simplicity to 
exchange variable- or constant-region antibody domains allowing cloning of different 
isotypes with any desired specificity. The HMW-MAA specific IgE and IgG4 antibody 
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Figure 4.9: Schematic representation of isotype swapping cloning procedure by 
PIPE. pVitroMAA-IgE expression vector is PCR linearised by C-Epsilon region 
flanking primers and subsequently Dpn I treated. Simultaneously, C-Gamma 4 region is 
PCR amplified for generation of vector terminal end-homology. The unpurified Dpn I 
treated linearised vector is mixed 1:1 (v/v) with unpurified C-Gamma 4 PCR product. 
The single-stranded DNA fragments anneal directionally across the complementary 
sequences and nicks and gaps are repaired in vivo after transformation, generating 
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4.3.5 Stable expression and purification of recombinant antibodies 
Having successfully adapted and optimised the PIPE cloning method for exchange of 
variable- or constant-region domains within the dual antibody expression cassette in 
pVITRO1, I then generated stable cell lines to support large-scale antibody production 
for subsequent use in animal model studies. The mammalian cell line, FreeStyleTM 293-
F cells (Life Technologies), is a suspension culture that has been adapted to grow in 
serum-free conditions. This makes it particularly suited for antibody production due to 
its easy scalability and for subsequent purification.  
The FreeStyleTM 293-F cells were transfected as previously described and Hygromycin-
selected cells expressing HMW-MAA specific IgE were expanded into a 1L shaker 
flask (Sigma), 1L spinner bottle (Sigma) or 5L WAVE bioreactor (GE Healthcare) 
(Figure 4.10A) 
To compare the final expression yields between the transient and stable antibody 
expression system, 293-F cells were transiently transfected with pSGH-MAA and 
pSGK-MAA vectors (Section 3.10), also coding for the expression of HMW-MAA 
specific IgE. Transiently transfected cells were cultured in IL shaker flasks and 1 ml 
samples were collected every 48 h, until day 21. At this point, as expected all of the 
cells were dead and the culture was therefore terminated. Antibody concentrations were 
determined by anti-human IgE ELISA.   
Transient antibody expression produced a maximal 1 mg/L expression yield by day 13 
(Figure 4.10B). In contrast, after 2 weeks selection, the stable cell lines expanded into 
1L shaker flask, 1L spinner and 5L WAVE bioreactor and produced 10 mg/L, 15 mg/L 
and 25 mg/L of respective antibody expression levels at 30 days post-transfection 
(Figure 4.10B). Using a 5L WAVE bioreactor, 125 mg total amount of antibody was 
produced within 30 days. The ELISA analysis showed the HMW-MAA specific IgG4 
antibody was expressed at 70 mg/L within 2 weeks using 1L spinner (Figure 4.11). 
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Figure 4.10A: Schematic representation of tissue culture vessels. The large-scale 
production of recombinant antibodies was conducted in shaker flasks (1L), spinners 
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Figure 4.10B: Stable cell line generation and large-scale production of 
recombinant antibodies. IgE ELISA comparison of antibody expression yields. 
Sample supernatants from two 293-F cell cultures transfected with either two transient 
monocistronic vectors pSG (in squares) or pVitro bicistronic expression vector (in 
circles) encoding for the HMW-MAA specific IgE antibody at different time points. 
pSG transfected cell cultures (in green) lacking a selection marker terminate within 3 
weeks post-transfection. pVitro transfected low volume cell cultures, undergoing a two-
week Hygromycin selection for generation of stable cell lines, are scaled up to larger 
volume shaker flasks (in blue), spinners (in orange) or bioreactors (in red).The antibody 
concentration at mg/L was determined by reference to a standard curve and the results 





Figure 4.10: Stable cell line generation and large-scale roduction of 
recombinant antibodies. Anti-human IgE ELISA result-based comparison of 
antibody expression yields. Two 293-F cell cultures transfected with either two 
transient monocistronic vectors (in squares) or pVitro bicistronic expression 
vector (in circles) encoding for the HMW-MAA specific IgE antibody at 
different time points. Transiently transfected cell cultures (in green) lacking a 
selection marker terminate within 3 weeks post-transfection. pVitro transfected 
low volume cell cultures, underging a two-week hygromycin selection for 
generation of stable cell lines, are scaled up to larger volume shaker flasks (in 
blue), spinners (in orange) or bioreactors (in red) for production of tens of 
milligrams of antibody per litre. The antibody concentration at mg/L was 
determined by reference to a standard curve and the results represent the mean 
of triplicate readings ± SD.  
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Figure 4.11: Stable expression of HMW-MAA specific IgG4. Anti-human IgG4 
ELISA analysis of HMW-MAA specific IgG4 stable expression in 1L spinner. The 
antibody concentration at mg/L was determined by reference to a standard curve and the 
results represent the mean of triplicate readings ± SD.  
 
The HMW-MAA-specific IgE isotype was purified by affinity chromatography using 
IgG4-Fc-(sFcεRIα)2  fusion protein, as previously described (Methods 3.2). The HMW-
MAA-specific IgG4 isotype was purified by affinity chromatography with a 5 ml 
HiTrap Protein-G HP column (GE Healthcare) using an ÄKTA Prime system 
(Amersham, Uppsala Sweden). The eluted IgG4 was present in fractions 2-7 with a 
shoulder elution profile characteristic for IgG elution (Figure 4.12). 
 
 
Figure 4.12: Affinity chromatography analysis of stably expressed IgG4. Elution 
profile from affinity purification of stably expressed IgG4 on a Protein G column by 

























Figure 4.12: Affinity chromatography analysis of stably expressed IgG4. Elution 
profil  from affinity purification of stably expressed IgG4 on a Protein G column by 
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4.3.6 Size-exclusion chromatography of affinity purified HMW-MAA IgE and 
IgG4. 
Size-exclusion chromatography was used for biophysical analysis of the affinity 
column-purified HMW-MAA specific IgE and IgG4 and 2 isotype controls; MOv18 IgE 
is an antibody directed against an ovarian cancer antigen and entering Phase I clinical 
trials (Karagiannis et al, 2003) and a commercially available human myeloma IgG4 
(Millipore) respectively, as previously described (Hunt et al, 2005). Gel filtration was 
performed on a Gilson HPLC system using a Superdex™ 200 10/300 GL column 
(Amersham, Uppsala Sweden) as previously described (Methods 3.2). The size-
exclusion chromatography analysis showed no aggregation and confirmed the affinity 
column-purified product consists of monomeric antibodies (Figure 4.13). 
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Figure 4.13: Size exclusion chromatography analysis of HMW-MAA specific IgG4 
and IgE. Elution profiles of recombinantly expressed and affinity purified HMW-MAA 
specific IgG4 (A) and IgE (B) antibodies from Superdex™ 200 gel filtration. The 
antibody profiles correspond to isotype controls human myeloma IgG4 and MOv18 IgE 
respectively, and confirm the affinity purified products consist of monomeric 
antibodies.  
 
4.3.7 SDS-PAGE analysis of affinity purified HMW-MAA IgE and IgG4 
The size and purity of affinity column-purified antibodies was assessed by SDS-PAGE 
analysis. 2 µg each HMW-MAA specific IgE and IgG4 and isotype controls MOv18 
IgE and human myeloma IgG4 (Millipore) were subjected to a gradient 5–12% 
polyacrylamide gel electrophoresis under non-reducing and 5–20% polyacrylamide gel 
under reducing conditions. SpectraTM Multicolor High Range Protein Ladder 
(Fermentas) was used to assess the molecular weight of the protein bands as visualised 
by Coomassie blue staining.  
 
Figure 4.13: Size exclusion chromatog aphy analysis of HMW-MAA 
specific IgG4 and IgE. Elution profiles of recombinantly expresse  and 
affinity purified HMW-MAA specific IgG4 (A) and IgE (B) antibodies from 
Superdex™ 200 gel filtration. The antibody profiles correspond to isotype 
controls human myeloma IgG4 and MOv18 IgE respectively, and confirm 
the affinity purified products consist of monomeric antibodies.  
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Under reducing conditions, protein bands corresponding to the heavy (52-72 kDa) and 
light chains were visible for both HMW-MAA specific IgG4 and the control human 
myeloma IgG4 (Figure 4.14B). Similarly, the HMW-MAA IgE and control MOv18 IgE 
were visible at 72-95 kDa, corresponding to the heavy chain with a lower band 
corresponding to the light chain. Under non-reducing conditions, molecular sizes were 
found to be in between 180-250 kDa for the heterotetrameric IgG4 and 250 kDa for 
heterotetrameric IgE antibody (Figure 4.14A).  
Free light or heavy chain was not detected, suggesting that the antibody chains are 
assembled into whole antibody molecules.  The molecular sizes correspond to the heavy 




Figure 4.14: SDS-PAGE analysis of HMW-MAA specific IgG4 and IgE. Affinity 
purified HMW-MAA IgG4 and IgE antibodies were analysed under non-reducing (A) 
and reducing conditions (B), alongside with isotype controls human myeloma IgG4 and 
MOv18 IgE respectively, visualised by Coomassie staining. (HC=heavy chain, 
LC=light chain) 
 
Figure 4.14: SDS-PAGE analysis of HMW-MAA specific IgG4 and IgE. Affinity 
purified antibodies were analysed under non-reducing (A) and reducing conditions 
(B), alongside with isotype controls human myeloma IgG4 and MOv18 IgE 
respectively, visualized by Coomassie staining. The represented antibody molecular 
masses are identical to isotype controls and show the secreted antibodies are 
properly folded and glycosylated.  
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4.3.8 Flow cytometric assessment of affinity purified HMW-MAA IgE and IgG4 
The functional characteristics of stably expressed and affinity column-purified 
recombinant HMW-MAA-specific IgE and IgG4, were tested by flow cytometry 
analysis of the both antigen and receptor binding activities of the antibodies. Both 
HMW-MAA-specific IgE and IgG4 antibodies bound to HMW-MAA+ A374 melanoma 
cells (Figure 4.15) but not HMW-MAA- primary melanocytes.  
 
The receptor-binding activity of the antibodies were analysed by binding to the 
monocytic cell line U937, which expresses Fcγ receptors at low densities or RBL cells 
expressing both human and rat FcεRI (Dibbern et al, 2003). IgE bound to human FcεR1 
receptor, expressed on RBL SX38 mast cells, and IgG4 bound to the surface of U937 
cells, expressing Fcγ receptors (Figure 4.15). 
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Figure 4.15: Flow cytometric assessment of HMW-MAA specific IgG4 and IgE. 
Recombinantly expressed HMW-MAA specific IgG4 (A) and IgE (B)  antibodies show 
specific binding to native HMW-MAA present on the cell surface of A375 melanoma 
cells and no binding above background to primary melanocytes. The Fc fragments of 
IgG4 isotype demonstrate effector-binding to U937 monocytic cell line, expressing 
human Fcγ receptors. The IgE antibody isotype also represent comparable binding to 
RBL SX38 mast cells, expressing human FcεR1 receptor. 
 
 
4.4 Discussion   
Recombinant monoclonal antibodies (mAbs) have become a key tool for basic research 
and diagnosis of a number of human diseases. Over the last decade, antibody-based 
immunotherapies have been developed for the treatment of cancer, autoimmunity and 
inflammatory diseases (Leavy, 2010). The therapeutic antibodies infliximab and 
adalimumab, specific for tumour necrosis factor-alpha (TNFα), are sucessfully used to 
treat rheumatoid arthritis, as well as Crohn’s disease and psoriasis. The human 
epidermal growth factor receptor 2 (HER2)- specific antibody trastuzumab and the 
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Figure 4.15: Flow cytometric assessment of HMW-MAA specific IgG4 and IgE. 
Recombinantly expressed HMW-MAA specific IgG4 (A) and IgE (B)  antibodies show 
specific binding to native HMW-MAA present on the cell surface of A375 melanoma cells 
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vascular endothelial growth factor A (VEGFA)-specific antibody bevacizumab, are used 
in the treatment of several types of cancer. The CD20-specific antibody rituximab is 
used to treat both rheumatoid arthritis and non-Hodgkin’s lymphoma. This has resulted 
in a significant improvement in antibody production systems, allowing 
biopharmaceutical communities to reach grams per liter expression levels. However, in 
academia a costly and labour intensive process due to the lack of a suitable 
manufacturing platform, ensuring consistent antibody production, restricts the 
development of recombinant antibody material. Antibody expression systems 
representing co-transfection of vectors coding for either the heavy- or light-chain cDNA 
(Boel et al, 2000; Furtado et al, 2002; Koelsch et al, 2007; Madritsch et al, 2011; Tiller 
et al, 2008) or vectors hosting a dual antibody expression cassette (Braren et al, 2007; 
Hecker et al, 2011; Wiberg et al, 2006) have been exploited. However, these systems 
rely on restriction enzyme- and ligation-dependent cloning methods, which are time-
consuming, prevent high-throughput analysis of antibody candidates and sometimes 
impractical due to the lack of compatible restriction sites. Therefore, I sought to 
generate an improved flexible system for the cloning and expression of antibodies of 
any species and isotype with any desired specificity.  
First, to eliminate the requirement for co-transfection of two vectors, coding for the 
expression of heavy and light antibody chains independently, I constructed a dual 
expression cassette in a single mammalian expression vector thus halving the time and 
effort needed for DNA preparation and transfection procedure. An optimal ratio of 
heavy to light chain genes is important for efficient recombinant antibody production 
(Schlatter et al, 2005). Therefore I took advantage of the differing activities of the 2 
enhancers in pVITRO1, placing the heavy chain cassette under the control of SV40 and 
the light chain cassette under the control of the more active CMV. Another advantage of 
vector pVITRO1 is the presence of hph gene, which confers resistance to Hygromycin 
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B in both E. coli and mammalian cells. This allows a selection step and generation of 
stable cell lines. To prevent the use of restriction enzyme- and ligation-dependent 
cloning methods, I took advantage of the Polymerase Incomplete Primer Extension 
(PIPE) cloning method, shown to be rapid, cost-effective, and highly efficient, and thus 
capable of supporting the high-throughput cloning of thousands of genes in parallel 
(Klock et al, 2008). Following basic primer design steps (Figure 4.5) for generation of 
overlapping sequences, I constructed the dual antibody expression cassette within 
pVITRO1 utilising the PIPE cloning method. To improve the system’s flexibility to 
seamlessly exchange variable regions, I have designed universal primer pairs flanking 
the variable regions and successfully exchanged the specificity of an IgE antibody in a 
single day. This demonstrates that the system is suitable for high-throughput screening 
of antibody candidates derived from antibody discovery programs. Moreover, to 
provide constructs coding for the expression of different antibody isotypes with the 
same antigen specificity, and thus supporting the paralleled characterisation and 
comparative functional studies between different isotypes, I have shown a cloning 
procedure for exchanging the isotype of a HMW-MAA specific IgE to IgG4. These 
cloning experiments represent the system’s simplicity to exchange variable- and/or 
constant-region antibody domains allowing cloning of different isotypes with any 
desired specificity. 
Having successfully adapted and optimised the PIPE cloning method for our antibody 
needs, I aimed to demonstrate the capacity of the stable antibody expression system to 
produce fully functional antibodies, by expressing and characterising the HMW-MAA 
specific IgE and IgG4. A small-scale transfection in 293-F cells, followed by 2 weeks 
selection with Hygromycin B and generation of stable cell lines, enabled the expansion 
and large-scale production of antibodies into 1L shaker flask, 1L spinner or a 5L 
WAVE bioreactor. The anti-human IgE ELISA analysis of sample supernatants showed 
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10–25 mg/L HMW-MAA specific IgE expression levels within 30 days post-
transfection, compared to 1 mg/L by the transient antibody expression system using the 
pSG vectors. Using a 5L WAVE bioreactor, 125 mg total amount of antibody was 
produced within 30 days. This quantity is sufficient to support in vivo animal model 
experiments. Similarly, the IgG4 ELISA results demonstrate that HMW-MAA-specific 
IgG4-producing stable cells reached 70 mg/L expression level within 2 weeks using 1L 
spinner. Although cloning the dual antibody cassette into pVITRO1 for expression in 
293-F cells has facilitated high expression yields, the cassette can be transferred to any 
compatible expression vector consisting of two transcription units for use in alternative 
systems, if required. 
Having optimised the stable expression system for large-scale production, I aimed to 
characterise the antibodies produced and demonstrate their functionality. The HMW-
MAA specific IgE isotype was purified by affinity chromatography using IgG4-Fc-
(sFcεRIα)2  fusion protein and the IgG4 isotype was purified on a Protein-G column 
using an ÄKTA Prime system. The purity and size of the antibodies were assessed by 
SDS-PAGE analysis. Under non-reducing conditions, free light or heavy chain was not 
detected, indicating the antibody chains are assembled into whole antibody molecules. 
None of the purified antibodies showed significant contamination with other proteins, as 
judged by the absence of bands of molecular weight inconsistent with those expected 
for an IgE antibody polypeptide chains, indicating the affinity column purification was 
effective in yielding pure IgEs. The represented molecular sizes in SDS–PAGE 
suggested that the secreted antibodies are properly folded and glycosylated, in particular 
the extensively glycosylated IgE antibody. The biophysical properties and aggregative 
tendencies of the purified IgE and IgG4 isotypes were analysed by size-exclusion 
chromatography. The analysis showed no aggregation and confirmed the affinity 
column-purified product consists of monomeric antibodies. 
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Finally, the biological functions of the stably expressed and affinity column-purified 
recombinant HMW-MAA specific IgE and IgG4, were analysed by flow cytometry 
analysis to demonstrate both antigen and receptor binding activities. Flow cytometric 
analysis of A375 melanoma cells incubated with the HMW-MAA specific IgE and 
IgG4 antibody, showed comparable specific binding properties to native HMW-MAA 
and no binding above background to primary melanocytes. Furthermore, the IgE bound 
to human FcεR1 receptor, expressed on RBL SX38 mast cells, and IgG4 bound to the 
surface of U937 cells, expressing Fcγ receptors, demonstrating functional receptor-
binding activity of the recombinant antibodies. 
 
To summerise, I have developed a useful method for one-step assembly of antibody 
heavy- and light-chain cDNAs in a single mammalian expression vector. The DNA 
fragments assembled in this reaction do not rely on restriction enzymes and ligase-
dependant methods, thus minimising the steps involved in the cloning procedure and 
allowing the reproducible generation of fully functional recombinant antibodies of any 
species and isotype with any desired specificity, at the level of tens of milligrams per 
litre. The combination of seamless one-day cloning of antibody genes in a single vector, 
combined with an easily scalable production process delivering sufficient material for 
large scale studies such as animal model experiments or pre-clinical studies provides an 
unbiased manufacturing platform compared to the currently available antibody 
expression methods in academia. This method enables the direct comparison of 
different antibody isotypes, that could readily be adapted for use in mechanistic studies 
of antigen-antibody interactions, and facilitates the parallel processing of a large panel 
of antibodies for identification of potential candidates for clinical applications. 
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5 IgE FOR THE TREATMENT OF SOLID TUMOURS    
5.1 Introduction  
Within the last decade, therapeutic monoclonal antibodies have been complementing the 
conventional treatments of some malignant diseases and have improved prognosis for 
many cancer patients. However, while more than half of these antibodies are approved 
for the treatment of blood malignancies, an antibody therapy is urgently needed for the 
treatment of solid, non-haematopoietic tumours. 
 
IgG, the most abundant antibody class in the blood, is the only antibody class examined 
in the immunotherapy of cancer and nearly all antibodies developed in the clinic for 
cancer therapy to date are of the IgG1 subclass (Scott et al, 2012). This arises from the 
early work of Neuberger, showing that IgG1 was the most efficacious of nine different 
antibody classes in complement-mediated lymphoma cell killing by human PBMC in 
vitro (Bruggemann et al, 1987). Subsequent clinical trials with antibodies recognising 
the B cell marker CD20 supported the inference that IgG1 would be the subclass best 
suited for immunotherapy of patients with B cell malignancies such as non-Hodgkin’s 
lymphoma (Alduaij & Illidge, 2011). However, poor tissue penetration of IgG 
antibodies and low affinity of IgGs for their receptors on immune cells may partly 
account for the weak immune responses observed and resulting poor performance of 
many IgG antibodies against solid tumours. IgE antibodies play a major role in the 
human allergic response, but are also key contributors to the body’s defence against 
parasitic infections. IgE antibodies differ from the more abundant IgG isotypes, in that 
they are unable to fix complement and do not bind to the Fcγ receptors. They can be 
transported from the circulation into tissues, where, through their strong affinity for 
their receptors on immune cells, they are known to trigger powerful immune responses. 
The concentration of IgE in the serum of normal individuals is minute, and unlike IgG, 
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the presence of IgE in the blood is short-lived (half-life of 1.5 days) (Gould & Sutton, 
2008; Gould et al, 2003; Ravetch & Kinet, 1991). Yet, IgE is sequestered in tissues and 
retained locally by powerful IgE receptor-expressing resident cells such as mast cells, 
macrophages and dendritic cells with a measured half-life of two weeks, proportionately 
longer than that of IgG (2-3 days) (Gould et al, 2003; Hellman, 2007). These properties 
of IgE antibodies may be redirected to enhance cytotoxicity and phagocytosis of tumour 
cells, as well as initiate IgE antibody-dependent antigen presentation by IgE receptor-
bearing antigen-presenting cells such as dendritic cells, B cells and macrophages. Thus, 
passive and active immunity against solid tumours could act in conjunction in tissues 
such as the skin which is naturally populated with IgE effector cells. The strength of 
IgE-mediated immune responses in tissues, then, carries the expectation of increased 
potency as well as longevity of immune surveillance by IgE and effector cells against 
skin tumours. We have found that the results of in vitro experiments using IgG1 do not 
translate well to the solid tumour environment, where other mechanisms may prevail 
(Bracher et al, 2007; Karagiannis et al, 2008b; Karagiannis et al, 2007; Reali et al, 
2001). We have demonstrated superior in vivo efficacy for the IgE subclass in 
comparison to IgG in the targeting of MOv18, an antibody directed against folate 
receptor, a tumour- specific antigen, in two murine xenograft models of human ovarian 
cancer (Gould et al, 1999; Karagiannis et al, 2003). Therefore, we believe the efficacy 
of cancer immunotherapy may be improved using IgE isotype in place of the currently 
conventional IgG and aimed to engineer an IgG1 and IgE against a melanoma-specific 
antigen, the High Molecular Weight Melanoma-Associated Antigen (HMW-MAA) 
(Chan & Murphy, 1999; Hafner et al, 2005; Kang et al, 2000; Luo et al, 2006), for 
comparative functional studies between the two isotypes. The work represented in this 
chapter is a result of a fruitful collaboration with Dr. Panos Karagiannis. 
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5.2 Methods  
5.2.1 Cloning of IgG1 expression construct  
The pVitroMAA-IgE vector was PCR linearised as previously described (see Section 
4.5), and subsequently treated by Dpn I (NEB) according to the manufacturer’s 
instructions to destroy the vector template. The human Cγ1 region was amplified, using 
previously optimised reaction conditions (see Section 4.4) and 10 seconds extension 
time, from an existing pSG vector (Karagiannis et al, 2009) using primer pair 
Gam1_Fwd and Gam1_Rev (Table 2.2), for generation of vector fragment terminal end-
homology. The Dpn I treated linearised vector and unpurified Cγ1 PCR product were 
mixed in 1:1 (v/v) ratio, followed by 30 minutes incubation at 60°C and 2 µl from the 
mixture transformed into XL1-Blue competent cells. The newly generated vector was 
named pVitroMAA-IgG1, coding for the expression of chimeric HMW-MAA specific 
IgG1 antibody. 
5.2.2 Immunofluoresence staining of A375 cells 
A375 metastatic melanoma tumour cells were seeded in LabTek glass chamber slides 
(Nunc) at a density of 2 x 104 cells/well. Cells were washed in PBS and fixed in 4% 
formaldehyde PBS for 15 min and then incubated with PBS-T, 10% goat serum, 0.05% 
Tween for 25 min at room temperature. HMW-MAA specific IgG1 and IgE or control 
NIP (hapten specific) IgG1 and IgE antibodies were incubated for 45 min with A375 
cells at a concentration of 0.01µg/µl. Cell-bound antibodies were detected with a 
secondary goat anti-human IgG or goat anti-human IgE antibody conjugated to FITC 
(Jackson ImmunoResearch; 1:250). Nuclei were stained with Hoechst dye for 3 mins. 
All washing steps were done in PBS and the final wash was performed with dH20. Cells 
were then mounted in Mowiol (Sigma) mounting medium. Fluorescence microscopy 
was performed on a Zeiss AxiovertZ.1 (40x objective) upright microscope. Acquisition 
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and analysis was performed with an AxioCamMR3 and AxioVision Software (Carl 
Zeiss). 
5.2.3 Degranulation assay  
RBL SX-38 cells were seeded at a concentration of 2x104 cells/well in 100µl media onto 
96-well round bottom plates (96 Nucleon, Nunc, Roskilde, Denmark) and incubated in a 
5% CO2 humidified incubator at 37°C. 24 h later, the cells were passively sensitised 
with 100ng/ml of HMW-MAA IgE or control anti hapten specific IgE (NIP) antibody 
and incubated for 2 hours. Cells were then washed twice with stimulation buffer 
(Hank’s Buffered Salt Solution, HBSS supplemented with 1% BSA) and left untreated 
(control) or triggered with either 2x103 A375 tumour cells per well, 100 ng/ml of 
polyclonal rabbit anti human-IgE (Dako, Ely, UK) antibody, or stimulation buffer alone 
for 30 mins at 37°C in a humidified incubator. Control supernatants obtained from 
untreated wells were considered background degranulation and the HBSS containing 
0.1% Triton-X100 as a total release (100% degranulation). Degranulation was 
terminated by placing the experiment on ice and 50µl of supernatant was transferred to 
96 polystyrene black MicroWellTM Plates (Nunc, Roskilde, Denmark) for analysis. 
Quantification was determined by measuring β- hexosaminidase release using a 
fluorogenic substrate (4-methylumbelliferyl-N-acetyl-β-D-glucosaminide) prepared 
according to a standard protocol (Casal et al, 2003; Linko-Lopponen & Makinen, 1985). 
Briefly, supernatants were incubated with an equal amount of fluorogenic substrate at 
37°C in the dark for 2 hour and then quenched using 0.5M Tris. Finally fluorescence 
was read on an Omega microplate reader (BMG Labtech, Aylesbury, UK) using 
excitation and emission filters at 360nm and 405nm. % of degranulation was calculated 
as relative to 100% degranulation with Triton-X100. 
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5.2.4 Three-color flow cytometric assay 
CFSE, a green fluorescence derived intracellular dye, was used to stain A375 tumour 
cells prior to incubation with U937 monocytic cells. After the incubation, U937 cells 
were stained with anti-CD89-PE and 7-AAD indicating effector cells and dead cells, 
respectively. A375 cells were stained 24 h prior to assays with 5.0 µM CFSE (5-(and 6-) 
carboxyfluorescein diacetate succinimidyl ester, Molecular Probes, Eugene, OR) in PBS 
for 10 min at 37oC, washed in DMEM medium supplemented with 10% FCS, 2 mM L-
glutamine, and returned to normal culture conditions. The following day, CFSE-labelled 
tumour cells were washed, mixed with unstained U937 effector cells at E:T cell ratio of 
4:1 with or without antibodies, followed by incubation for 3 h at 37oC. Antibodies were 
tested at a concentration of 4 µg/mL. CFSE-labelled tumour cells were detected in FITC 
(530/30 nm band pass filter and a 502 long pass filter), CD89-PE-labelled monocytic 
effector cells in PE (585/42 nm band pass filter and a 556LP) and 7-AAD+ dead cells in 
APC (660/20 nm band pass filter) channels, while control samples were set for 
compensation adjustments between CFSE and PE. Two dual colour flow cytometric dot 
plots were generated to calculate ADCC and ADCP as previously described (Bracher et 
al, 2007; Karagiannis et al, 2008a; Karagiannis et al, 2008b; Karagiannis et al, 2007). 
Briefly, one dot plot depicted CFSE+ tumour cells on the x-axis and 7-AAD+ cells on 
the y-axis, allowed quantification of double positive cells (CFSE+/7-AAD+ cells) 
indicating tumour targets killed externally by effector cells (ADCC, cytotoxicity). The 
second dot plot depicted CFSE+ tumour cells on the x-axis and CD89-PE+ effector cells 
on the y-axis in order to quantify total CFSE+ tumour cells and the number of tumour 
cells material present within PE+ effector cells, indicating phagocytosis (ADCP) by 
effector cells (CFSE+/PE+ cells). No antibody or 4µg of Mov18 antibody isotypes 
directed against FRα, which is not expressed on A375 tumour cells, were used as 
controls and assay conditions ran in triplicates. 
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5.3 Results 
5.3.1 Cloning, expression and purification of HMW-MAA specific IgG1 
In chapter 4, I have described the construction of a dual antibody expression cassette in 
pVITRO1 and the subsequent PIPE cloning of HMW-MAA specific IgE and IgG4 
expression vectors. A stable cell line expressing the HMW-MAA specific IgE has been 
generated and frozen in liquid nitrogen. Thus to support the parallel characterisation and 
comparative functional studies between IgE and IgG1 isotypes, I proceeded with PIPE 
cloning of HMW-MAA specific IgG1 expression vector (Figure 5.1). 
 
Having successfully cloned the pVitroMAA-IgG1 vector, I continued with the 
expression of the HMW-MAA specific IgG1 antibody. 293-F cells were transfected as 
previously described (Methods 4.2). The cells were kept under Hygromycin selection 
for 2 weeks and a stable cell line was generated. Simultaneously, frozen cells expressing 
the HMW-MAA specific IgE were thawed and cultured to recover. The IgG1 and IgE 
expressing cell lines were expanded into 1L shaker flasks and sample supernatants 
collected after 12 days for antibody quantification by anti-human IgE/IgG1 ELISA as 
described previously (Gilbert et al, 2011; McCloskey et al, 2007). The ELISA analysis 
showed 13mg/L IgG1 and 10mg/L IgE expression levels (Figure 5.2), consistent with 
previous measurements using shaker flasks. This result further confirmed that the stable 
antibody expression system was capable of generating material in quantities that could 
support animal model experiments, enabling me to continue with the purification 
process.  
The HMW-MAA specific IgE isotype was purified by affinity chromatography using 
IgG4-Fc-(sFcεRIα)2  fusion protein, as previously described (Methods 3.2). The HMW-
MAA specific IgG4 isotype was purified on a Protein-G column as previously described  
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Figure 5.1: Schematic representation of HMW-MAA specific IgG1 cloning. 
pVitroMAA-IgE expression vector is PCR linearised by C-Epsilon region flanking primers 
and subsequently Dpn I treated. Simultaneously, C-Gamma 1 region is PCR amplified for 
generation of vector terminal end-homology. The unpurified Dpn I treated linearised vector 
is mixed 1:1 (v/v) with unpurified C-Gamma 1 PCR product. The single-stranded DNA 
fragments anneal directionally across the complementary sequences and nicks and gaps are 
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Figure 5.2: Quantification of HMW-MAA specific IgG1 and IgE expression levels 
by ELISA. Supernatants from recombinantly expressed antibodies were analysed by 
IgG1 (A) and IgE (B) isotype-specific ELISA after 12 days incubation of stable cell 
lines in shaker flasks. Samples from IgE expressing cells, used as a negative control, did 
not give a signal above background levels on the IgG1 specific ELISA.  Similarly 
supernatants from IgG1 expressing cells gave no signal on the IgE specific ELISA. The 
concentration of antibody in mg/L was determined by reference to a standard curve and 
results represent the mean of triplicate readings ± SD.  
 
 
5.3.2 Characterisation of HMW-MAA specific IgG1 and IgE 
The biophysical properties of affinity column-purified HMW-MAA specific IgE and 
IgG1 and previously characterised isotype controls MOv18 IgE and IgG1 (Karagiannis 
et al, 2003) were analysed by size-exclusion chromatography, as previously described 
(Methods 4.2). The size-exclusion chromatography analysis showed no aggregation and 
confirmed the affinity column-purified product consists of monomeric antibodies 
(Figure 5.3). 
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Figure 5.3: Size exclusion chromatography analysis of HMW-MAA specific IgG1 
and IgE. Elution profiles of recombinantly expressed and affinity purified HMW-MAA 
specific IgG1 (A) and IgE (B) antibodies, compared to previously-characterised isotype 
controls MOv18 IgG1/IgE respectively, from Superdex™ 200 gel filtration. The 
antibody profiles correspond to isotype controls and confirm the affinity purified 
products consist of monomeric antibodies.  
 
 
The size and purity of affinity column-purified antibodies HMW-MAA specific IgE and 
IgG1 and isotype controls MOv18 IgE and IgG1 respectively, were assessed by SDS-
PAGE analysis as previously described (Methods 4.2). Under reducing conditions 
(Figure 5.4), protein bands corresponding to molecular size between 52-72 kDa of the 
protein ladder represented the IgG1 heavy chains. Lower bands corresponding to the 
antibody light chains were also visualised. Similarly, protein bands of molecular size 
between 72-95 kDa and lower bands were visualised suggesting the heavy and light 
chains respectively, of the IgE antibodies. Under non-reducing conditions, molecular 
Figure 5.3: Size exclusio  chromat graphy analysis of HMW-MAA specific 
IgG1 and IgE. Elution profiles of recombinantly e pressed and affinity purified 
HMW-MAA specific IgG1 (A) and IgE (B) antibodies, compared to previously-
characterised isotype controls MOv18 IgG1/IgE respectively, from Superdex™ 200 
gel filtration. The antibody profiles correspond to isotype controls and confirm the 
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sizes of the visualised protein bands were found to be in the range of 180-250 kDa for 
the heterotetrameric IgG1 and 250 kDa for heterotetrameric IgE antibody. Free light or 
heavy chain was not detected, suggesting that the antibody chains are assembled into 
whole antibody molecules.  Thus, the represented molecular sizes in SDS–PAGE 
suggest that the secreted antibodies are properly folded and glycosylated, in particular 
the extensively glycosylated IgE antibody. 
 
Figure 5.4: SDS-PAGE analysis of HMW-MAA specific IgG1 and IgE. Affinity 
purified HMW-MAA specific IgG1 and IgE antibodies were analysed under non-
reducing (A) and reducing conditions (B), alongside with previously-characterised 
isotype controls MOv18 IgG1/IgE respectively, visualised by Coomassie staining. The 
represented antibody molecular masses are identical to isotype controls and show the 
secreted antibodies are properly folded and glycosylated.  
 
 
The functional studies of affinity column-purified recombinant HMW-MAA specific 
IgE and IgG1, were pursued by flow cytometry analysis to demonstrate both antigen 
and receptor binding activities of the antibodies. The flow cytometric assessments were 
used to compare antigen specificity of HMW-MAA IgE and IgG1 to native HMW-
Figure 5.4: SDS-PAGE analysis of HMW-MAA specific IgG1 and IgE. 
Affinity purified HMW-MAA specific IgG1 and IgE antibodies were analysed 
under non-reducing (A) and reducing conditions (B), alongside with previously-
characterised isotype controls MOv18 IgG1/IgE respectively, visualized by 
Coomassie staining. The represented antibody molecular masses are identical to 
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MAA as presented on the cell surface of A375 melanoma cells and to primary human 
melanocytes, normally present in the skin of healthy volunteers. The receptor-binding 
activity of the IgG1 antibody isotype was analysed by binding to the surface of 
monocytic cell line U937, which expresses Fcγ receptors at low densities. The receptor-
binding activity of the IgE antibody isotype was analysed by binding to RBL SX38 
mast cells expressing both human and rat FcεRI (Dibbern et al, 2003). The flow 
cytometric experiment was performed as previously described (Methods 4.2). Flow 
cytometric analysis (Figure 5.5) of A375 melanoma cells incubated with the HMW-
MAA specific IgE and IgG1 antibody, shows a clear right shift of fluorescence 
intensity, suggesting that both antibodies had comparable specific binding properties to 
native HMW-MAA as detected by >95% positive populations (gating above isotype 
controls MOv18 IgE and IgG1) and no binding above background to primary 
melanocytes. Furthermore, the IgE bound to human FcεR1 receptor, expressed on RBL 
SX38 mast cells, and IgG1 bound to the surface of U937 cells, expressing Fcγ receptors, 
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Figure 5.5: Flow cytometric assessment of HMW-MAA specific IgG1 and IgE. 
Recombinantly expressed IgG1 (A) and IgE (B)  antibodies show specific binding to 
native HMW-MAA present on the cell surface of A375 melanoma cells and no binding 
above background to primary melanocytes. The Fc fragments of IgG1 isotype 
demonstrate effector-binding to U937 monocytic cell line, expressing human Fcγ 
receptors. The IgE antibody isotype also represent comparable binding to RBL SX38 
mast cells, expressing human FcεR1 receptor. Antibody binding was detected using a 
goat anti-human IgG-FITC (A) or IgE-FITC (B) antibody. 
 
5.3.3 Immunofluoresence staining of A375 cells grown on glass chamber slides 
Having successfully analysed antigen and receptor binding activities of HMW-MAA 
specific IgG1 and IgE antibodies by flow cytometry, I aimed to confirm their specific 
binding to HMW-MAA as presented on the cell surface of A375 cells by 
immunofluorescence microscopy.  
Binding of the HMW-MAA specific IgG1 and IgE antibodies to the surface of the A375 
tumour cells was confirmed by immunofluorescence microscopy, while a hapten 
specific isotype control, NIP-IgE and NIP-IgG1 did not show binding above 
background (Figure 5.6). Therefore, the flow cytometry and immunofluorescence of 
Figure 5.5: Flow cytometric assessment of HMW-MAA specific IgG1 and IgE. 
Recombinantly expressed IgG1 (A) and IgE (B)  antibodies show specific binding to 
native HMW-MAA present on the cell surface of A375 melanoma cells and no binding 
above background to primary melanocytes. The Fc fragments of IgG1 isotype 
demonstrate effector-binding to U937 monocytic cell line, expressing human Fcγ 
receptors. The IgE antibody isotype also represent comparable binding to RBL SX38 
mast cells, expressing human FcεR1 receptor. Antibody binding was detected using a 
goat anti-human IgG-FITC (A) or IgE-FITC antibody. 
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HMW-MAA specific IgG1 and IgE confirmed the antibodies recognised the expected 
tumour target and immune effector cells. 
 
Figure 5.6: Immunofluorescence staining of HMW-MAA specific IgG1 and IgE to 
A375 cells. Antibodies bound to A375 melanoma tumour cells were detected by goat 
anti-human IgG/IgE-FITC antibodies. The immunofluorescence confirms specific 
binding of HMW-MAA IgG1 (A) and HMW-MAA IgE (C) to A375 cells and no 
background binding with isotype controls hapten specific NIP-IgG1 (B) or NIP-IgE (D). 














C                                            D 
A                                            B A375 / HMW-MAA IgG1 A375 / NIP IgG1 
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Figure 5.6: Immunofluorescence staining of HMW-MAA specific IgG1 and 
IgE to A375 cells. Antibodies bound to A375 melanoma tumour cells were 
detected by a goat anti-human IgG/IgE-FITC antibodies. The immunofluorescence 
confirms specific binding of HMW-MAA IgG1 ( ) and HMW-MA  IgE (C) to 
A375 cells and no background bi ding with isotype controls hapten specific NIP-
IgG1 (B) or NIP-IgE (D). Images were captured using a 63x oil objective. Scale 
bar = 20 µm. 
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5.3.4 HMW-MAA specific IgE effector cell activation 
Flow cytometry and immunofluorescence experiments, showed the binding of both 
IgG1 and IgE to the expected tumour target and immune effector cells. Next, I sought to 
examine the ability of HMW-MAA specific IgE antibody to trigger functional 
degranulation due to the recognition of HMW-MAA expressed on tumour cells and 
cross-linking of the human high affinity IgE (FcεRI) receptors, expressed on RBL SX-
38 mast cells (Dibbern et al, 2003), in an antigen-dependent manner. This was 
performed using mast cell degranulation assay, measured by β-hexosaminidase release 
depicting mast cell activation. 
The degranulation assay showed that the HMW-MAA specific IgE antibody alone did 
not induce degranulation (Figure 5.7). However, the antibody potentiated β-
hexosaminidase release of RBL SX-38 cells following stimulation with a polyclonal 
anti-human IgE antibody. The HMW-MAA specific IgE induced significant 
degranulation of RBL-SX38 cells following stimulation with 2x103 A375 cells (used for 
titration, data not shown), expressing HMW-MAA. This data suggests that IgE exhibits 
an intrinsic potential to cross-link the FcεRI and activate effector cells in an antigen-
dependent manner. Furthermore, this represents the use of recombinant human IgE 
antibodies of defined specificity as a useful tool to investigate mechanisms underlying 
IgE-mediated reactions. 
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Figure 5.7: Degranulation of mast cells by HMW-MAA specific IgE. Degranulation 
(%) was measured by β-hexosaminidase release depicting mast cell activation, relative 
to Triton X-100. Minimal degranulation was seen with cells alone, control antibody 
NIP-IgE or HMW-MAA specific IgE alone. Significant degranulation is observed with 
samples given HMW-MAA specific IgE + polyclonal anti-IgE and NIP-IgE + 
polyclonal anti-IgE. Scale bars indicate mean values ± SD of n = 3 experiments, all 
conditions were tested in triplicate. Figure courtesy of Debra Josephs (PhD student, 
KCL).  
 
5.3.5 Flow cytometric ADCC/ ADCP assay of HMW-MAA specific IgE and IgG1 
Having observed that the HMW-MAA specific IgE is effective in cross-linking the 
FcεRI and activating effector cells in an antigen-dependent manner, we aimed to 
examine the ability of IgE and IgG1 to directly signal tumour cell death. We adapted a 
modified three-color flow cytometric assay (Bracher et al, 2007; Karagiannis et al, 
2008a; Karagiannis et al, 2008b; Karagiannis et al, 2007) to simultaneously measure 
tumour cell cytotoxicity (ADCC) and phagocytosis (ADCP) of A375 melanoma cells, 
where U937 monocytic cells were employed as effector cells.  
The three-color flow cytometric assay showed that after 3 hours in culture, U937 cells 
mixed with HMW-MAA specific IgG1 and A375 mediated significant levels of ADCP 
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8.34%; Figure 5.8A). However, U937 cells mixed with HMW-MAA specific IgE and 
A375 mediated predominantly ADCC above that seen with samples incubated with the 
isotype control MOv18 IgE (18.23 vs. 5.74%; Figure 5.8B). In addition, incubation with 
HMW-MAA specific IgE induced only minimal tumour cell ADCP compared to control 
MOv18 IgE (6.22 vs. 8.79%; Figure 5.8B). Thus, the flow cytometric ADCC/ADCP 
assay measurements confirmed that HMW-MAA specific IgE mediated significant 
levels of ADCP of A375 tumour cells by monocytic cells (p<0.001, Two-way Anova, 
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Figure 5.8: Three-colour flow cytometric tumour cell killing assessment of HMW-
MAA specific IgG1 and IgE. Quantification of HMW-MAA IgG1-mediated (A) or 
IgE-mediated (B) A375 tumour cell killing by U937 monocytes is measured by ADCC/ 
ADCP assay. HMW-MAA specific IgG1 induces tumor cell killing via phagocytosis 
and HMW-MAA IgE kills tumour cells via cytotoxicity. Cytotoxicity: grey bars; 
phagocytosis: gold bars. Results are means ± SD of three independent experiments. 
(n=5; *p<0.05; **p<0.01; ***p<0.001; ns: p>0.05). Figure courtesy of Panos 
Karagiannis (PhD student, KCL).  
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Figure 5.8: Three-colour flow cy ome ric tumour cell killing assessment of HMW-MAA 
spec fic IgG1 and IgE. Q antification of HMW-MAA IgG1-mediated (A) or IgE-mediated (B) 
A375 tumour cell killing by U937 monocytes is measured by ADCC/ ADCP assay. HMW-MAA 
specific IgG1 induces tumor cell killing phagocytosis and HMW-MAA IgE kills tumour 
cells via cyt toxicity  Cytotoxicity: gr y bars; phagocytosis: gold bars. Results are means ± SD 
of three independent experiments. (n=5; *p<0.05; **p<0.01; ***p<0.001; ns: p>0.05). Figure 
courtesy of Panos Karagiannis (PhD student, KCL).  
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5.3.6 Human melanoma xenograft mouse model  
Ultimately, the efficacy of all potential therapeutics is tested in vivo using relevant 
models. The murine xenograft model of human ovarian cancer, shown to be very 
effective in comparing IgG1 and IgE (Gould et al, 1999; Karagiannis et al, 2003), 
represented a suitable model for targeting solid tumours. To study the potential tumour 
growth restricting capacity of the HMW-MAA specific IgE and IgG1 antibodies, we 
used this established immunodeficient mouse (NOD/SCID γ-/- mouse of BALB/c 
background) model of human melanoma. 
 
5 x 105 A375 melanoma cells per mouse were injected subcutaneously in the flank. 
Following tumour challenge and engraftment of human PBLs to provide human effector 
cells, antibodies were administered weekly at 10 mg/kg doses by the intravenous route. 
The treatment with weekly doses of HMW-MAA specific IgE resulted in severely- 
restricted melanoma tumour growth over a period of 30 days, while tumours in mice 
treated with the corresponding HMW-MAA specific IgG1 antibody were smaller than 
the control antibodies MOv18 IgE and IgG1 against the tumour antigen FRα, which is 
not expressed on A375 melanoma cells (Figure 5.9). Xenografts given no antibody 
treatments grew exponentially up to 750mm3 over the same time period. These initial 
experiments suggest that the HMW-MAA specific IgE antibody and to a lesser extent, 
HMW-MAA specific IgG1, are capable of mounting  anti-tumoural responses in vivo.  
Further immunohistochemical evaluations of the melanoma tumour marker HMW-
MAA, normally expressed by A375 melanoma cells in culture, were performed on 
previously excised and snap-frozen tumours. Expression of the HMW-MAA on A375 
subcutaneous melanoma tumours grown in NOD/SCID γ-/- mice was confirmed (Figure 
5.10), suggesting the A375 melanoma xenograft model may be used to evaluate the 
therapeutic potential of monoclonal antibodies recognising this antigen. This is very 
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advantageous for the future evaluation of antibody candidates derived from our 
antibody discovery program (described in details in chapter 6). 
 
Figure 5.9: Tumour growth restriction efficacy of IgG1/IgE in a subcutaneous 
melanoma tumour model.  Monitoring subcutaneous growth (mm3) of melanoma 
tumours in NOD/SCID γ-/- mice at different time points following tumour challenge and 
engraftment of human  PBLs as effector cells. Weekly treatment of HMW-MAA 
specific IgE severely restricted melanoma tumour growth, compared to mice treated 
with HMW-MAA specific IgG1 and control antibodies MOv18-IgG1/IgE. Figure 
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Figure 5.10: Immunohistochemical analysis of A375 metastatic melanoma cells. 
Subcutaneous tumour model of A375 metastatic melanoma cells, labelled for expression 
of melanoma marker HMW-MAA (left) and mouse IgG isotype control antibody 
(right). Images were captured using a 10x objective. Scale bar = 150 µm. Figure 
courtesy of Panos Karagiannis (PhD student, KCL).  
 
 
5.4 Discussion  
Some tumour antigen-specific monoclonal IgG antibodies have already been approved 
for therapeutic use and nearly all antibody therapies developed to date have relied on 
only one of the nine human antibody classes, namely IgG1 (Scott et al, 2012). This 
arises from the early work of Neuberger, showing that IgG1 was the most efficacious of 
nine different antibody classes in complement-mediated lymphoma cell killing by 
human PBMC in vitro (Bruggemann et al, 1987). However, it is known that IgG 
diffuses inefficiently into solid tissues, and binds with low affinity to receptors on 
immune effector cells.  
IgE antibodies differ from the more abundant IgG isotypes, in that they can be 
transported from the circulation into tissues, where, through their strong affinity for 
their receptors on immune cells, they are known to trigger powerful immune responses. 
We have found that the results of in vitro experiments using IgG1 do not translate well 
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2007; Karagiannis et al, 2008b; Karagiannis et al, 2007; Reali et al, 2001). We have 
demonstrated superior in vivo efficacy for the IgE subclass in comparison to IgG in the 
targeting of MOv18, an antibody directed against folate receptor, a tumour- specific 
antigen, in two murine xenograft models of human ovarian cancer (Gould et al, 1999; 
Karagiannis et al, 2003). Therefore, we aimed to engineer an IgG1 and IgE antibody 
against a melanoma-specific antigen, the High Molecular Weight Melanoma-Associated 
Antigen (HMW-MAA) (Chan & Murphy, 1999; Hafner et al, 2005; Kang et al, 2000; 
Luo et al, 2006), for comparative functional studies between the two isotypes. 
Having successfully adapted and optimised the PIPE cloning method for swapping 
constant regions in chapter 4, I seamlessly exchanged human Cε in vector pVitroMAA-
IgE with human Cγ1 and created vector pVitroMAA-IgG1, coding for the expression of 
HMW-MAA specific IgG1. Following a small-scale transfection in 293-F cells and 2 
weeks selection with Hygromycin B, a stable cell line expressing HMW-MAA specific 
IgG1 was generated. Cell expressing IgG1 and IgE were expanded into 1L shaker flasks 
and after 12 days incubation, 13mg/L IgG1 and 10mg/L IgE expression levels were 
observed. The antibodies were purified by affinity chromatography and assessed by 
SDS-PAGE analysis. Under non-reducing conditions, free light or heavy chain was not 
detected, indicating the antibody chains are assembled into whole antibody molecules. 
None of the purified antibodies showed significant contamination with other proteins, as 
judged by the absence of bands of molecular weight inconsistent with those expected 
for an IgE or IgG1 antibody polypeptide chains, indicating the affinity purification was 
effective in yielding pure antibodies. The represented molecular sizes in SDS–PAGE 
suggested that the secreted antibodies are properly folded and glycosylated, in particular 
the extensively glycosylated IgE antibody. The biophysical properties and aggregative 
tendencies of the purified IgE and IgG1 isotypes were analysed by size-exclusion 
chromatography. The analysis showed no aggregation and confirmed the affinity 
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column-purified product consists of monomeric antibodies. This is an example of the 
effectiveness of our antibody cloning system in swapping C regions, simplifying the 
subsequent antibody production in sufficient quantities, capable of supporting the 
parallel characterisation and comparative functional studies between different isotypes. 
 
The antigen and receptor binding activities of IgE and IgG1 were analysed by flow 
cytometry. Flow cytometric analysis of A375 melanoma cells incubated with the 
HMW-MAA specific IgE and IgG1 antibody, showed comparable specific binding 
properties to native HMW-MAA and no binding above background to primary 
melanocytes. Furthermore, the IgE bound to human FcεR1 receptor, expressed on RBL 
SX38 mast cells, and IgG1 bound to the surface of U937 cells, expressing Fcγ receptors, 
demonstrating functional receptor-binding activity and recognition of immune effector 
cells. The binding of the HMW-MAA specific IgG1 and IgE antibodies to the surface of 
the A375 tumour cells was also confirmed by immunofluorescence microscopy.  
Following flow cytometry and immunofluorescence experiments, we examined the 
capacity of the HMW-MAA specific IgG1 and IgE antibodies to target and kill tumour 
cells, by employing Fc receptor-mediated effector cell activation in in vitro assays such 
as functional degranulation and ADCC/ADCP assays. In a functional degranulation 
assay measuring % β-hexosaminidase release by RBL SX-38 mast cells expressing 
human FcεRI, the HMW-MAA specific IgE antibody alone did not potentiate β-
hexosaminidase release. However, the antibody induced significant degranulation of 
RBL SX-38 cells following stimulation with a polyclonal anti-human IgE antibody, 
demonstrating the ability of this antibody to activate immune effector cells through 
engagement of its high affinity receptor. Furthermore, both antibodies were capable of 
activating immune effector cells to kill cancer cells in vitro with similar effectiveness, 
- 143 - 
but each by different mechanisms: the chimaeric IgG1 activated human monocytes to 
kill tumour cells by ADCP, while the IgE mediated ADCC of tumour cells.  
 
Finally, an immunodeficient mouse model of human melanoma grown subcutaneously 
in NOD/SCID γ-/- mice of BALB/c background was used to assess the ability of the 
melanoma antigen-specific antibodies to restrict tumour growth in vivo. The murine 
xenograft model of human ovarian cancer has been shown to be very effective in 
comparing IgG1 and IgE in targeting solid tumours (Gould et al, 1999; Karagiannis et 
al, 2003) and represented a suitable model of human melanoma. Using this 
subcutaneous in vivo model of melanoma and engraftment of human immune effector 
cells in these mice, treatment with weekly doses of HMW-MAA specific IgE (10mg/kg) 
resulted in severely-restricted melanoma tumour growth over a period of 30 days 
compared to those treated with the corresponding IgG1 at the same doses and to those 
given non-specific antibody controls. Furthermore, immunohistochemical evaluations 
confirmed the melanoma tumour lesions were positive for the HMW-MAA antigen, 
normally expressed by A375 melanoma cells in culture. Therefore, despite similar 
levels of tumour cell killing efficiencies in vitro, we observed improved efficacy with 
HMW-MAA specific IgE compared to the corresponding IgG1 of the same specificity 
in vivo. This result suggests that treatment with melanoma antigen-specific IgE antibody 
was superior in inducing tumour growth restriction in vivo compared to the 
corresponding IgG1. 
 
The data presented in this chapter demonstrated that engineering antibodies with IgE-Fc 
regions can improve antibody effector functions, which is particularly advantageous in 
the case of solid tumours, since these are frequently refractory to treatment with IgG 
antibodies. With a serum half-life of 21-24 days, compared to a half-life of 2-3 days in 
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tissues, IgG antibodies may be the most effective antibody class to target blood-resident 
tumours and circulating tumour cells, while their ability to exert tumour surveillance in 
tissues may be less potent (Hellman, 2007; Ravetch & Kinet, 1991). Other parameters 
that may modulate IgG anti-tumoural functions could be slow or ineffective recruitment 
and/or local suppression of activator immune effector cells by tumour cells in lesions 
and the presence/induction of immunoregulatory cells by tumours in situ (Brigati et al, 
2002). For antibodies of the IgG class that do localise in tumour lesions, overcoming 
these immunomodulatory environments may be challenging. Additionally, factors such 
as the low affinity of IgG for its Fc gamma receptors and the presence of the inhibitory 
receptor FcγRIIb in tumour-infiltrating immune cells such as macrophages may 
negatively influence the efficacy of IgG antibodies in tissues (Kraft & Kinet, 2007; 
Maenaka et al, 2001). 
 
Since each antibody class operates in different anatomic compartments, and functions 
through unique Fc-receptors and immune effector cells, we have focused on antibodies 
of the IgE class, commonly known for their role in the allergic response and parasite 
protection. Antibodies of this class function through their specific high-affinity Fc 
receptors (FcεRl with Ka=1011 M-1 is 102-105 times higher than that of IgGs for their 
receptors) on a different spectrum of effector cells to IgG, and naturally reside in tissues 
where they exert immunological surveillance. Our results demonstrate that these 




In conclusion, antibodies of different classes may present different functional properties 
against cancer cells, due to their ability to activate different families of Fc receptors on 
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immune effector cells to destroy tumours. In the context of melanoma, the two 
chimaeric monoclonal antibodies IgG1 and IgE of the same specificity against HMW-
MAA, which is over-expressed by more than 80% of melanomas, had differential 
effects in vivo.  Due to differential immune effector cell-mediated melanoma tumour 
killing by each antibody, the IgE antibody had superior efficacy compared to the 
corresponding IgG1 in an in vivo xenograft model of melanoma. Future mouse models 
will further investigate the mechanisms by which these antibodies engage and activate 
different compartments of the immune response. Ultimately, this will help evaluate 
novel immunotherapeutic tools for the treatment of solid cancers, and will enrich our 
understanding of therapeutically-relevant antibody-mediated mechanisms of action 
against cancer cells. Furthermore, comparative SPECT imaging preclinical studies using 
radiolabeled IgE and IgG1 will investigate the efficacy of trafficking to and retention in 
tumour for each antibody class. The biology of IgE predicts superior biodistribution 
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6 DISCOVERY OF NOVEL ANTIBODIES AGAINST 
MELANOMA ANTIGENS 
 
6.1 Introduction  
Melanoma, highly aggressive and most lethal form of skin cancer affects people of all 
ages with incidence rates rising by 5% per year, faster than any other cancer in the UK 
(Karim-Kos et al, 2011). Currently, surgical excision remains the standard of care for 
the treatment of melanoma and yet about 20% of the primary melanomas progress to 
metastatic disease for which the treatment options are limited with a median survival of 
8-18 months (Balch et al, 2009). Therefore, effective treatments are urgently needed for 
patients with this disease. Significant progress has been made in the treatment of 
advanced stage disease, with the FDA approval of Vemurafenib (BRAF V600E kinase 
inhibitor) and Ipilimumab (humanised mAb targeting the inhibitory molecule cytotoxic 
T-lymphocyte antigen 4) (Lacy et al, 2012). However, despite the partial success and 
promise of various immunotherapeutic strategies, including antibodies, there are 
presently no promising antibody therapies that directly target antigens on the surface of 
melanoma cells. 
 
Immunising mice with specific human antigens, mainly in the form of tumour cell 
lysates, proteins or epitopes of tumour-associated proteins resulted in the generation of 
murine antibodies with tumour antigen-specific variable regions. These antibodies were 
produced using hybridoma technology in vitro, which allowed for sufficient amounts of 
antibodies to be produced for further investigation of their efficacy in cancer 
immunotherapy. However, the murine antibody is expected to induce HAMA (human 
anti-murine antibody) responses in patients, resulting in neutralisation of the antibody 
and rapid clearance from the circulation, thereby significantly reducing any efficacy 
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against tumour cells. In addition, the murine Fc region is not expected to effectively 
recruit FcR-expressing human immune effector cells which may target and kill tumour 
cells by mechanisms such as cytotoxicity and/or phagocytosis. This has resulted in the 
construction of chimaeric (murine variable and human constant regions), humanised 
(human framework and murine CDR/s) or fully human antibodies which do not induce 
an immune response (Jakobovits et al, 2007; Lanzavecchia et al, 2007; Winter & Harris, 
1993) by recombinant DNA technologies. One of the most recent technologies is the 
use of human transgenic mice such as XenoMouse and VelocImmune (Jakobovits et al, 
2007). These mice express human immunoglobulin gene loci and therefore, after 
immunisation with antigens, fully-human antibodies are secreted and subsequently 
produced by standard hybridoma technology in vitro (Jakobovits et al, 2007). Another 
technique Phage display, has been established for the discovery of fully-human 
antibodies by mimicking the natural immune process of antibody affinity maturation in 
an in vitro setting. A limitation of this technique, however, is that the antibodies 
produced must be matched with random light chains to obtain a fully affinity matured 
antibody (Winter & Harris, 1993). 
  
Other methods for discovery of fully-human monoclonal antibodies derived from 
human B lymphocytes have also been exploited. B cells isolated from human blood, 
grown in culture and immortalised with Epstein Barr virus (EBV), have been activated 
with the toll-like receptor 9 (TLR-9) agonist CpG and screened against the SARS virus 
for selection of cells secreting antibodies specific for virus envelope proteins. 
Subsequently, 35 neutralising monoclonal antibodies against the SARS coronavirus 
from a convalescent patient have been generated (Lanzavecchia et al, 2006; Traggiai et 
al, 2004). Two years later, another group demonstrated that constant activation of B 
lymphocytes by exogenous stimuli (CD40L and IL-4) bears a close resemblance to 
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physiological T cell-driven clonal expansion, and is sufficient to conditionally 
immortalise these cells (Wiesner et al, 2008). The establishment of long- term antigen 
specific B cell lines by retroviral transduction of B lymphocytes with constructs 
expressing the Bcl-6 and Bcl-xL, proteins responsible for rescuing B cells from terminal 
differentiation into short-lived plasma cells in the germinal centers of lymphoid organs, 
has also been described (Diehl et al, 2008; Kwakkenbos et al, 2010). 
 
The human monoclonal antibodies generated by majority of the above mentioned 
studies are highly specific against their antigens and are able to recruit the full immune 
response, thus representing a relatively quick identification approach for discovery of 
fully-human antibodies which in theory are naturally affinity-matured in vivo. Inspired 
by these studies, in the constant search for antibody therapies that directly target 
antigens on the surface of melanoma cells, fellow students at Karagiannis lab (Division 
of Genetics and Molecular Medicine, KCL) have developed novel methods for 
identification of antibodies against melanoma cancer antigens. A novel cell-based 
ELISA for screening of tumour cell-specific antibodies secreted by cultured patient-
derived B cells was developed by Dr. Amy Gilbert (Gilbert et al, 2011). A direct single 
cell sorting technique using B cell markers and A375 melanoma cell line derived 
surface antigen markers (Figure 1.1) for isolation of cells secreting melanoma antigen-
specific antibodies has been developed by Mr. Panos Karagiannis  (manuscript in 
preparation) 
Initially, B cells derived from cancer patients were screened for the production of 
tumour antigen-specific antibodies using the cell-based ELISA or single cell sorting in 
Karagiannis lab. My major contribution to this project included cDNA preparation from 
B cells clones or single sorted cells secreting antigen-specific antibodies, PCR 
amplification of antibody variable region genes using nested PCR reactions to create 
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natural antibody libraries, cloning and expression of recombinant IgG1 antibodies, 
confirmation of their ability to recognise tumour and effector cells and finally to test 
their potential therapeutic efficacy to target melanoma cells. 
 
 
Figure 6.1: Schematic representation of single cell sorting. Single cell sorting of 
cancer patient derived B cells using  CD19/CD22 B cell markers, CD45 leukocytes 
marker and A375 melanoma cell line derived surface antigen markers for isolation of 
cells secreting antibodies with specificity for melanoma antigens. Figure courtesy of 











Figure 6.1: Schematic r presentation of single cell sorting. Single cell sorting of cancer patient 
derived B cells using  CD19/CD22 B cell markers, CD45 leukocytes marker and A375 melanoma 
cell line derived surface antigen markers for isolation of cells secreting antibodies with specificity 
for melanoma antigens. 
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6.2 Methods 
6.2.1 cDNA preparation  
Cultured patient-derived B cell clones were pelleted by centrifugation.  The supernatant 
was completely removed by aspiration and the pellet was resuspended in RLT lysis 
buffer (Qiagen) containing 10% β-mercaptoethanol.  Cells were homogenised by briefly 
pulsing with a hand held cordless motor homogeniser (Anachem).  RNA was isolated 
from the homogenate using Qiagen’s RNeasy Protect Mini Kit following the 
manufacturer’s instructions and eluted from the columns in 30µl RNase free water. 1µg 
RNA was reverse transcribed to cDNA using 400U M-MLV Reverse Transcriptase 
(Invitrogen), 0.05ng random primers, 0.2ng oligo dT primers (both Promega), 0.4mM 
dNTPs and 8U RNase OUT (Invitrogen) in 1 x 1st strand buffer (Invitrogen) and 5mM 
DTT (Invitrogen).  The reverse transcription reaction was incubated at 37°C for 10 
minutes, 42°C for 45 minutes then 50°C for 10 minutes. The production of cDNA was 
analysed by a PCR reaction to detect the housekeeping enzyme GAPDH gene. 20 µl of 
PCR reaction per sample were prepared using PhusionTM Flash High-Fidelity PCR 
Master Mix (Finnzymes) containing 0.5µM GAPDH primers (Table 2.2) and 2 µl 
cDNA. Reaction mixtures were denatured at 98°C for 1 minute followed by 35 thermal 
cycles of: 98°C for 10 seconds; 60°C for 30 seconds; and 72°C for 15 seconds. PCR 
products were analysed by gel electrophoresis on 1.5% agarose gel (Figure 6.2). The gel 
electrophoresis showed single bands, indicating amplified GAPDH cDNA (~450 bp), 
for single sorted B cell M394 and B cell clones M80-F2 and M80-F4, which were 
selected for further assessments.  
 
- 151 - 
6.2.2 Cloning IgG1 constructs 
Following the primer design steps outlined in Figure 4.5, I have designed primer 
LinearG1_Fwd (Table 2.2) to work in conjunction with previously designed 
Linear_Krev and primer pair Linear_Kfwd and Linear_Hrev (Figure 6.4). Thus, 
expression vector pVitroMAA-IgG1 was linearised by primer pair Linear_Kfwd and 
Linear_Hrev, and primer pair LinearG1_Fwd and Linear_Krev in two independent PCR 
reactions as previously described (Section 4.5). Simultaneously, the sequenced VH and 
VK nested PCR products of M394, M80-F2 and M80-F4 clones were amplified by 
primer pairs M394H_Fwd and M394H_Rev, M394K_Fwd and M394K_Rev, M80-
F2H_Fwd and M80-F2H_Rev, M80-F2K_Fwd and M80-F2K_Rev, M80-F4H_Fwd and 
M80-F4H_Rev, M80-F4K_Fwd and M80-F4K_Rev respectively (Table 2.2) for 
generation of vector fragment terminal end-homology as previously described (Section 
4.5).  The Dpn I treated vector fragments were mixed with unpurified VH and VK PCR 
products in 1:1:1:1 (v/v) ratio and 2 µl from the mixture transformed into XL1-Blue 
competent cells as previously described (Methods 4.2) 
 
6.3 Results 
6.3.1 cDNA synthesis and amplification of antibody variable region genes from 
patient derived B cells 
To isolate cDNA, single sorted B cells and cultured patient-derived B cell clones from 
Karagiannis lab were treated differently. cDNA from single sorted B cells was prepared 
as previously described (James et al, 2012). The antibody variable regions were 
amplified by two rounds of nested PCRs using nested set of VH, Vκ and Vλ primers 
designed to cover all possible human V genes as previously described (James et al, 
2012) 
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The amplified PCR products were analysed by gel electrophoresis on 1.5% agarose gel 
(Figure 6.3). The gel electrophoresis showed amplification of VH and VL in all three 
clones and the PCR products were sent for DNA sequencing to confirm their identity. 
DNA sequencing result confirmed three sets of VH and VL genes, which were 
subsequently analysed on BLAST 2.0 (http://blast.ncbi.nlm.nih.gov/) to conform 
sequence homology to other published sequences of human IgG. Further analysis of 
clonal families and rearrangement was performed using IMGT/V-Quest 
(http://www.imgt.org/IMGT_vquest/share/textes). The analyses showed that the 
variable region DNA M80-F2 clone belonged to VH3 family with kappa light chain 
antibody, variable region from M80-F4 clone belonged to VH4 family with kappa light 
chain and clone M394 antibody variable region matched to VH3 family with kappa light 
chain antibody (data not shown). 
 
Figure 6.2: Amplification of GAPDH from patient derived cDNA. The 
housekeeping enzyme GAPDH gene (~450bp) was used to verify cDNA sample 
preparation from cancer patient derived single sorted B cells (M394) or B cell 
clones (M80-B2, M80-B4, M80-F2, M80-F4 and 2G3), alongside 1kb DNA Ladder 
(NEB) and HEK293 (+) control. 
 
Figure 6.2: Amplification of GAPDH from patient derived cDNA. The ubiquitously expressed 
gene GAPDH (~450bp) used for verification of cDNA preparation from cancer patient derived 
single sorted B cells (M394) or B cell clones (M80-B2, M80-B4, M80-F2, M80-F4 and 2G3), 
alongside 1kb DNA Ladder (NEB) and HEK293 (+) control. 
0.5kb 
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Figure 6.3: Amplification of VH and VL genes from patient derived cDNA. VH and 
VL gene transcripts were RT-PCR amplified from cancer patient derived single sorted B 
cell (M394) or B cell clones (M80-F2 and M80-F4) cDNA using nested forward 
primers specific to each VH and VL family and nested reverse primers specific for the 
first domain of the IgG, Igκ and Igλ constant  region, alongside 100bp DNA Ladder 
(NEB).  
 
6.3.2 Generation of IgG1 constructs with patient derived variable regions   
As mentioned in chapter 4, I have successfully utilised the PIPE cloning method for 
swapping variable regions in IgE expression constructs. Our antibody discovery 
program provided me with an ideal opportunity to test the method and support the 
program by generating IgG1 constructs with patient derived variable regions. DNA 
sequencing of single colonies confirmed the correct assembly of the vector fragments 
with the patient derived VH and VK regions by the PIPE cloning reaction and the newly 
generated vectors were named pVitroM80-F2-IgG1, pVitroM80-F4-IgG1 and 
pVitroM394-IgG1. This cloning experiment once again confirmed the seamless 
exchange of the specificity of an antibody by the PIPE cloning method, and potential 
capability of supporting the high-throughput screening of antibody candidates derived 
from antibody discovery programs. 
Figure 6.3: Amplification of VH and VL genes from patient derived cDNA. VH and VL genes 
transcripts RT-PCR amplified from cancer patient derived single sorted B cell (M394) or B cell 
clones (M80-F2 and M80-F4) cDNA using nested forward primers specific to each VH  and VL 
family and nested reverse primers specific for the first domain of the IgG, Igκ and Igλ constant  
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Figure 6.4: Schematic representation of B cell derived V genes swapping cloning 
procedure. pVitroMAA-IgG1 vector is linearised by two VH and VK flanking primer 
pairs, resulting in two vector fragments subsequently treated by Dpn I. Simultaneously, 
VH and VL genes transcripts are RT-PCR amplified from patient derived cDNA using 
nested sets of primers and subsequently amplified for generation of vector fragment 
terminal end-homology. The Dpn I treated vector fragments are mixed 1:1:1:1 (v/v) 
with unpurified M394 VH and VK. The single-stranded DNA fragments anneal 
directionally across the complementary sequences and nicks and gaps are repaired in 
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6.3.3 Production and characterisation of IgG1 antibodies with patient derived 
variable regions  
Having successfully cloned pVitroM80-F2-IgG1, pVitroM80-F4-IgG1 and 
pVitroM394-IgG1 vectors, I continued with the expression of the IgG1 antibodies. 293-
F cells were transfected as previously described (Methods 4.2). The cells were kept 
under Hygromycin selection for 2 weeks and stable cell lines were generated. The IgG1 
expressing cell lines were expanded into 1L shaker flasks and sample supernatants 
collected after 14 days for antibody quantification by anti-human IgG1 ELISA as 
described previously (Gilbert et al, 2011; McCloskey et al, 2007). The ELISA analysis 
showed 28mg/L M80-F2 IgG1, 20mg/L M80-F4 IgG1 and 18mg/L M394 IgG1 
expression levels (Figure 6.5). This result further confirmed that the stable antibody 
expression system was capable of generating material in quantities that could support 
animal model experiments, enabling me to continue with the purification process.  
 
Figure 6.5: Stable expression of B cell derived IgG1 antibodies. Anti-human IgG1 
ELISA analysis of supernatants from recombinantly expressed B cell derived clones 
cultured in 1L spinners. The antibody concentration at mg/L was determined by 
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The IgG1 antibodies were purified on a Protein-G column as previously described 
(Methods 5.2). The affinity column-purified products were analysed by size-exclusion 
chromatography (Hunt et al, 2005) together with isotype control MOv18 IgG1 
(Karagiannis et al, 2003). The size-exclusion chromatography analysis showed no 
aggregation and confirmed the affinity column-purified product consists of monomeric 
antibodies (Figure 6.6). The size and purity of affinity column-purified IgG1 antibodies, 
were assessed by SDS-PAGE analysis as previously described (Methods 4.2). Under 
non-reducing conditions (Figure 6.7), molecular sizes of the visualised protein bands 
were found to be in the range of 148-250 kDa of the protein ladder representing the 
heterotetrameric IgG1 antibody. Free light or heavy chain was not detected, suggesting 
that the antibody chains are assembled into whole antibody molecules.  Thus, the 
represented molecular sizes in SDS–PAGE suggest that the secreted antibodies are 
properly folded and glycosylated. 
 
Figure 6.6: Size exclusion chromatography analysis of B cell derived IgG1 
antibodies. Elution profiles of recombinantly expressed cancer patient derived IgG1 
antibodies, compared to previously-characterised isotype control MOv18 IgG1, from 
Superdex™ 200 gel filtration. The antibody profiles correspond to isotype control and 
confirm the affinity purified products consist of monomeric antibodies.  
 




















- 157 - 
 
 
Figure 6.7: SDS-PAGE analysis of B cell derived 
IgG1 antibodies. Affinity purified recombinantly 
expressed cancer patient derived IgG1 antibodies 
were analysed under non-reducing conditions, 
alongside SeeBlue® Plus2 Pre-Stained Standard, 
visualised by Coomassie staining. The represented 
antibody molecular masses show the secreted 





6.3.4 Flow cytometric assessment of IgG1 antibodies with patient derived 
variable regions 
The reactivity of the affinity column-purified recombinantly expressed IgG1 antibodies, 
with patient derived variable regions, against melanoma cells was analysed by flow 
cytometry. The flow cytometric assessments were used to compare specificity of M80-
F2, M80-F4 and M394 IgG1 clones to native antigens on the cell surface of A375 
melanoma cells, compared to previously characterised HMW-MAA specific IgG1 
(Chapter 5).  
Flow cytometric analysis (Figure 6.8) of A375 melanoma cells incubated with M80-F2 
and M80-F4 IgG1 antibodies, did not show a clear shift of fluorescence intensity, 
suggesting that these clones do not have specificity for melanoma antigens. However, 
M394 IgG1 clone had a small but noticeable shift of fluorescence intensity, compared to 
100% binding of HMW-MAA specific IgG1, suggesting potential specificity for 
Figure 6.7: SDS-PAGE analysis of B cell derived IgG1 antibodies. Affinity 
purified recombinantly expressed cancer patient derived IgG1 antibodies were 
analysed under non-reducing conditions, alongside SeeBlue® Plus2 Pre-Stained 
Standard, visualized by Coomassie staining. The represented antibody molecular 
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melanoma antigens as presented on the cell surface of A375 cells. Therefore, the M394 
IgG1 clone was subjected to further flow cytometric assessments using primary 
melanoma cells and cell lines from skin, lung and lymph metastases and primary 
keratinocytes and melanocytes. 
 
Flow cytometric analysis (Figure 6.9) of cell lines from skin metastases (A375 and G-
361), lung metastasis (Malme-3M), lymph metastasis (A2058) and primary melanoma 
(Wm-115) cells showed specific binding of M394 IgG1 clone to melanoma cells and no 
binding above background to primary keratinocytes and melanocytes. Furthermore, the 
IgG1 bound to the surface of U937 cells (data not shown), expressing Fcγ receptors, 




Figure 6.8: Flow 
cytometric assessment of B 
cell derived IgG1 
antibodies. Recombinantly 
expressed cancer patient 
derived B cell clones M80-
F2 and M80-F4 do not bind 
to the cell surface of A375 
melanoma cells. The single 
sorted B cell derived M394 
recombinant antibody shows 
weak binding to A375 cells, 
compared to 100% binding 
of previously characterised 
HMW-MAA specific IgG1. 
Antibody binding was 
detected using a goat anti-
human IgG-FITC antibody. 
Figure 6.8: Flow cytometric assessment of B cell derived IgG1 antibodies. 
Recombinantly expressed cancer patient derived B cell clones M80-F2 and M80-F4 do 
not bind to the cell surface of A375 melanoma cells. The single sorted B cell derived 
M394 recombinant antibody shows weak binding to A375 cells, compared to 100% 
binding of previously characterised HMW-MAA specific IgG1. Antibody binding was 
detected using a goat anti-human IgG-FITC antibody. 
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Figure 6.9: Flow cytometric assessment of M394 IgG1 clone. The single sorted B cell 
derived recombinantly expressed M394 IgG1 antibody shows binding to primary 
melanoma cells and cell lines from skin, lung and lymph metastases and no binding 
above background to primary keratinocytes and melanocytes. Antibody binding was 
detected using a goat anti-human IgG-FITC antibody. Figure courtesy of Panos 
















































































































Figure 6.9: Flow cytometric assessment of M394 IgG1. The single sorted B cell derived 
recombinantly expressed M394 IgG1 antibody shows binding to primary melanoma cells and 
cell lines from skin, lung and lymph metastases and no binding above background to primary 
keratinocytes and melanocytes. Antibody binding was detected using a goat anti-human IgG-
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6.3.5 Flow cytometric ADCC/ ADCP assessment of M394 IgG1 
Having successfully demonstrated that the recombinantly expressed M394 IgG1 clone 
shows specific binding to melanoma as well as immune effector cells by flow 
cytometry, I aimed to examine the ability of M394 IgG1 to directly signal tumour cell 
death, measured by tumour cell cytotoxicity (ADCC) and phagocytosis (ADCP) of 
A375 melanoma cells as previously described (Section 5.6) 
The three-color flow cytometric assay showed that after 3 hours in culture, U937 
monocytic cells, employed as effector cells, mixed with M394 IgG1 and A375 did not 
mediate significant levels of ADCP above that seen with samples incubated with the 
unspecific isotype control MOv18 IgG1 (Figure 6.10). However, the antibody mediated 
predominantly ADCC with a 2-fold increase above that seen with samples incubated 
with the HMW-MAA specific IgG1, an antibody previously shown to kill melanoma 
cells by ADCP (Section 5.6). Thus, the flow cytometric ADCC/ADCP assay 
measurements confirmed that the recombinantly expressed M394 IgG1 antibody 
mediated significant levels of ADCC of A375 tumour cells by monocytic cells, 
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Figure 6.10: Three-colour flow cytometric tumour cell killing assessment of M394 
IgG1. Quantification of M394 IgG1-mediated A375 tumour cell killing by U937 
monocytes is measured by ADCC/ ADCP assay. The single sorted B cell derived M394 
recombinant antibody induces tumor cell killing via cytotoxicity. Cytotoxicity: grey 
bars; phagocytosis: gold bars. Results are means ± SD of three independent 
experiments. (n=5; *p<0.05; **p<0.01; ***p<0.001; ns: p>0.05). Figure courtesy of 
Panos Karagiannis (PhD student, KCL).  
 
6.4 Discussion 
The most lethal and highly aggressive form of skin cancer, melanoma, affects people of 
all ages with incidence rates rising every year, faster than any other cancer in the UK 
(Karim-Kos et al, 2011). Surgical excision remains the standard of care for the 
treatment of melanoma and yet about 20% of the primary melanomas progress to 
metastatic disease for which the treatment options are limited (Balch et al, 2009). 
Despite the partial success and promise of various immunotherapeutic strategies, 
including antibodies (Lacy et al, 2012), there are presently no promising antibody 
therapies that directly target antigens on the surface of melanoma cells and effective 
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Tumour antigen-specific antibodies have been generated using hybridoma technology in 
vitro, in sufficient amounts for further investigations of their efficacy in cancer 
immunotherapy. However, the murine antibody is likely to induce human anti-murine 
antibody responses in patients, resulting in neutralisation of the antibody and rapid 
clearance from the circulation, reducing the efficacy against tumour cells. In addition, 
the murine Fc region is not expected to effectively recruit FcR-expressing human 
immune effector cells which may target and kill tumour cells by mechanisms such as 
cytotoxicity and/or phagocytosis. Recombinant DNA technologies have been developed 
to tackle these limitations by constructing chimaeric, humanised or fully human 
antibodies which do not induce an immune response (Jakobovits et al, 2007; 
Lanzavecchia et al, 2007; Winter & Harris, 1993). Another technique Phage display, has 
been established for the discovery of fully-human antibodies with the limitation of 
matching the antigen specific heavy chain with random light chains to obtain a fully 
affinity matured antibody (Winter & Harris, 1993). Fully human monoclonal antibodies, 
highly specific against their antigens, have also been discovered by EBV immortalised 
human B lymphocytes (Lanzavecchia et al, 2006; Traggiai et al, 2004).  
Taking advantage of these studies, a novel cell-based ELISA for screening of tumour 
cell-specific antibodies secreted by cultured patient derived B cells (Gilbert et al, 2011) 
and a direct single cell sorting technique using B cell markers and A375 melanoma cell 
line derived surface antigen markers (Figure 1.1) for isolation of cells secreting 
antibodies with specificity for melanoma antigens have been developed in Karagiannis 
lab. Single sorted B cells and cultured patient derived B cell clones from Karagiannis 
lab were used for cDNA preparation and nested PCR amplification of antibody variable 
regions as previously described (James et al, 2012). Gel electrophoresis of the amplified 
PCR products showed bands representing three sets of VH and VL genes for one single 
sorted B cell clone (M394) and two cultured patient derived B cell clones (M80-F2 and 
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M80-F4) respectively. The VH and VL genes were subsequently confirmed by DNA 
sequencing and analysis of clonal families and rearrangement was performed using 
IMGT/V-Quest. The analysis showed all three clones possessed kappa light chain and 
revealed the M80-F2 and M394 clones belonged to VH3 family, whilst M80-F4 was 
derived from VH4 family. 
 
Having successfully adapted and optimised the PIPE cloning method for swapping 
variable regions in chapter 4, I aimed to exchange the HMW-MAA specific VH and VK 
in vector pVitroMAA-IgG1 with the melanoma patient derived variables. Following an 
additional primer design, specific to human Cγ1, and previously described cloning 
procedure, vectors pVitroM80-F2-IgG1, pVitroM80-F4-IgG1 and pVitroM394-IgG1 
were generated in a single day. This cloning experiment confirmed the seamless 
exchange of the specificity of an antibody by the PIPE cloning method, capable of 
supporting the high-throughput screening of antibody candidates derived from antibody 
discovery programs.  
 
Having successfully cloned the patient derived antibody variable regions into pVITRO 
IgG1 expressing vector, stable 293-F cell lines were generated by a small-scale 
transfection and 2 weeks selection with Hygromycin B. Following cell line expansion 
into 1L shaker flasks and 14 days incubation, the antibody expression yields were 
quantified by anti-human IgG1 ELISA. The ELISA analysis showed 28mg/L M80-F2 
IgG1, 20mg/L M80-F4 IgG1 and 18mg/L M394 IgG1 expression levels, confirming the 
stable antibody expression system was capable of generating material in quantities that 
could support animal model experiments, enabling me to continue with the purification 
process. 
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The IgG1 antibodies were purified on a Protein-G column and the affinity column-
purified products were analysed by size-exclusion chromatography. The analysis 
showed no aggregation and confirmed the affinity column-purified product consists of 
monomeric antibodies. The size and purity of affinity column-purified IgG1 antibodies, 
were assessed by SDS-PAGE analysis. Under non-reducing conditions, free light or 
heavy chain was not detected, indicating the antibody chains are assembled into whole 
antibody molecules and that the affinity purification was effective in yielding pure 
antibodies. The represented molecular sizes in SDS–PAGE suggested that the secreted 
antibodies are properly folded and glycosylated. These results represent the 
effectiveness of our antibody cloning system in swapping variable regions, simplifying 
the subsequent antibody production in sufficient quantities, capable of supporting the 
parallel characterisation and comparative functional studies between different 
melanoma patient derived antibodies with clinical potential. 
 
Biological reactivity of the affinity column-purified recombinantly expressed IgG1 
antibodies, with patient derived variable regions, against melanoma cells was analysed 
by flow cytometry. The flow cytometric analysis of A375 melanoma cells incubated 
with the two cultured patient derived B cell clones (M80-F2 and M80-F4), show no 
binding, suggesting that these clones were not specific for melanoma antigens. 
However, the single sorted B cell clone (M394) showed a weak binding compared to 
100% binding of HMW-MAA specific IgG1, suggesting potential specificity for 
melanoma antigens as presented on the cell surface of A375 cells. In subsequent flow 
cytometric experiments, the M394 IgG1 clone showed specific binding to skin, lung and 
lymph metastasis and primary melanoma cells and no binding above background to 
primary keratinocytes and melanocytes. Furthermore, the IgG1 bound to the surface of 
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U937 cells, expressing Fcγ receptors, demonstrating functional receptor-binding activity 
of the recombinant antibody.  
 
Finally, to assess the ability of M394 IgG1 clone to directly signal tumour cell death, 
the tumour cell cytotoxicity (ADCC) and phagocytosis (ADCP) of A375 melanoma 
cells, were measured where U937 monocytic cells were employed as effector cells. The 
three-color flow cytometric assay showed that after 3 hours in culture, the M394 IgG1 
was capable of activating immune effector cells to kill cancer cells in vitro, mediating 
predominantly ADCC, indicating a potential clinical application for the treatment of 
melanoma. We have shown that the HMW-MAA specific IgE antibody had superior 
efficacy compared to the corresponding IgG1 in an in vivo xenograft model of 
melanoma. Future cloning of M394 as an IgE antibody, will enable the comparative 
functional studies between IgG1 and IgE isotypes in mouse models, dissecting the 
mechanisms by which these antibodies engage and activate different compartments of 
the immune response.  
In conclusion, we have developed an efficient method using single cell sorting of 
melanoma patient derived B cells to discover antibodies specific for melanoma 
antigens. The patient derived antibody variable regions were seamlessly integrated into 
IgG1 expression construct using our antibody cloning system, which proved to be very 
effective, readily adaptable for the high-throughput screening of antibody candidates, 
simplifying the subsequent antibody production in quantities, capable of supporting the 
parallel characterisation and functional studies of a number of antibodies with clinical 
potential. We discovered an antibody clone (M394) that specifically binds melanoma 
cells, and is capable of tumour cell killing via ADCC in an in vitro assay, encouraging 
us to continue developing the antibody discovery method and pursuing melanoma 
specific antibodies for future effective antibody therapies of melanoma. 
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7 FINAL DISCUSSION 
Over 100 years since the discovery of the “magic bullet”, recombinant monoclonal 
antibodies, capable of recognising millions of antigens and executing different effector 
functions depending on the isotype, have become a key tool for basic research, 
diagnosis and treatment of human diseases. The increasing demand for therapeutic 
antibodies has resulted in a significant improvement in antibody production systems. 
However, the lack of a suitable manufacturing platform, which ensures consistent 
antibody production, has always been one of the major impediments to the development 
of recombinant antibody material in academia.  
 
Conventional methods for recombinant expression of antibodies such as the 
establishment of cell lines tend to be a lengthy, low efficiency process involving 
extensive selection and screening and is consequently unfavourable for the rapid 
production of large numbers of antibodies for functional studies, as may be required 
after generating a variable gene library. To tackle this, tailoring the antibody expression 
cassettes for use in a vector suitable for transient transfection in mammalian HEK293E 
cells has enabled rapid antibody production (Baldi et al, 2005; Berntzen et al, 2005; Li 
et al, 2007; Wright et al, 2003). Furthermore, antibody variable region genes isolated 
from single cells have been integrated into human IgG1 expression constructs.  
However, the restriction sites used in these vectors are not compatible with all human 
constant gene isotypes.  
 
To fulfil these limitations, our lab had previsouly designed and constructed a set of 
cloning cassettes for antibody heavy chain, as well as kappa and lambda light chains in 
which restrictions sites, compatible with all human C gene isotypes and all human and 
murine germline V genes, flanking the V and C domains have been introduced by silent 
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mutation (Figure 3.2).  This has enabled the production of any conceivable human or 
mouse-human chimeric antibody by a transient expression system (Gan, 2008). I have 
used this system as a model for my current studies and as a standard for further 
optimisations. After successfully achieving previously reported expression levels (Gan, 
2008), I continued with the system optimisation for better yields. Important parameters 
including transfecting agent affecting cell toxicity (Godbey et al, 2000), light : heavy 
chain ratio influencing Ig production (Baldi et al, 2005; Schlatter et al, 2005) and 
Tryptone N1 (Pham et al, 2005) or Optimab (Invitrogen) media supplementation  were 
investigated. Most favourable cell viability and maximum antibody expression level 
was achieved at 4µg PEI : 1µg DNA ratio and 2:1 light : heavy chain DNA ratio. This 
optimisation halved the DNA amount of the light chain previously used (4:1) (Gan, 
2008) to transfect cells, hence shortening the DNA production process required for 
transfection. The Tryptone N1 media supplementation had a 4-fold decrease in antibody 
expression level, compared to media alone, suggesting the peptone depletion was not 
limiting antibody production yield in HEK293E cells. Although the Optimab 
supplementation represented a 2-fold increase in volumetric antibody productivity, soon 
after the optimisation step was conducted, Invitrogen discontinued Optimab and no 
appropriate alternatives have been found so far. 
 
Utilising the new optimised conditions, I swapped existing antibody variable regions 
with those specific for a High Molecular Weight Melanoma-Associated Antigen 
(HMW-MAA) within pSG vectors (Figure 3.11) and produced a fully functional 
antibody using the transient expression system. Following construct generation, using 
the optimised protocol, the HMW-MAA specific IgE antibody was transiently 
expressed and its antigen specificity and receptor-binding activity confirmed by flow 
cytometry.  
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Different vectors hosting a dual antibody expression cassette have been exploited and 
shown to produce higher antibody expression levels (Braren et al, 2007; Hecker et al, 
2011; Wiberg et al, 2006). To eliminate the requirement for co-transfection of two 
vectors, coding for the expression of heavy and light antibody chains independently, I 
constructed a dual expression cassette in a single mammalian expression vector (Figure 
4.6) thus halving the time and effort needed for DNA preparation and transfection 
procedure. I took advantage of the Polymerase Incomplete Primer Extension (PIPE) 
cloning method, shown to be rapid, cost-effective, and highly efficient, and thus capable 
of supporting the high-throughput cloning of thousands of genes in parallel (Klock et al, 
2008), without the use of restriction enzymes- and ligation-dependent cloning. Having 
successfully constructed the dual cassette, I designed universal primer pairs flanking the 
variable regions and exchanged the specificity of an IgE antibody in a single day 
(Figure 4.7). This system enables high-throughput screening of antibody candidates 
derived from antibody discovery programs. Moreover, the construct codes for the 
expression of different antibody isotypes with the same antigen specificity, and thus 
supports the parallel characterisation and comparative functional studies between 
different isotypes. For example, I was able to successfully exchange the isotype of a 
HMW-MAA specific IgE to both IgG4 and IgG1 (Figure 4.9 and Figure 5.1). These 
cloning experiments represent the system’s simplicity to exchange variable- and/or 
constant-region antibody domains allowing cloning of different isotypes with any 
desired specificity.  
 
Due to the presence of a Hygromycin resistant gene in pVITRO1 vector, it was possible 
to perform a small-scale transfection, followed by 2 weeks selection and generation of 
stable cell lines. This enabled the subsequent expansion and large-scale production of 
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antibodies to support in vivo animal model experiments. Following affinity column 
purification, the recombinantly produced antibodies were assessed by SDS-PAGE, size-
exclusion chromatography and flow cytometric analysis. The analysis demonstrated 
properly folded and glycosylated product, consisting of monomeric antibodies, capable 
of specifically recognising the target antigen, with functional receptor-binding activity. 
 
Having successfully optimised the cloning and expression system for large-scale 
production of fully functional antibodies, I implemented it for parallel comparative 
functional studies between two different isotypes with the same specificity using 
validated in vitro and ex vivo assays. Tumour antigen-specific monoclonal IgG 
antibodies have already been approved for therapeutic use, but nearly all antibody 
therapies developed to date rely on IgG1 isotype (Scott et al, 2012). However, it is 
known that IgG diffuses inefficiently into solid tissues, and binds with low affinity to 
receptors on immune effector cells, while IgE antibodies can be transported from the 
circulation into tissues, where, through the strong affinity for their receptors on immune 
cells, they are known to trigger powerful immune responses. We have found that the 
results of in vitro experiments using IgG1 do not translate well to the solid tumour 
environment, where other mechanisms may prevail (Bracher et al, 2007; Karagiannis et 
al, 2008b; Karagiannis et al, 2007; Reali et al, 2001). We have demonstrated superior in 
vivo efficacy for the IgE subclass in comparison to IgG in the targeting of MOv18, an 
antibody directed against folate receptor, a tumour- specific antigen, in two murine 
xenograft models of human ovarian cancer (Gould et al, 1999; Karagiannis et al, 2003). 
Following successful characterisation and confirmation of the specific antigen 
recognition and functional receptor-binding activity by flow cytometry and 
immunofluorescence experiments, we examined the capacity of the HMW-MAA 
specific IgG1 and IgE antibodies to target and kill melanoma tumour cells. In a 
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functional degranulation assay measuring % β-hexosaminidase release by RBL SX-38 
mast cells expressing human FcεRI, the IgE isotype demonstrated its ability to activate 
immune effector cells through engagement of its high affinity receptor. This isotype was 
also capable of activating immune effector cells to kill cancer cells in vitro by ADCC. 
Furthermore, treatment with melanoma antigen-specific IgE antibody was superior in 
inducing tumour growth restriction in vivo compared to the corresponding IgG1. This 
data suggests that engineering antibodies with IgE-Fc regions can improve antibody 
effector functions, which is particularly advantageous in the case of solid tumours, since 
these are frequently refractory to treatment with IgG antibodies. With a serum half-life 
of 21-24 days, compared to a half-life of 2-3 days in tissues, IgG antibodies may be the 
most effective antibody class to target blood-resident tumours and circulating tumour 
cells, while their ability to exert tumour surveillance in tissues may be less potent 
(Hellman, 2007; Ravetch & Kinet, 1991). The presence of the inhibitory receptor 
FcγRIIb in tumour-infiltrating immune cells such as macrophages may also negatively 
influence the efficacy of IgG antibodies in tissues (Kraft & Kinet, 2007; Maenaka et al, 
2001). On the contrary, the IgE antibodies function through their specific high-affinity 
Fc receptors (FcεRl with Ka=1011 M-1 is 102-105 times higher than that of IgGs for their 
receptors) on a different spectrum of effector cells to IgG, and naturally reside in tissues 
where they exert immunological surveillance. Our results demonstrate that these 
properties may translate to superior efficacy in targeting tissue-resident tumours such as 
melanoma. Future mouse models will further investigate the mechanisms by which 
these antibodies engage and activate different compartments of the immune response to 
help evaluate novel immunotherapeutic tools for the treatment of solid cancers. 
Evaluating the potential clinical use of IgE for the treatment of solid tumours will help 
translate this isotype from the laboratory bench to the clinic. 
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Having demonstrated the anti-tumour activity of a recombinantly produced chimeric 
antibody specific for a known melanoma antigen (HMW-MAA), we had a golden 
standard to use as a control for the evaluation of patient-derived fully-human melanoma 
antigen-specific antibodies. To support the third aim of the antibody discovery program, 
patient-derived single sorted B cells from Karagiannis lab were used for cDNA 
preparation and antibody variable regions were amplified by a nested PCR reaction. 
DNA sequencing confirmed variable gene pairs were seamlessly cloned into IgG1 
expression vectors and produced using the stable antibody expression system. Flow 
cytometric experiments of a recombinantly expressed IgG1 antibody, with patient 
derived variable regions, showed specific binding to cell lines from skin, lung and 
lymph metastasis and primary melanoma cells and no binding above background to 
primary keratinocytes and melanocytes. Furthermore, the antibody was capable of 
activating immune effector cells to kill cancer cells in vitro, mediating predominantly 
ADCC, encouraging us to continue developing the antibody discovery method and 
pursuing melanoma antigen-specific antibodies with clinical potential. Future cloning 
and expression of the CSPG 4 antigen will allow screening of antibody libraries by 
means of Phage Display as an alternative method to antibody discovery (Hoogenboom, 
2005). Should these investigations help discover novel antibodies with specificity for 
melanoma antigens, they may reveal new therapeutic options for future effective 
antibody therapies of melanoma. 
 
In conclusion, we have developed a useful method for one-step antibody cloning in a 
single mammalian expression vector, allowing the reproducible generation of fully 
functional recombinant antibodies of any species and isotype with any desired 
specificity, at the level of tens of milligrams per litre. This method enables the direct 
comparison of different antibody isotypes that could readily be adapted for use in 
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mechanistic studies of antigen-antibody interactions, and facilitates the parallel 
processing of a large panel of antibodies for identification of potential candidates for 
clinical applications. This is particularly advantageous for expression of whole 
antibodies derived from Phage Display screening of antibody libraries (Hoogenboom, 
2005).  
The system is recognised as an unbiased manufacturing platform in academia and is 
now being applied to other projects, including ovarian cancer antigen, grass pollen 
allergen and peanut allergen specific antibodies. In addition to all the antibodies 
characterised in this thesis, the antibody cloning and expression system has enable the 
generation of all the constructs present in Table 7.1 as well as the cloning, production 
and characterisation of 7 allergen-specific human isotypes (Figure 7.1). Further 
reconstruction of the antibody expression cassette into the Flp-InTM system 
(Invitrogen) for the generation of stable cell lines will provide a number of advantages. 
An integration of the FRT site into Flp-InTM host cell line will permit polyclonal 
selection and allows subsequent generation of isogenic stable cell line expressing the 
antibody of interest much faster and more efficiently. 
 
Table 7.1: Antibody expression vectors. pVITRO1 antibody expression vectors 
generated by PIPE cloning method. Apart from the murine IgG1/k, all other constructs 
have been used for antibody expression and characterisation. The rat antibodies are used 
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Figure 7.1: SDS-PAGE analysis of Phl p 7 specific recombinant antibodies. Grass 
pollen allergen Phl p 7 specific antibody variable regions (James et al, 2012) have been 
cloned in 7 different isotype constructs within a single day using the PIPE cloning 
method and produced by the stable antibody expression system. Affinity purified 
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Figure 4.14: SDS-PAGE analysis of Phl p 7 specific recombinant antibodies. 
Affinity purified grass pollen allergen Phl p 7 specific antibodies were analysed 
under reducing conditions and visualized by Coomassie staining.  
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